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Abstract 
Background: Due to an aging population, rates of dementia are rising in Canada 
increasing the incidence of Lewy body dementia. To provide quality care to individuals 
with this disease, nursing staff need to be aware of evidence-based practices to ensure 
resident-centered care. Within Eastern Health, nursing staff in long-term care are well 
versed in dementia care, but there is no training specific to Lewy body dementia. 
Purpose:  To develop educational resources related to nursing care of individuals with 
Lewy body dementia, to be used by nursing staff in long-term care settings to enhance 
resident-centered care. 
Methods: 1) An integrative literature review was conducted to assess relevant evidence-
based information related to the nursing care of individuals with Lewy body dementia; 2) 
Key stakeholders, both locally and provincially, were consulted to determine relevant 
strategies and perspectives on nursing care of individuals with Lewy body dementia; 3) 
Educational resources related to Lewy body dementia were developed for nursing staff in 
long-term care. 
Results: The findings from the literature review and the consultation process guided the 
development of a presentation and resource manual for nursing staff in long-term care 
focusing specifically on Lewy body dementia. 
Conclusion: The proposed educational resources regarding Lewy body dementia will 
address the lack of awareness regarding LBD among nursing staff in LTC to improve 
quality of care and positively influence quality of life for residents with LBD. 
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Due to the population advancing in age, dementia is a growing global concern. 
Worldwide in 2015, 47.5 million people were living with dementia (Alzheimer Society of 
Canada, 2015a). This number is expected to triple within the next 35 years (Alzheimer 
Society of Canada, 2015a). Globally, the most common dementias in ranked order are 
Alzheimer’s disease which affects 60-80% of people diagnosed with dementia; vascular 
dementia which affects 20% of people diagnosed; and Lewy body dementia (LBD) which 
affects 15-20% of people diagnosed (Alzheimer Society of Canada, 2015b). Parkinson’s 
disease dementia occurs in about 50-80% of people diagnosed with Parkinson’s disease 
(Alzheimer Association, 2016a). In Canada, Alzheimer’s disease (AD) accounts for 64% 
of dementia cases while vascular dementia accounts for 20% and Lewy body dementia 
accounts for 5-15% of cases (Alzheimer Society of Canada, 2015b).  As a result of this 
global increase in dementia diagnoses, nursing staff will encounter more residents 
diagnosed with LBD in long-term care (LTC) settings in the future. Education regarding 
LBD is needed for nursing staff to develop interventions that are resident-centered and 
improve quality of life of residents with LBD in LTC. 
There is considerable overlap of clinical manifestations between LBD, AD, and 
Parkinson’s disease (PD) which impacts diagnosis and care delivery. Appropriate staff 
training is needed so that nursing staff can differentiate between LBD, AD, and PD which 
will lead to improved care practices. LBD education should be a priority area for 
healthcare to increase understanding of the disease process and care practices, as a result, 
improving quality of life for individuals diagnosed with LBD in LTC. 
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The following report will include an overview of the practicum objectives and the 
methods used to accomplish these objectives. Full reports of the integrative literature 
review and the consultation process, as well as the developed educational resources are 
also included. A discussion of the advanced nursing practice competencies (Canadian 
Nurses Association [CNA], 2008) demonstrated throughout the practicum is also 
included.  
 
Objectives 
The objectives of the practicum were:  
1. Conduct a thorough literature review to assess relevant evidence-based 
information and clinical practice guidelines related to the nursing care of 
individuals with LBD. 
2. Conduct consultations with key stakeholders to determine relevant strategies and 
perspectives on nursing care of individuals with LBD. 
3. Develop a resource manual outlining information related to nursing care of 
individuals with LBD. 
4. Disseminate information related to nursing care of individuals with LBD, along 
with dissemination of the completed resource manual to improve care of 
individuals with LBD. 
5. Demonstrate advanced nurse practice competencies such as clinical practice, 
researcher, leadership, and consultation/collaboration. 
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Objectives three and four did change once the consultation results were determined. 
Instead of developing a resource manual alone, the new objectives were to develop a 
presentation and a resource manual for nursing staff related to LBD. 
Methods 
Summary of Literature Review 
An integrative literature review was conducted (see Appendix A) using the 
following databases: CINAHL, PubMed, Cochrane Library, and Google Scholar with the 
following search terms to identify articles relevant to the care of individuals with LBD: 
Lewy body dementia and non-pharmacological treatment, pharmacological treatment, 
signs and symptoms, quality of life, and nursing care. A hand search of article reference 
lists was also conducted to retrieve additional information. Articles were not limited to a 
specific geographic location, clinical setting, or year of publication in an effort to 
maximize search results. Nine relevant research articles were identified and were 
critically appraised according to the Public Health Agency of Canada [PHAC] Infection 
Prevention and Control Guidelines Critical Appraisal Toolkit (2014). There were two 
randomized control trial studies (Culo et al., 2010; Larsson et al., 2011); a cohort and 
respective cohort study (Auning et al., 2011; Ballard et al., 2001); and five cross-
sectional studies (Bostrom, Jonsson, Minthon, Londos, 2007; Galvin et al., 2010a; Galvin 
et al., 2010b; Leggett, Zarit, Taylor, & Galvin, 2010; McKeith et al., 2006). The grey 
literature was also searched and had useful information related to LBD that better 
summarized evidence that was found to be contradictory in the research. 
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After the literature review it was determined that there is a lack of strong research 
design and nursing research regarding LBD. Many of the articles addressed LBD in 
comparison to AD or PD. These articles are relevant as they portray the overlap of 
symptoms in dementia and what distinguishes LBD from other types of dementia. The 
predominant themes depicted in the research included the overlapping symptoms of LBD, 
AD, and PD,  quality of life of individuals living with LBD, managing LBD symptoms, 
and the challenge of providing a differential diagnosis of LBD. 
LBD is an umbrella term for two related diagnoses: dementia with Lewy bodies 
(DLB) and Parkinson’s disease dementia (PDD) (Lewy Body Dementia Association 
[LBDA], 2016a). The central feature in each diagnosis is dementia and the time frame of 
the dementia will determine the exact diagnosis (LBDA, 2016a). Individuals can have 
three clinical presentations: 1) If a person presents with a movement disorder, they are 
diagnosed with Parkinson’s disease. If dementia develops a year or more later, then the 
person is diagnosed with PDD (LBDA, 2016a); 2) If a person presents with a cognitive 
disorder before or within one year of Parkinson’s symptoms, then it is diagnosed as 
dementia with Lewy bodies (DLB) (LBDA, 2016a); 3) If a person presents with 
neuropsychiatric symptoms, such as hallucinations, behavioral problems, and issues with 
complex activities, the diagnosis is DLB (LBDA, 2016a). The three clinical presentations 
have different symptoms initially, but over time will develop similar cognitive, physical, 
sleep, and behavioral problems (LBDA, 2016a). 
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Overlapping Symptoms of LBD, AD, and PD 
There are two diagnostic tools used to diagnose LBD: the Diagnostic and Statistic 
Manual of Mental Health Disorders, fifth edition (DSM-5) and the Consortium on 
Dementia with Lewy Bodies Consensus Guidelines (McKeith et al., 2005; Walter, 
Edwards, Griggs, & Yehle, 2014). Both diagnostic tools have the same criteria for 
diagnosing LBD, and the literature does not indicate which tool is more valid and reliable 
for diagnosing LBD. The Lewy Body Dementia Association (LBDA) uses the four 
categories of symptoms as specified by the Consortium on Dementia Consensus 
Guidelines  to diagnosis LBD (LBDA, 2016a): 1) Central features include dementia with 
problems in the areas of planning, judgment, processing, and understanding information. 
Memory impairment is usually not present upon diagnosis; 2) Core (hallmark) symptoms 
include fluctuating cognition with variations in attention and alertness with short-term 
memory intact in early stages. Recurrent, vivid visual hallucinations that are well-formed 
and detailed and spontaneous features of Parkinsonism such as tremors, stiffness, 
slowness, and difficulty walking; 3) Suggestive features include rapid eye movement 
(REM) sleep behavior disorder that involves talking and acting out dreams while asleep, 
severe sensitivity to neuroleptics, and low levels of dopamine reuptake on brain imaging 
that can cause depression, apathy, anxiety, and agitation; 4) Supportive features include 
repeated falls and fainting, short-term unexplained loss of consciousness, autonomic 
dysfunction such as blood pressure control, temperature regulation, and bowel and 
bladder control; hallucinations that involve touch or hearing; problems processing and 
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interpreting visual information such as the ability to orient oneself in the environment, 
and other psychiatric disturbances such as delusions and paranoia. 
 There are concerns with the Consortium Guidelines because, although it has high 
specificity in identifying those who do not have LBD, it has a low sensitivity in correctly 
detecting those who have LBD. This could lead to misdiagnosis and underdiagnosis of 
LBD. Both diagnostic tools are being used in practice, and this could be creating issues 
with receiving a definitive diagnosis of LBD. As well, healthcare providers may lack 
clinical familiarity with the diagnostic tools for LBD which could be contributing to the 
two year lag between onset of symptoms and diagnosis (LBDA, 2016c). 
   The research indicated that the common presenting symptoms of LBD and AD 
have similar characteristics but the symptoms occur at different stages of the disease 
continuum (Auning et al., 2011; Ballard et al., 2001; Walter et a., 2014). In LBD, the 
deficits in cognitive reaction time, slowing of cognitive processing, and fluctuations of 
attention are significantly more prominent than in AD. The attentional deficits that occur 
early in LBD do not occur until advanced stages of AD. Combined with their awareness 
of this, quality of life of individuals with LBD is considerably impacted early in the 
disease course.  
There are similar symptoms between LBD, AD, and PD, further increasing 
misdiagnosis and underdiagnosis of LBD (Barber, Panikkar, & McKeith, 2001; McKeith, 
Perry, & Perry, 1999; Oliveria, Sampaio, Chen, & Bertolucci, 2015). Therefore, nursing 
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staff need educational resources that clearly distinguish the clinical manifestations of 
LBD to improve resident-centered care and quality of life in LTC settings. 
Quality of Life and LBD 
 Research indicates that individuals with LBD have more impaired quality of life, 
and more severe functional impairments than AD (Bostrom et al., 2007; McKeith et al., 
2006). Neurological and psychiatric symptoms, and functional impairments related to 
daily living were more debilitating in LBD than in AD. Early in the LBD disease 
trajectory, dependence on others is high because of extrapyramidal symptoms such as 
bradykinesia, tremors, and gait disturbances along with cognitive symptoms which 
severely impact basic care needs and mobility (McKeith et al., 2006). Individuals with 
LBD require earlier admission to nursing homes, have increased mortality, and die earlier 
in comparison to other types of dementia (Khotianov, Singh, & Singh, 2002; Zupancic, 
Mahajan, & Handa, 2011; Zweig & Galvin, 2014). Evidence gathered from individuals 
with LBD and caregivers indicate that quality of life is significantly lower in those with 
LBD than AD (Bostrom et al., 2007). As a result of a lowered quality of life, individuals 
with LBD and their families have an increased use of healthcare services (Bostrom et al., 
2007). Therefore, prompt, resident-centered care for individuals with LBD to manage 
symptoms effectively can promote optimal outcomes (Bostrom et al., 2007). 
Managing LBD Symptoms 
There was limited information regarding the use of non-pharmacological 
approaches to manage LBD specifically, but research did indicate approaches are similar 
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to those used with other types of dementia such as, behavioral and communication 
strategies, reminiscence, doll therapy, aromatherapy, and music therapy (Neef & Walling, 
2006; McKeith, 2004; McKeith et al., 2005; Yuhas, McGowan, Fontaine, Czech & 
Gambrell-Jones, 2006; Zupancic et al., 2011). As well, studies analyzing quality of life 
and pharmacological interventions in LBD are limited.  
There are limited pharmacological options for those diagnosed with LBD due to 
lack of approved medications to treat the disease (Larsson et al., 2011). As a result, 
medications are generally used off label in the treatment of LBD (LBDA, 2016b). The 
greatest concern with pharmacological management is best course of treatment of 
symptoms and control of side effects (Culo et al., 2010; Larsson et al., 2011). Research 
indicates the recommended medications for management of LBD are cholinesterase 
inhibitors, N-Methyl-D-receptor antagonists (NMDA), Levodopa-carbidopa, 
benzodiazepines, and atypical antipsychotics (Culo et al., 2010; Larsson et al., 2011; 
LBDA, 2016b; Lewy Body Dementia Society, 2015). 
Cognitive symptoms are more severe earlier in LBD when compared to AD, 
therefore proper management is crucial to improve quality of life (Culo et al., 2010). 
Cholinesterase inhibitors, such as Aricept (donepezil HCl), are the recommended first 
course of treatment for the cognitive symptoms of LBD (LBDA, 2016b; Lewy Body 
Dementia Society, 2015).
 
These medications decrease the loss of acetylcholine in mild to 
moderate dementia which will help decrease problems with memory, thinking, and 
alertness (LBDA, 2016b; Lewy Body Dementia Society, 2015).  
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A more recent pharmacological intervention for LBD is the use of N-methyl-D-
receptor antagonists that are commonly used in AD and PDD (Larsson et al., 2011; 
Shagham, 2009). NMDA for example, Ebixa (Memantine HCl) is used in moderate to 
severe stages of dementia when cholinesterase inhibitors are ineffective or the person has 
a sensitivity to them (LBDA, 2016b; Shagham, 2009). These medications may slow the 
loss of learning and memory skills such as, toileting and dressing, improving overall 
quality of life and functional capacity of individuals with LBD (Larsson et al., 2011; 
Shagham, 2009). 
Levodopa-carbidopa, such as Sinemet,
 
is
 
a combination medication that is 
commonly used with LBD (LBDA, 2016b; Lewy Body Dementia Society, 2015).  The 
carbidopa increases the uptake of levodopa to improve motor symptoms such as restless 
leg syndrome, rigidity, and tremors (LBDA, 2016b; Lewy Body Dementia Society, 
2015). This medication is the initial treatment protocol for PD and is beneficial for 
management of Parkinson symptoms in LBD (LBDA, 2016b; Lewy Body Dementia 
Society, 2015). Levodopa-carbidopa
 
should be started at the lowest dose and titrated 
slowly to allow for close monitoring of adverse effects (LBDA, 2016b; Lewy Body 
Dementia Society, 2015).  
Benzodiazepines for example, Clonazepam (Klonopin)
 
are
 
used to treat REM 
sleep disorder and restless leg syndrome (Vallerand & Sanoski, 2015). These medications 
produce a sedative effect in the central nervous system (Vallearand & Sanoski, 2015).  
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Typical antipsychotics are often used to manage the behavioral and psychological 
features demonstrated in other types of dementia, but with LBD these medications are 
never used because they produce severe and fatal side effects known as neuroleptic 
sensitivity and neuroleptic malignant syndrome (Culo et al., 2010; LBDA, 2016b; 
McKeith et al., 2005; Walter et al., 2014). Neuroleptic sensitivity results in worsening of 
cognitive symptoms, hallucinations, and Parkinsonism and occurs in up to 50% of LBD 
patients treated with atypical antipsychotics (LBDA, 2016b). Neuroleptic malignant 
syndrome is a rare life-threatening adverse effect that produces symptoms of fever, 
generalized rigidity, and breakdown of muscle tissue that can result in kidney failure and 
death (LBDA, 2016b). 
Atypical antipsychotics can be used to treat hallucinations and/or delusions that 
occur in LBD (Culo et al., 2010; LBDA, 2016b; Lewy Body Dementia Society, 2015).
 
Extreme caution and close monitoring is required when atypical antipsychotics are 
prescribed because neuroleptic sensitivity and neuroleptic malignant syndrome are 
possible (LBDA, 2016b; Lewy Body Dementia Society, 2015). The recommended 
atypical antipsychotics to be prescribed are Quetiapine and Clozapine, in this order 
(LBDA, 2016b; Lewy Body Dementia Society, 2015; McKeith et al., 2005; Walter et al., 
2014).These medications are only used if long-term cholinesterase inhibitors have been 
ineffective or better behavioral control is warranted (LBDA, 2016b; Lewy Body 
Dementia Society, 2015; McKeith et al., 2005; Walter et al., 2014).  When atypical 
antipsychotics are prescribed, the lowest dose should be used for the shortest amount of 
time (LBDA, 2016b; Lewy Body Dementia Society, 2015; McKeith et al., 2005; Walter 
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et al., 2014). Atypical antipsychotics are safer than typical antipsychotics, but there is no 
antipsychotic medication that is absolutely safe for the management of LBD behavioral 
symptoms since all antipsychotics increase the chance of death in people with dementia 
(LBDA, 2016b; Lewy Body Dementia Society, 2015). 
Certain medications should also be avoided in the management of LBD. Atypical 
antipsychotics Risperidone and Olanzapine, should be avoided as they have an increased 
likelihood of increasing side effects such as increased Parkinson symptoms, sedation, and 
orthostatic hypotension (LBDA, 2016b). As well, the following medications used with 
Parkinson’s disease should be avoided as they worsen cognitive impairment: 
Amantadine, Catechol-O-methyltransferase (COMT) inhibitors (ex: Entacapone), 
Monoamine oxidase (MAO) inhibitors (ex: Selegiline), and anticholinergics (ex: 
Benztropine). Dopamine agonists such as Pramipexole and Bromocriptine should also be 
avoided because they cause excessive daytime sleepiness and swelling of the legs 
(LBDA, 2016b). It is important to also avoid over-the-counter sleep agents such as 
Tylenol or Advil PM, and bladder control medications as they may cause agitation 
(LBDA, 2016b). 
 It is evident that LBD symptom management requires a complex and different 
pharmacological approach than with other dementias to effectively manage the symptoms 
of the disease and improve quality of life.  
Non-pharmacological interventions such as behavioral and communication 
strategies, music therapy, doll therapy, aromatherapy, and reminiscence aid in the 
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management of behavioral and psychological symptoms by lessen disruptive behaviors 
for example agitation, anxiety and aggression (Azcurra, 2012; Bisiani & Angus, 2012; 
Forrester et al., 2014; Haslem et al., 2014; Lin et al., 2011; Raglio et al., 2008; 
Subramaniam, Woods, & Whitaker, 2014; Sung, Lee, Li, & Watson, 2012;  Van Bogaert 
et al., 2013; Yuhas et al., 2006). The non-pharmacological interventions improve quality 
of life by calming residents and promoting relaxation, sleep, memory recall, and 
attachment needs (Azcurra, 2012; Bisiani & Angus, 2012; Forrester et al., 2014; Haslem 
et al., 2014; Lin et al.,  2011; Raglio et al., 2008; Subramaniam et al., 2014; Sung et al., 
2012; Van Bogaert et al., 2013; Yuhas et al., 2006) 
The Challenge of Providing a Differential Diagnosis of LBD 
Healthcare professionals lack awareness regarding LBD (Galvin et al., 2010a; 
Galvin et al., 2010b; Leggett et al., 2010). Families have described the challenge of 
having a loved one correctly diagnosed with LBD and in a timely manner (Galvin et al., 
2010a; Galvin et al., 2010b; Leggett et al., 2010). Research consistently demonstrated 
that there was a two year lag between onset of symptoms and a LBD diagnosis which 
could be due to the lack of clinical familiarity among primary care providers regarding 
LBD diagnostic criteria (Galvin et al., 2010a; Galvin et al., 2010b; Leggett et al., 2010).  
Studies that utilized input from family experiences of the LBD journey can be 
used to influence the direction of educational needs and resources for healthcare 
professionals. The literature suggests there are few educational programs and other 
resources for healthcare professionals regarding LBD (Galvin et al., 2010a; Galvin et al., 
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2010b; Leggett et al., 2010). Increasing awareness of LBD among health care providers 
will most likely lead to earlier diagnosis, enhanced care for individuals living with LBD, 
and better support for family members. As a result, quality of life for individuals with 
LBD will improve. 
Summary of Consultations 
Consultations were conducted with 15 nursing leaders and front-line nurses. 
Nursing leaders from the following LTC sites agreed to participate: one site in Edmonton, 
Alberta; one in Vancouver, British Columbia; one in Waterloo, Ontario; one in Halifax, 
Nova Scotia; and three within rural Avalon Eastern Health authority. As well, front-line 
nurses from the dementia unit at Harbour Lodge Nursing Home (one senior and one 
junior RN, two senior and one junior LPN, and one senior and one junior PCA) 
participated. Also, a physician from urban Eastern Health Authority who specializes in 
neurocognitive disorders in geriatrics participated. Purposive sampling was used to 
recruit participants. An information letter was sent via email to each potential participant 
outlining the purpose of the consultation process and full disclosure of how the data 
collected would be utilized to develop the LBD educational resources. Interviews were 
completed with the participants after an email confirming agreement to participate was 
received by the MN student. Verbal agreement was also obtained at the time of the 
interview. Notes were taken during each interview and analyzed for themes. There were 
five major themes that emerged from the consultation process: lack of education 
resources specific to LBD in LTC, knowledge gaps of nursing staff in LTC regarding 
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LBD, lack of clinical knowledge regarding diagnosis and care specific to individuals 
living with LBD, preferred learning styles of nursing staff related to LBD in LTC, and 
impact of LBD education on care delivery in LTC (see Appendix B). The findings of the 
consultations were consistent with those of the literature review. 
Lack of Education Resources Specific to LBD in LTC 
The consultations demonstrate that the majority of staff orientation is based on 
dementia in general, with a focus on AD. Very limited information is provided regarding 
LBD. Findings indicate that most LTC sites focus on programs geared toward AD 
specifically. For example, in Eastern Health, nursing staff complete a Gentle Persuasive 
Approaches (GPA) course and Dementia Care Orientation course related to responsive 
behaviors in AD. Both these programs focus mainly on AD with little information 
regarding LBD.  
Education related to dementias other than AD is self-initiated by nursing staff 
through internet websites such as the Alzheimer Society of Canada. Some facilities have 
handbooks covering dementia in general for families which nursing staff use as well to 
increase their knowledge base regarding dementia. All participants stated there was a 
need for resources specific to LBD for nursing staff. 
Knowledge Gaps of Nursing Staff in LTC Regarding LBD 
Numerous areas of knowledge deficits among nursing staff in LTC were evident 
in the consultation process. The main learning needs identified focused on the following 
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areas: What is LBD? What are the signs and symptoms of LBD that distinguish it from 
other dementia types? What are the risks for being diagnosed with LBD? What are the 
pharmacological and behavioral management options? What are some Canadian 
resources related to LBD? Many members of the nursing staff were only aware of care 
approaches to be used with AD residents and not for residents with LBD which impacts 
resident-centered care for these individuals.  A major issue with pharmacological 
management of LBD is knowing when to use particular classes of medications, what 
classes of medication not to use or with great caution, and when behavioral approaches 
are more appropriate to manage signs and symptoms. Nursing staff need to be aware of 
current and relevant alternatives to antipsychotic use due to their severe side effects. With 
more education nursing staff will be better able to differentiate the clinical manifestations 
of LBD from other dementia types and provide interventions that are appropriate and safe 
for LBD to promote optimal care.  
Lack of Clinical Knowledge Regarding Diagnosis and Care Specific to Individuals 
Living with LBD  
It was deemed by nursing leaders and nursing staff that not many residents in 
LTC are definitively or appropriately diagnosed with LBD; they are generally given an 
umbrella diagnosis of dementia. This impacts the ability of nursing staff to provide 
resident-centered care in LTC settings. Nurses expressed frustration in managing 
hallucinations and behavioral symptoms of LBD using general dementia approaches. 
Nursing staff also indicated that the pharmacological interventions used with AD are not 
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effective in managing hallucinations and behavioral symptoms in LBD. By not being 
properly informed regarding LBD, nursing staff cannot effectively provide individualized 
care which negatively impacts quality of life. As a result, nursing staff feel specialized 
plans of care should be put into place for LBD residents based on current, evidence-based 
practices which will also help nurses relay pertinent information regarding LBD to 
families to help with the coping process of LBD diagnosis. 
Preferred Learning Styles of Nursing Staff Related to LBD in LTC 
 Nursing leaders and nursing staff identified that educational resources were 
needed to enhance knowledge regarding LBD so that staff can be more confident and 
competent in delivering resident-centered care to LBD residents thus improving quality 
of life and well-being for residents. The preferred types of educational resources were a 
presentation related to key areas of concern identified in the consultations and a detailed 
resource manual to remain on the dementia unit. As well, nursing leaders and nursing 
staff indicated the importance of videos and case studies to apply new knowledge and to 
use problem-solving skills which would enhance retention of the new information. 
Impact of LBD Education on Care Delivery in LTC 
The nursing leaders and nursing staff agreed that the presentation and resource 
manual regarding LBD will increase the knowledge base of nursing staff and improve 
resident-centered care for LBD residents, resulting in enhanced well-being and quality of 
life. Nursing staff will be more attuned to identifying symptoms of LBD and use effective 
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interventions to manage disease symptoms. Better management of the symptoms will 
promote positive changes on the dementia unit for residents, families, and staff. 
Theoretical Framework 
After identifying the common themes in the literature review and the concerns 
identified by staff in the consultation process, it was determined that the principles of 
Knowle’s Adult Learning Theory would be incorporated into the development of the 
educational resources for nursing staff in LTC (Chesbro, 2002; Milligan, 1997; Mitchell 
& Courtney, 2005). The six principles of Knowle’s Adult Learning Theory include self-
concept, experience, readiness to learn, orientation to learning, motivation to learn, and 
relevance (Chesbro, 2002; Milligan, 1997; Mitchell & Courtney, 2005). Self-concept of 
the nursing staff was maintained as they were involved in the planning and evaluation of 
the presentation and resource manual. The educational resources build upon the 
knowledge and experience of the nursing staff regarding dementia care. The content of 
the educational resources was determined by the nursing staff and is pertinent to their 
work environment, therefore learning will occur. The new knowledge related to LBD will 
be readily applied with the use of case studies, interactive questions during the 
presentation, and pre-post tests as well as in clinical practice, upholding the principle of 
orientation to learning. Knowing there was a lack of educational resources regarding 
LBD and being self-aware of their learning needs will motivate the nurses to learn about 
LBD. The nursing staff are aware that with the increased aging population a diagnosis of 
LBD is more likely and there will inevitably be more residents with LBD on the unit. As 
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a result, being informed of LBD will enhance care delivery and better meet the needs of 
residents with LBD. 
In order to know if the manual has enhanced the knowledge of nursing staff 
regarding LBD, evaluation must occur. Kirkpatrick’s Four-Level Model of Evaluation 
will be used to evaluate the educational resources (Kirkpatrick, 1996; Kirkpatrick & 
Kirkpatrick, 2006; Smidt, Balandin, Sigafoos, & Reed, 2009). Level one is concerned 
with how participants felt about the learning experience. At the end of the presentation 
and resource manual, an evaluation survey will be completed by participants to determine 
satisfaction and to offer comments for improvements to the educational resources. Level 
two will assess if there is an increase in knowledge and/or skill among the nursing staff as 
a result of the LBD resource manual. A pre-test and post-test will be given to nursing 
staff to assess the extent of advancement in knowledge levels regarding LBD. Level 
three, behavior or transfer, assesses the ability of the nursing staff to apply what they 
have learned from the LBD educational resources. On a small scale, this will be assessed 
among nursing staff using case studies in both educational resources to enhance problem-
solving abilities that are relevant in the care of residents with LBD.  On a larger scale, 
informal discussions with the Resident Care Manager and nursing staff will determine a 
change in confidence and competency regarding the care and assessment of LBD 
residents. As well, a survey of nursing staff could be conducted to determine changes in 
confidence levels. Level four, results, looks beyond the educational resources on a larger 
scale to determine the effectiveness and impact of the program on the care of residents 
with LBD and staff performance. This will occur in an informal manner through a 
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discussion with the Resident Care Manager on the dementia unit to assess the outcomes 
of comparing quality of life indicators of residents with LBD before and a specified time 
period after the completion of the LBD training. As well, the Resident Care Manager can 
assess changes in  performance indicators for nursing staff  such as assessment skills of 
LBD residents, before and a specified time period after the training to note if there is 
improvement in staff performance regarding the care of residents with LBD and track 
quality of care indicators.  
Summary of Materials Developed 
LBD Presentation  
A 45 minute presentation was developed that will introduce the basic information 
related to LBD. It will be given to the Clinical Nurse Specialist to use in orientation 
training of new staff to LTC and continuing education for current staff (see Appendix C). 
The topics covered are: dementia information in general, LBD clinical presentations and 
categories, pharmacological and non-pharmacological management, importance of 
resident-centered care with LBD, topics to be addressed in the resource manual, and a 
LBD case study. A video is used to illustrate the life of an individual with LBD and links 
to other relevant LBD videos and relevant organizations are provided. The presentation is 
practical for nursing staff in that it is short in nature, visibly appealing with colored fonts, 
and images to keep them interested. As well, the slides are written in active voice, in 
short sentences, in bulleted format, and an easy reading level to promote understanding 
and enhance learning. 
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LBD Resource Manual 
The resource manual provides extensive detail regarding LBD and is readily 
available to nursing staff during work hours so they can set the learning pace (see 
Appendix D). The manual is practical in that it has a table of contents that can direct 
nursing staff to a particular topic and an overview that informs the nursing staff about the 
rationale of the manual and how it will help them in their nursing practice. As well, the 
manual contains color, graphics, ample white space, headings, and subheadings with 
short sentences in bulleted format to keep the reader focused and promote 
comprehension. The resource manual is composed of five chapters that cover the 
following topics: Chapter 1 – Dementia; Chapter 2 – Clinical Manifestations of Lewy 
Body Dementia, Alzheimer’s Disease and Parkinson’s Disease; Chapter 3 – 
Pharmacological Management of Lewy Body Dementia; Chapter 4 – Non-
pharmacological Management of Lewy Body Dementia; Chapter 5 – LBD Resources. 
There is also a pre-post test, two case studies, and an evaluation survey.  
Advanced Nursing Practice Competencies 
Advanced Nursing Practice refers to a higher level of nursing knowledge that is 
derived from graduate preparation, critical thinking, expert nursing knowledge, and 
expertise in meeting the health needs of others (CNA, 2008). Distinct to advanced 
nursing practice are core competencies which are based on nursing knowledge, theory, 
research, and clinical experience. The advanced nurse practice competencies include 
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clinical, research, leadership, and consultation/collaboration. Throughout the practicum I 
have demonstrated and become proficient in the following competencies: 
 Clinical Practice 
Through the process of critical appraisal, data gathering, analysis, and 
dissemination during the development of the LBD educational resources, I have a better 
understanding of this disease and strengthened my knowledge base. As a result, I can be a 
resource person and leader for nursing staff in LTC in accordance with my position as an 
Advanced Practice Nurse. Through interactions with various levels of healthcare 
providers, I have developed resources that are based on evidence-based practices and 
research to promote holistic care for residents with LBD.  
Researcher 
During the literature review and consultation process, I interpreted research 
results and incorporated the findings into the LBD educational resources that will be used 
to assist in care delivery in LTC. The analysis and interpretation of the research findings 
used in the educational resources will increase the knowledge base of nursing staff and 
improve nursing care for residents with LBD in LTC. 
Leadership 
Both residents and the Eastern Health organization will benefit from my 
knowledge as an educational leader related to LBD. As a leader, I can enhance nursing 
staff knowledge to improve care delivery to LBD residents in LTC. The lack of 
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educational resources and policies in LBD care practice in rural Avalon LTC facilities 
drives the need for a leader in this area.  
Consultation/Collaboration 
I consulted with nursing staff, Resident Care Managers, the Clinical Nurse 
Specialist, and the Program Manager of rural Avalon Eastern Health, along with nursing 
leaders in other regional health authorities, both locally and provincially, to enhance 
current dementia care practices in LTC. I also consulted with professional associations, 
organizations, and other experts in the field of LBD provincially, nationally, and 
internationally. By doing this I am effectively enhancing nursing knowledge and 
benefiting my professional practice as a LBD resource person for nursing staff.  
Next Steps 
The next step is to implement the LBD educational resources on the dementia unit 
of Harbour Lodge Nursing Home.  The Clinical Nurse Specialist will use the presentation 
and resource manual as part of orientation for new nursing staff and continuing education 
for current staff in rural Avalon Eastern Health LTC sites and has taken the responsibility 
of updating the resource manual and presentation as necessary. Furthermore, the results 
of the evaluation process for both the presentation and resource manual will aid the 
revision process to ensure the LBD educational resources meet the needs of the nursing 
staff.  
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Conclusion 
LBD is likely to become a more common diagnosis in the future due to an aging 
population. As a result of the challenging symptoms and complex care needs of this 
diagnosis, admission to LTC sites is probable. Therefore, nursing staff in LTC need to be 
informed regarding LBD and effective care interventions. Review of the literature and the 
consultation process provided information to guide the development of the LBD 
educational resources for nursing staff in LTC to improve nursing care and enhance 
quality of life for residents with LBD. The LBD educational resources were developed in 
accordance with Knowle’s Adult Learning Theory to meet the needs of the nursing staff. 
Evaluation using Kirkpatrick’s Four-Level Model of Evaluation will be ongoing and will 
allow for revisions in both the presentation and resource manual to determine their 
impact on nursing care for residents with LBD in LTC. These LBD educational resources 
will improve resident-centered care for individuals with LBD in LTC as well as improve 
quality of life and well-being.  
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Abstract 
Lewy body dementia is a growing concern in the aging population. The literature 
indicates that there is a lack of knowledge among health care professionals about this 
type of dementia, which greatly impacts quality of life for individuals diagnosed. This is 
further complicated by an overlap of symptoms between Lewy body dementia, 
Alzheimer’s disease, and Parkinson’s disease which increases the difficulty for nursing 
staff differentiating one disease from the other. No literature specifically exists related to 
nursing knowledge of Lewy body dementia in long-term care or the quality of care for 
individuals with Lewy body dementia in this setting. Therefore, it is reasonable to assume 
that nursing staff in LTC settings have limited knowledge related to Lewy body 
dementia. The literature indicates that a diagnosis of Lewy body dementia is challenging, 
quality of life is more significantly impacted in Lewy body dementia and management of 
the disease is different than with other types of dementia. Therefore, an educational 
resource manual related to Lewy body dementia is a beneficial resource that can be 
utilized by nursing staff in long-term care to promote resident-centered care and quality 
of life for individuals diagnosed with this disease. The resource manual will be designed 
using Knowles' Adult Learning Theory and will aim to enhance care to individuals 
diagnosed with Lewy body dementia in long-term care settings. Furthermore, the 
resource manual will contain information related to evidence-based practices that were 
revealed through the literature review and consultation process. 
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 Rates of Lewy body dementia (LBD) are rising because of an aging population 
(Lewy Body Dementia Association [LBDA], 2016a). Nursing staff are encountering 
more patients diagnosed with LBD in long-term care (LTC) facilities as a result. 
Informational resources are lacking in LTC facilities related to LBD, hence relevant 
education is needed to enhance nursing care for individuals diagnosed with this disease 
(S. Hawco, personal communication, September 15, 2015). Evidence-based practices 
related to LBD in LTC will improve care delivery to individuals with this diagnosis. 
Continued nursing education related to LBD is needed for nursing staff to develop 
therapeutic nursing interventions that better meet the needs of residents with LBD in 
LTC. 
LBD is an umbrella term for two related diagnoses: dementia with Lewy bodies 
(DLB) and Parkinson’s disease dementia (PDD) (LBDA, 2016b). Dementia is the main 
feature in each diagnosis and the time frame of the dementia will determine the exact 
type (LBDA, 2016b). Individuals can have three clinical presentations (LBDA, 2016b): 
1) a diagnosis of Parkinson’s disease is given when a person has symptoms of a 
movement disorder. If dementia develops a year or more later, then the person is 
diagnosed with PDD; 2) A diagnosis of DLB is given when a person has symptoms of a 
cognitive disorder before or within one year of Parkinson’s symptoms; 3) A diagnosis of 
DLB is also given when a person presents with neuropsychiatric symptoms, such as 
hallucinations, behavioral problems, and issues with complex activities (LBDA, 2016b). 
Initially, the three clinical presentations have different symptoms, but eventually affected 
persons will develop similar cognitive, physical, sleep and behavioral problems (LBDA, 
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2016b). LBD is a challenging and complex multisystem disease to manage effectively 
(LBDA, 2016c). 
Individuals with LBD require LTC services earlier, have increased mortality, and 
die earlier in comparison to other types of dementia (Khotianov, Singh, & Singh, 2002; 
Zupancic, Mahajan, & Handa, 2011; Zweig & Galvin, 2014). It is believed the greatest 
risk factor for LBD is advanced age, but contradictory evidence exists that risk may or 
may not increase with a family history of the disease (LBDA, 2015a; Neef & Walling, 
2006; Walter, Edwards, Griggs, & Yehle, 2014).  
Appropriate staff training is needed so that nursing staff will be able to more 
effectively differentiate between LBD, Alzheimer’s disease (AD), and Parkinson’s 
disease (PD) which will lead to improved caregiving practices. Evidently, LBD education 
should be a priority to increase understanding of the disease process and care guidelines 
for nursing staff and, as a result, improve quality of life for individuals diagnosed with 
LBD in LTC.  
Epidemiological Information 
 There are several types of dementia, but AD and LBD are two of the most 
common. AD occurs in 10 per 100 people commonly over 65-69yers old and accounts for 
60-80% of dementia cases worldwide (Alzheimer Association, 2016a; Walter et al., 
2014). LBD occurs in 7 out of 1000 people over 75 years of age and older and accounts 
for 15-20% of dementia cases worldwide (LBDA, 2016a; Walter et al., 2014). 
Parkinson’s disease occurs in 8 per 1000 people over 80 years of age and 50-80% of 
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people with this disease will develop Parkinson’s disease dementia (PDD) (Alzheimer 
Association, 2016b; Walter et al., 2014). Globally, the total healthcare costs of dementia 
amount to 1% of the gross domestic product (Alzheimer Society of Canada, 2015a). 
The World Health Organization estimates there were 35.6 million cases of 
dementia worldwide in 2010 and this number is expected to double by 2030 and triple by 
2050 (Public Health Agency of Canada PHAC, 2014c; Walter et al., 2014).  In Canada, 
LBD accounts for 5 – 15% of dementia diagnoses while AD accounts for 64% 
(Alzheimer Society of Canada, 2015b; Alzheimer Society of Canada, 2015c). Therefore, 
AD is the most common form of dementia in Canada and LBD ranks third (Alzheimer 
Society of Canada, 2015b; Alzheimer Society of Canada, 2016c).  It was estimated that 
the number of Canadians over 65 years of age experiencing various types of dementia 
will double from 310, 000 in 2011 to 639, 700 by 2031 (PHAC, 2014b; PHAC, 2014c). 
In this same time, the number of new cases for all types of dementia in Canada will 
increase by 90% (360 to 530 cases per 100, 000 population) (PHAC, 2014b). This 
increase in prevalence and incidence rates will result in a large percentage of the senior 
population living with dementia. Furthermore, in 2011 men were diagnosed at an earlier 
age with LBD and have an earlier onset of symptoms than women (PHAC, 2014b). On 
average, men are diagnosed with LBD at 72.2 years of age and women at 73.6 years of 
age (PHAC, 2014b). However, it is possible for LBD to occur as early as 50 years of age 
but it is most common after 60 years of age (Lewy Body Dementia Society, 2015; Walter 
et al., 2014). For both sexes there is a two year lag between onset of symptoms and a 
confirmed diagnosis of LBD (PHAC, 2014b). Generally, individuals with LBD will die 
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5-7 years after diagnosis (LBDA, 2015a). In 2011 approximately 11% of deaths in the 
general population occurred because of dementia-related complications (Statistics 
Canada, 2014).  
As is evident, the number of Canadians affected by dementia is vast and incidence 
will increase as the population advances in age. In 2011, 3-5% of the population in LTC 
facilities had a dementia diagnosis (PHAC, 2014b). There were no statistics for 
prevalence of LBD in LTC noted in the literature. The complex care needs that coincide 
with a dementia diagnosis are best managed in LTC facilities; therefore as the aging 
population increases, these facilities will experience great demands in the future (PHAC, 
2014c).  
Diagnostic Tools for LBD 
There are two diagnostic tools used to diagnose LBD, the Diagnostic and Statistic 
Manual of Mental Health Disorders, Fifth Edition (DSM-5) and the Consortium on 
Dementia with Lewy Bodies Consensus Guidelines (McKeith et al., 2005; Walter et al., 
2014).  
The Consortium on Dementia Consensus Guidelines specifies four categories of 
symptoms (LBDA, 2016b; McKeith et al., 2005). The first category, central feature, is 
dementia with problems noted in planning, judgment, processing and understanding 
information. At this early stage of LBD, memory impairment is usually not present. The 
second category, core (hallmark) symptoms includes fluctuating cognition with variations 
in attention and alertness and short-term memory is intact. Also there are recurrent, vivid 
 40 
 
visual hallucinations that are well-formed and detailed along with spontaneous features of 
Parkinsonism such as tremors, stiffness, slowness, and difficulty walking. The third 
category, suggestive features includes rapid eye movement (REM) sleep behavior 
disorder that involves talking and acting out dreams while asleep, severe sensitivity to 
neuroleptics, low levels of dopamine reuptake on brain imaging that can cause 
depression, apathy, anxiety, and agitation. The final category, supportive features 
includes repeated falls and fainting, short-term unexplained loss of consciousness, 
autonomic dysfunction such as blood pressure control, temperature regulation, and bowel 
and bladder control; auditory and tactile hallucinations; problems processing and 
interpreting visual information such as the ability to orient oneself in the environment, 
and other psychiatric disturbances such as delusions and paranoia. The Lewy Body 
Dementia Association follows these guidelines. 
The DSM-5 criteria, which is based on more recent research, incorporates the 
Consortium Guidelines into its diagnostic tool but identifies the similarities and 
differences between LBD, AD, and PD (Walter et al., 2014). The use of both diagnostic 
tools may well be contributing to the two year lag between onset of symptoms and 
diagnosis (PHAC, 2014b).  
Both diagnostic tools are being used in practice but the literature does not indicate 
which is more valid and reliable. The literature does indicate there is a lack of awareness 
among health care professionals of when exactly symptoms occur at each stage in LBD, 
AD, and PD (Auning et al., 2011; Ballard et al., 2001). However, the most recent 
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Consensus Guidelines have high specificity in identifying those who do not have LBD 
but it has low sensitivity in correctly detecting those who have LBD (McKeith, Perry, & 
Perry, 1999). This may lead to issues with misdiagnosis and underdiagnosis that are 
alluded to in the literature (Barber, Panikkar, & McKeith, 2001; McKeith, Perry, & Perry, 
1999; Oliveria, Sampaio, Chen, & McKeith, 2001). The aim of this integrated literature 
review is to explore and critically appraise the literature on LBD (see Tables 1-9 in 
Appendix 1). Specific objectives are to provide a synthesis of the literature and identify 
common themes in the literature. As well, the literature review will identify the gaps in 
knowledge among health care professionals related to LBD, and justify the need for a 
LBD resource manual as an educational tool for nursing staff to improve care delivery in 
LTC settings for individuals with LBD. 
Literature Review 
 An online search was conducted in the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), PubMed, Cochrane Library, and Google Scholar using the 
following search terms to identify articles relevant to the care of individuals with LBD: 
Lewy body dementia and non-pharmacological treatment, pharmacological treatment, 
signs and symptoms, quality of life, and nursing care. Key questions to guide the search 
were: What is LBD? How is quality of life impacted by LBD? What is the nursing role in 
providing care to individuals with LBD? What are the current treatment options for 
LBD? What are the knowledge gaps of nurses regarding LBD? A hand search of article 
reference lists was also conducted to retrieve additional information. Articles were not 
 42 
 
limited to a specific geographic location, clinical setting, or year of publication in an 
effort to maximize search results. The grey literature was also searched and had useful 
information related to LBD that better summarized evidence that was found to be 
contradictory in the research. 
 Nine relevant research articles were identified and were critically appraised 
according to the Public Health Agency of Canada [PHAC] Infection Prevention and 
Control Guidelines Critical Appraisal Toolkit (2014a). There is a lack of qualitative 
research regarding LBD, but numerous articles of a clinical nature exist to assist 
healthcare professionals in care delivery. There are two randomized control trial studies 
with small samples that evaluate the effectiveness of pharmacological therapy in 
managing LBD symptoms (Culo et al., 2010; Larsson et al., 2011). Culo et al., (2010) 
used the following instruments to assess neuropsychiatric symptoms: Neuropsychiatric 
Inventory (NPI) scale and the Empirical Behavioral Pathology in Alzheimer’s disease (E-
BEHAVE-AD) scale. As well, cognitive status was assessed using the Mini Mental 
Status Exam (MMSE). Larsson et al., (2011) utilized the Quality of Life Alzheimer 
Disease (QOL-AD) scale to assess quality of life during pharmacological management of 
LBD.  
Ballard et al., (2001) conducted a cohort study with a small sample that examined 
attention and fluctuating attention in LBD and AD. Auning et al., (2011) conducted a 
retrospective cohort study of small sample size that examined the early and presenting 
symptoms of LBD using the Neuropsychiatric Inventory (NPI) scale. 
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There are five cross-sectional American studies with moderately large samples 
that examined quality of life, functional impairments, and caregiver experiences related 
to LBD (Bostrom, Jonsson, Minthon, Londos, 2007; Galvin et al., 2010a; Galvin et al., 
2010b; Leggett, Zarit, Taylor, & Galvin, 2010; McKeith et al., 2006;).  Bostrom et al., 
(2007) examined quality of life in a small sample, using the EuroQol-5D (EQ-5D) 
instrument and Quality of Life- Alzheimer disease (QOL-AD) instrument as well as the 
Neuropsychiatric Inventory (NPI) scale to evaluate behavioral disturbance, the Mini 
Mental Status Exam (MMSE) to assess cognitive function, and the Disability Assessment 
for Dementia scale to assess dependency in instrumental activities of daily living (I-
ADL). McKeith et al., (2006) examined functional impairments in LBD and AD in a 
small sample. The following instruments were used: the Neuropsychiatric Inventory 
(NPI) scale to assess neuropsychiatric symptoms, the Bristol Activities of Daily Living 
Scale (BADLS) to assess functional impairment, the United Parkinson’s Disease Rating 
Scale part III motor examination (UPDRS-III) to assess extrapyramidal motor symptoms, 
and the Mini Mental Status Exam to assess global cognitive function. Galvin et al., 
(2010a), Galvin et al., (2010b) and Leggett et al., (2010) used the same survey with the 
same moderately large population to examine different aspects of caregiver experiences 
in LBD. The Zarit Burden Interview was used as a data collection instrument. These three 
cross-sectional studies also used the same sample of participants that completed one 
survey from which three publications arose, which is a major limitation. 
Different data collection instruments were used in all the studies to assess the 
impact of LBD on individuals, and this could be considered a limit of the research. 
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Several of the research studies demonstrated selection bias because they did not utilize 
randomization techniques (Auning et al., 2011; Ballard et al., 2001; Galvin et al., 2010a; 
Galvin et al., 2010b; Leggett et al., 2010; McKeith et al., 2006). The studies by Bostrom 
et al., (2007), Auning et al., (2011), Galvin et al., (2010a), Galvin et al., (2010b) and 
Leggett et al., (2010) also demonstrated recall bias because they relied on information 
sought from past experiences which may have led to inaccuracies and incomplete data 
collection.  
As is evident, there is a lack of strong research design and nursing research 
regarding LBD. Many of the articles addressed LBD in comparison to AD or PD. These 
articles are relevant as they portray the overlap of symptoms in dementia and what 
distinguishes LBD from other types of dementia. The predominant themes depicted in the 
research included the overlapping symptoms of LBD, AD, and PD, quality of life in 
LBD, managing symptoms of LBD, and the challenge of providing a differential 
diagnosis of LBD. 
Overlapping Symptoms of LBD, AD, and PD  
Two studies of moderate quality have confirmed that the common presenting 
symptoms of LBD are slowing of cognitive processing, fluctuating attention, and visual 
hallucinations (Auning et al., 2011; Ballard et al., 2001). As well, these studies concluded 
that the most common early symptom of AD is impaired memory. These results are 
consistent with the clinical article by Walker et al., (2014) that distinguishes the hallmark 
symptoms between LBD, AD, and PD. Ballard et al., (2001) strongly suggests that LBD 
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patients experience immense difficulty maintaining attention which severely impacts 
every day activities and quality of life. This study concluded that while LBD and AD 
may have similar clinical manifestations, the manifestations occur at different points 
along the disease trajectory. Deficits of cognitive reaction time, slowing of cognitive 
processing, and fluctuations of attention are significantly more pronounced in LBD than 
in AD. Attentional deficits that occur early in LBD do not occur until advanced stages of 
AD, therefore individuals with LBD experience a significant impact on quality of life 
early in the disease trajectory (see Table 3 in Appendix 1).  
 Caregivers play a central role in gathering information related to a diagnosis of 
LBD. Auning et al., (2011) questioned caregivers regarding early and presenting 
symptoms of LBD. This study agrees with the Consortium on Dementia with Lewy 
Bodies Consensus Guidelines and the DSM-5 criteria that visual hallucinations are a 
common early symptom of LBD and impaired memory is the common early symptom of 
AD. However, this study indicates that memory impairment is also a common presenting 
symptom of LBD which is in contrast to the Consensus Guidelines and the DSM-5 
criteria (McKeith et al., 2004; Walter et al., 2014).  All dementias have cognitive 
impairments but visual hallucinations and fluctuating attention in LBD cognitive states 
occur specifically in early stages of the disease, which is in contrast to other types of 
dementia (see Table 4 in Appendix 1).  
Lewy body dementia. 
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With LBD fluctuating cognition may cause the person to have a vacant stare, be 
extremely drowsy, and have disorganized thoughts but at other times to be alert, 
competent in activities of daily living and logical conversation (Auning et al., 2011; 
Ballard et al., 2001; Lewy Body Dementia Society, 2015; Walter et al., 2014). This is the 
complex symptom of LBD because short-term memory is still intact in the early stages 
and individuals are aware of their changes in cognition. The hallucinations that occur 
with LBD can be severely distressing for the person and can result in agitation and 
aggression (Lewy Body Dementia Society, 2015). The symptoms of fluctuating cognition 
and visual hallucinations do not often occur during examination by a physician which can 
make an accurate diagnosis difficult (Lewy Body Dementia Society, 2015) 
The motor symptoms that occur during LBD may be subtle at first but become 
more pronounced in later stages of the disease (Auning et al., 2011; Ballard et al., 2001; 
Lewy Body Dementia Society, 2015; Walter et al., 2014).  Individuals experiencing LBD 
may demonstrate many symptoms of Parkinson’s disease such as muscle rigidity or 
stiffness, shuffling gait, slow movement, freezing of movements, tremor of the hands 
even at rest, balance problems resulting in falls, issues with handwriting, difficulties with 
facial expressions and swallowing, and decreased strength of voice. These symptoms 
severely impact independence and quality of life early in the disease course of LBD 
(Bostrom et al., 2007; McKeith et al., 2006).   
Behavioral changes also occur in LBD. Individuals with LBD can experience 
apathy, anxiety and agitation (LBDA, 2016b; Lewy Body Dementia Society, 2015). 
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Anxiety and agitation can be a result of the confusion and visual hallucinations but can 
also be present in the absence of hallucinations. 
Sleep problems are also very common in individuals with LBD (LBDA, 2016b; 
Lewy Body Dementia Society, 2015). REM sleep behavior disorder involves acting out 
vivid dreams while asleep through talking and violent movements. Even though 
individuals with LBD may get sufficient sleep at night they often experience excessive 
day time sleepiness as well. Some individuals with LBD may experience insomnia where 
they cannot fall asleep or stay asleep at night. Restless leg syndrome may occur in people 
with LBD so that their legs are constantly twitching and moving in an attempt to decrease 
unusual sensations and discomfort in the legs. 
Involuntary activities are affected in individuals with LBD due to autonomic 
dysfunction (LBDA, 2016b;
 
Lewy Body Dementia Society, 2015). Variations may occur 
in the following areas: Body temperature, blood pressure, dizziness, fainting, sensitivity 
to temperature changes, falls, problems with sexual functioning, constipation, and 
changes to the sense of smell (LBDA, 2016b; Lewy Body Dementia Society, 2015).  
Alzheimer’s disease. 
The hallmark symptoms of AD are problems with short-term memory loss and 
early symptoms of recall, learning, and orientation deficits (Walter et al., 2014). AD 
progresses at a much slower rate than LBD (Alzheimer Society of Canada, 2015c). Early 
in the AD course the symptoms are similar to the late stages of LBD such as problems 
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with planning, problem-solving, and judgment along with disorientation to person, place, 
and time (Walter et al., 2014). As AD progresses, psychiatric symptoms such as 
hallucinations and delusions are common, along with problems with movement, speech, 
activities of daily living (ADL’s), and long-term memory(Walter et al., 2014). Once 
individuals with AD reach this point there is no intact memory (Dementia Care Central, 
2016).  
Parkinson’s disease.  
The symptoms of Parkinson’s disease are the result of Lewy bodies found in the 
midbrain and this disease is most common in individuals over the age of 70 years (Walter 
et al., 2014).
 
Most individuals with PD will progress to LBD (Alzheimer Association, 
2016b). The risk of males developing PD is 1.5 times greater than females (Walter et al., 
2014). The hallmark symptom of PD is tremors and the early symptoms of PD are 
movement problems such as stiffness, difficulty with balance, and coordination (Walter 
et al., 2014). As well, cognition, problem-solving, planning, and memory dysfunctions 
can also occur early in the disease (Walter et al., 2014). As the disease progresses, the 
motor symptoms become severe resulting in safety issues for those diagnosed such as 
swallowing, bathing, and falls. 
    Because similar symptoms occur in LBD, AD, and PD there is often misdiagnosis 
or underdiagnosis of LBD (Barber et al., 2001; McKeith et al., 1999; Oliveria et al., 
2015). As a result, information related to distinguishing clinical manifestations is needed 
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to increase nursing staff awareness of LBD and to improve resident-centered care and 
quality of life in LTC settings. 
 Qualify of Life and LBD 
 Two studies of low and moderate quality respectively, indicate that individuals 
with LBD have more impaired quality of life and more severe functional impairments 
than AD (Bostrom et al., 2007; McKeith et al., 2006). Data demonstrates that 
neurological and psychiatric symptoms, and functional impairments related to daily 
living, were more severe in LBD than AD (see Tables 5, 6 in Appendix 1). McKeith et 
al., (2006) attributes higher levels of dependency for individuals in early LBD to 
extrapyramidal symptoms such as bradykinesia, tremors, and gait disturbances. These 
symptoms have a major impact on activities of daily living, such as basic care needs and 
mobility. It is evident from the research that LBD and AD affect individuals differently 
and care needs are quite different as well (McKeith et al., 2006). Regardless of whether 
quality of life was assessed directly from individuals with LBD or their caregivers, 
evidence indicates that quality of life is significantly lower in those with LBD compared 
to AD (Bostrom et al., 2007).  Lowered quality of life is associated with increased use of 
healthcare services by individuals with LBD and their families (Bostrom et al., 2007). 
The more severe clinical manifestations of LBD require prompt, resident-centered care 
that promotes optimal outcomes (Bostrom et al., 2007). Prompt and effective 
management of LBD symptoms will preserve quality of life for both residents and 
families (Bostrom et al., 2007). 
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 It must be noted that the studies by Bostrom et al., (2007) and McKeith et al., 
(2006) are limited by the use of self-reported and proxy-reported data collection 
instruments which may contribute to recall bias. Accordingly, the results should be used 
cautiously but support the need for more research related to LBD. 
Managing LBD Symptoms 
There was limited information regarding the use of non-pharmacologlical 
approaches to manage LBD specifically, but research did indicate approaches are similar 
to those used with other types of dementia such as, behavioral and communication 
strategies, reminiscence, doll therapy, aromatherapy, and music therapy (Neef & Walling, 
2006; McKeith, 2004; McKeith et al., 2005; Yuhas, McGowan, Fontaine, Czech & 
Gambrell-Jones, 2006; Zupancic et al., 2011). As well, studies analyzing quality of life 
and pharmacological interventions in LBD are limited.  
Pharmacological management targets the loss of the neurotransmitters 
acetylcholine and dopamine as the disease progresses (LBDA, 2016c; Lewy Body 
Dementia Society, 2015; Walter et al., 2014). Pharmacological treatment is different 
depending on what symptoms present first. Cognitive symptoms are initially treated with 
cholinesterase inhibitors, motor symptoms are initially treated with levodopa-carbidopa 
and neuropsychiatric symptoms are initially treated with atypical antipsychotics (LBDA, 
2016c). The medications can improve some symptoms but worsen others so caution 
should be exercised and residents monitored closely for adverse reactions during the 
medication regimen. 
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 The greatest concern with pharmacological management is proper treatment of 
symptoms and control of side effects (Culo et al., 2010; Larsson et al., 2011). There are 
limited pharmacological options for those diagnosed with LBD due to lack of approved 
medications to treat the disease (Larsson et al., 2011). As a result, medications are 
generally used off label in the treatment of LBD (LBDA, 2016c). Research indicates the 
recommended medications for management of LBD are cholinesterase inhibitors, N-
Methyl-D-receptor antagonists (NMDA), levodopa-carbidopa, benzodiazepines, and 
atypical antipsychotics (Culo et al., 2010; Larsson et al., 2011; LBDA, 2016c). 
In LBD cognitive symptoms are more severe earlier in the disease when compared 
to AD, therefore proper management is crucial to improve quality of life (Culo et al., 
2010) (see Table 1 in Appendix 1). Cholinesterase inhibitors, such as Aricept (donepezil 
HCl) are the recommended first course of treatment for mild to moderate LBD (LBDA, 
2016c; Lewy Body Dementia Society, 2015).
 
These medications help decrease problems 
with memory, thinking, and alertness (LBDA, 2016c; Lewy Body Dementia Society, 
2015). Cholinesterase inhibitors are long-term drugs so it may take time to see 
improvements in symptoms. These medications are safe and tolerated well in individuals 
with LBD (LBDA, 2016c; Lewy Body Dementia Society, 2015). Cholinesterase 
inhibitors should be discontinued if cognitive improvement is not possible due to 
progressing severity of dementia or if side effects are intolerable. 
A more recent pharmacological intervention for LBD is the use of N-methyl-D-
receptor antagonists that is commonly used in AD and PD (Larsson et al., 2011; 
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Shagham, 2009). NMDA for example, Ebixa (Memantine HCl), is used in moderate to 
severe stages of dementia (Shagham, 2009). These medications can be used when 
cholinesterase inhibitors are ineffective or the person has a sensitivity to them (LBDA, 
2016c). NMDA medications may slow the loss of learning and memory skills such as 
toileting and dressing, improving overall quality of life and functional capacity of 
individuals with LBD (Larsson et al., 2011; Shagham, 2009). Discontinue when there is 
no longer any potential to preserve cognitive functioning or side effects become 
intolerable (see Table 2 in Appendix 2). 
Levodpa-carbidopa, such as Sinemet
 
is
 
a combination medication that is 
commonly used with LBD (LBDA, 2016c; Lewy Body Dementia Society, 2015).  The 
carbidopa increases the uptake of levodopa to improve motor symptoms such as restless 
leg syndrome, rigidity, and tremors (Lewy Body Dementia Society, 2015). Carbidopa 
controls Parkinsonism with lower doses of levodopa.
 
The low doses of levodopa 
decreases the incidence of nausea and vomiting experienced with levodopa alone, allows 
for more rapid titration and a better response to levodopa.
 
This medication is the initial 
treatment protocol for PD and is beneficial for management of Parkinson symptoms in 
LBD (LBDA, 2016c; Lewy Body Dementia Society, 2015). Medications containing 
levodopa can cause increased hallucinations so they may not be recommended if motor 
symptoms are mild (LBDA, 2016c). Levodopa-carbidopa
 
should be started at the lowest 
dose and titrated slowly to allow for close monitoring of adverse effects (LBDA, 2016c; 
Lewy Body Dementia Society, 2015). Dosing should be kept at the lowest effective level 
to control symptoms and adverse effects (LBDA, 2016c; Lewy Body Dementia Society, 
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2015). Dosage depends on whether the person is presently taking levodopa. The dosage 
of levodopa should be decreased if involuntary movements occur, as this should be 
regarded as a sign of levodopa toxicity and an indicator of overdosing.
 
Discontinue if 
Parkinson symptoms are not controlled and/or neuropsychiatric symptoms and confusion 
worsen. 
Benzodiazepines for example, Clonazepam (Klonopin)
 
are
 
used to treat REM 
sleep disorder and restless leg syndrome (Vallerand & Sanoski, 2015). The individual 
may have paradoxical episodes of sedation and agitation that may result in 
discontinuation (LBDA, 2016c). Discontinue if there is worsening of cognitive 
symptoms, anxiety, paradoxical agitation and sedation, falls, and impulsive behavior. 
Typical antipsychotics are often used to manage the behavioral and psychological 
features demonstrated in other types of dementia, but with LBD these medications are 
never used because they produce severe and fatal side effects known as neuroleptic 
sensitivity and neuroleptic malignant syndrome (Culo et al., 2010; LBDA, 2016c; 
McKeith et al., 2005; Walter et al., 2014). Neuroleptic sensitivity results in worsening of 
cognitive symptoms, hallucinations, and Parkinsonism and occurs in up to 50% of LBD 
patients treated with atypical antipsychotics (LBDA, 2016c). Neuroleptic malignant 
syndrome is a rare life-threatening adverse effect that produces symptoms of fever, 
generalized rigidity, and breakdown of muscle tissue that can result in kidney failure and 
death (LBDA, 2016c). 
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Atypical antipsychotics can be used to treat hallucinations and/or delusions that 
occur in LBD (Culo et al., 2010; LBDA, 2016c; Lewy Body Dementia Society, 2015).
 
Extreme caution and close monitoring is required when atypical antipsychotics are 
prescribed because neuroleptic sensitivity and neuroleptic malignant syndrome are 
possible (LBDA, 2016c; Lewy Body Dementia Society, 2015). The recommended 
atypical antipsychotics to be prescribed are Quetiapine and Clozapine in this order 
(LBDA, 2016c; Lewy Body Dementia Society, 2015; McKeith et al., 2005; Walter et al., 
2014).With quetiapine, changes can occur to blood glucose, therefore regular blood sugar 
checks should be ordered to monitor sugar levels. With clozapine blood monitoring for 
agranulocytosis is required. Atypical antipsychotics are discontinued if there is worsening 
of Parkinson and cognitive symptoms and increased sedation is noted. These medications 
are only used if long-term cholinesterase inhibitors have been ineffective or better 
behavioral control is warranted (LBDA, 2016c; Lewy Body Dementia Society, 2015; 
McKeith et al., 2005; Walter et al., 2014).  When atypical antipsychotics are prescribed, 
the lowest dose should be used for the shortest amount of time (LBDA, 2016c; Lewy 
Body Dementia Society, 2015; McKeith et al., 2005; Walter et al., 2014). Atypical 
antipsychotics are safer than typical antipsychotics, but there is no antipsychotic 
medication that is absolutely safe for the management of LBD behavioral symptoms 
since all antipsychotics increase the chance of death in people with dementia (LBDA, 
2016c; Lewy Body Dementia Society, 2015). 
Certain medications should also be avoided in the management of LBD. If 
cholinesterase inhibitors are effective, atypical antipsychotics are not prescribed because 
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they have serious side effects including death (LBDA, 2016c).  Atypical antipsychotics 
Risperidone and Olanzapine, should be avoided as they have an increased likelihood of 
increasing side effects such as increased Parkinson symptoms, sedation, and orthostatic 
hypotension (LBDA, 2016c). As well, the following medications used with Parkinson’s 
disease should be avoided: Amantadine, Catechol-O-methyltransferase (COMT) 
inhibitors (ex: Entacapone), Monoamine oxidase (MAO) inhibitors (ex: Selegiline), and 
anticholinergics (ex: Benztropine) because they worsen cognitive impairment. Dopamine 
agonists such as Pramipexole and Bromocriptine should also be avoided because they 
cause excessive daytime sleepiness and swelling of the legs (LBDA, 2016c). It is  
important to also avoid over-the-counter sleep agents such as Tylenol or Advil PM and 
bladder control medications may cause agitation (LBDA, 2016c). 
 It is evident that LBD symptom management requires a complex and different 
pharmacological approach than with other dementias to effectively manage the symptoms 
of the disease and improve quality of life.  
 The studies by Culo et al., (2010) and Larsson et al., (2011) have strong 
randomized control design and quality which is not a common finding in LBD research. 
Even though sample sizes are small, the results are beneficial because they confirm that 
not all types of dementia can be pharmacologically managed the same. Pharmacological 
treatments used in AD have the potential to cause neuroleptic sensitivity in LBD resulting 
in worsening of disease symptoms.   
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The lack of evidence regarding pharmacological and non-pharmacological 
management of LBD is problematic as this can lead to problems with care delivery and 
quality of life. Specific education concerning pharmacological and non-pharmacological 
management of LBD symptoms is of utmost importance to ensure that interventions do 
not negatively impact quality of life.  
The Challenge of Providing a Differential Diagnosis of LBD  
A lack of awareness among health care professionals regarding LBD is a common 
theme in the research (Galvin et al., 2010a; Galvin et al., 2010b; Leggett et al., 2010). 
Families have described the challenge of getting a diagnosis of LBD for a loved one 
(Galvin et al., 2010a; Galvin et al., 2010b; Leggett et al., 2010). Therefore, it is 
reasonable to assume that the difficulty of getting a diagnosis is indicative of a lack of 
awareness regarding LBD among health care professionals. The research consistently 
demonstrated that there was a two year lag between onset of symptoms and a LBD 
diagnosis which could have been the result of physicians lacking clinical familiarity with 
LBD diagnostic criteria (Galvin et al., 2010b; Leggett et al., 2010).  There is no 
information in the literature related to nurses’ knowledge of LBD; however, information 
does exist regarding nurses’ knowledge and general dementia care (Broughton et al., 
2011; Crater & Hughes, 2012; Furaker & Nilsson, 2009; Page & Hope, 2013; Robinson 
et al., 2014). Furthermore, based on an analysis of the literature there is no research to 
demonstrate quality care of LBD residents in LTC facilities. 
 57 
 
The overlapping symptoms between LBD, AD, and PD complicate the diagnosis 
and care delivery process. There is little research regarding when the symptoms of LBD 
and AD specifically occur in the disease trajectory, consensus on diagnostic criteria for 
LBD, and healthcare provider knowledge of the disease. Health care professionals have 
trouble diagnosing LBD, and nursing care provided to these individuals in LTC is 
compromised by lack of awareness among nursing staff related to LBD. 
Walter et al., (2014) identifies the common characteristics between LBD, AD, and 
PD according to the DSM-5. LBD occurs more commonly in men over 60 years of age 
with no family history of the disease. The issue of family history is contradicted in the 
research (LBDA, 2015a). The hallmark symptom of LBD is fluctuating cognition, 
specifically attention and alertness, along with early stage symptoms of recurrent and 
vivid visual hallucinations, and Parkinsonism within one year of diagnosis.  In contrast, 
AD occurs equally in men and women over 60 years of age and is more likely with a 
family history of the disease. AD does not have fluctuating cognition; the hallmark 
symptom is short-term memory loss and early stage symptoms consist of recall and 
learning deficits and recent orientation deficits. Furthermore, the hallmark symptom of 
PD is tremors and early symptoms consist of motor dysfunction, visual hallucinations, 
and executive dysfunction.  In late stages of LBD, AD, and PD the following symptoms 
are common: agitation, aggression, memory loss, apraxia, dependency for ADLs, and 
executive and visuospatial deficits.  
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Pathologically, LBD and PD are characterized by Lewy body protein deposits in 
various areas of the brain and a lack of acetylcholine and dopamine neurotransmitters. In 
LBD, the sequence of changes in neurotransmitters determines the type: DLB or PDD 
(LBDA, 2016b). In DLB, the neurotransmitter acetylcholine is decreased first which 
produces the fluctuations in alertness and confusion (Walter et al., 2014). This is 
followed by a decrease in dopamine, which produces the Parkinsonian symptoms (Walter 
et al., 2014). In PDD, the neurotransmitter dopamine is affected first which produces the 
movement symptoms. This is followed by a decrease in acetylcholine, resulting in 
cognitive changes (Walter et al., 2014). Pathologically, in AD neuronal plaques and 
neurofibrillary tangles occur throughout the brain with deficits of the neurotransmitter 
acetylcholine (Alzheimer Society of Canada, 2015c). 
It must be noted that the studies by Galvin et al., (2010a), Galvin et al., (2010b) 
and Leggett et al., (2010) were of  weak design but moderate quality and were all based 
on a national internet survey from the Lewy Body Dementia Association. Each study 
used the results of a survey with the same population to examine different aspects of the 
caregiver experience, which is a major limitation. The respective studies had large sample 
sizes, but self-reported data collection instruments were also a limitation of the studies. 
However, these studies exhibit relevant findings regarding the lack of awareness in health 
care professionals related to LBD and highlight the need for additional informational 
resources on the disease (Galvin et al., 2010a; Galvin et al,. 2010b; Leggett et al., 2010).  
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Understanding the experiences of families as they progress along the LBD 
continuum could be an important influence directing education needs and resources for 
healthcare professionals (see Tables 7, 8, 9 in Appendix 1). The studies by Galvin et al., 
(2010a); Galvin et al., (2010b), and Leggett et al., (2010) further explained that the lack 
of communication and resources surrounding LBD is also a challenge for families.  
Increasing awareness will lead to early diagnosis of LBD and appropriate management of 
the disease and better care when placed in LTC facilities. As well, increased awareness 
among nursing staff in LTC will provide more support to caregivers of individuals with 
LBD. Receiving adequate support from health care professionals will help to enhance 
quality of life for individuals with LBD. LBD is beginning to be recognized as a separate 
entity from other types of dementia especially AD, therefore it is essential to increase 
awareness of nurses in LTC to ensure adequate and efficient management of the disease 
(Galvin et al., 2010b; Leggett et al., 2010).  
A LBD resource manual addressing specific clinical manifestations, non-
pharmacological and pharmacological treatment options, as well as other relevant 
evidence-based information has the potential to improve resident-centered care and 
quality of life for individuals with LBD. The manual will increase awareness of LBD 
among nursing staff in LTC facilities so that care needs will be holistic, individualized, 
and based on evidence-based practices.  
Theoretical Framework 
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 The LBD resource manual for nursing staff in LTC will be developed in 
accordance with Knowles’ Adult Learning Theory so that learning is self-directed, 
practical, and relevant (Chesbro, 2002; Milligan, 1997; Mitchell & Courtney, 2005). 
Eastern Health defines nursing staff as Registered Nurses, Licensed Practical Nurses, and 
Personal Care Attendants. The resource manual will be developed through an interactive 
consultation process with nursing staff and management at rural Avalon Eastern Health. 
The newly acquired knowledge from the manual will increase nursing staff knowledge 
related to LBD care. As adult learning is the primary focus of the resource manual, the 
Adult Learning Theory is the most appropriate to use to guide the development of the 
manual and to promote knowledge enhancement.  
 The six basic principles of Adult Learning Theory will be adhered to in the 
development of the manual (Chesbro, 2002; Milligan, 1997; Mitchell & Courtney, 2005). 
The six principles include self-concept, experience, readiness to learn, orientation to 
learning, motivation to learn, and relevance. The first principle, self-concept, requires the 
learner to be involved in the planning and evaluation of the resource manual so that 
learning is self-directed. The second principle, experience, indicates that life experiences 
provide a basis for adult learning. The third principle, readiness to learn, indicates that 
learning is more likely to occur if the content is relevant and realistic to job performance 
and constructed so that it coincides with the learners’ readiness to progress. The fourth 
principle, orientation to learning, specifies that immediate application of new knowledge 
and problem-solving are central to learning. The fifth principle, motivation to learn, 
assumes that internal factors promote learning for adults. The sixth principle, relevance, 
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specifies that adults need to know why they need to learn something new. Consultation 
and collaboration with nursing staff and management using a pre-survey to discover what 
the staff know, what they need to know, and how they want the information presented, 
and explaining to nursing staff the importance of this information to dementia care 
practice, along with a post-evaluation of the material presented in the manual will address 
the following principles of Adult Learning Theory: self-concept, readiness to learn, 
motivation to learn, and relevance. The Adult Learning Theory principles of experience 
and orientation to learning will be addressed through the use of case studies and pre- and 
post-tests which will build upon staff experiences and knowledge base through active 
learning and problem solving.  
Benefits of a Resource Manual 
 A resource manual is a form of self-directed learning that correlates to the 
principles of Adult Learning Theory.  Carcich and Rafti (2007) and Sparling (2001) are 
in agreement that there are many advantages of a resource manual. As nurses are 
expected to be committed to life-long learning, a resource manual is a useful tool for 
continued competency (Carcich & Rafti, 2007; Sparling, 2001). The LBD resource 
manual will be easily accessible and can be reviewed at the convenience of the staff, 
thereby promoting flexibility and portability of the manual as a learning tool (Carcich & 
Rafti, 2007; Sparling, 2001). As well, the nursing staff will be assuming responsibility for 
their learning by using the resource manual when time permits and progressing through 
the contents of the manual at their own pace (Carcich & Rafti, 2007; Sparling, 2001). 
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Overall, the resource manual is less costly than other forms of educational delivery and 
can reach many members of nursing staff, thereby promoting high rates of participation 
in the learning process (Sparling, 2001). Likewise, the use of the resource manual is well 
supported by research and is the most common chosen method of continued education for 
nurses (Sparling, 2001). The LBD resource manual will be maintained and updated by 
the Clinical Nurse Specialist in rural Avalon Eastern Health as this is her specialty area 
and she is responsible for nursing staff education in LTC settings.  
 The LBD resource manual will be beneficial to Eastern Health because it will 
increase knowledge among nursing staff in LTC regarding LBD to improve care delivery. 
Improving knowledge of nursing staff related to LBD will reduce health care costs 
because nursing staff in LTC will be more informed therefore, immediate care needs of 
residents will be addressed and managed more effectively (PHAC, 2014b). As well, 
better resident-centered care will positively impact quality of life for residents, families, 
and nurses because the disease symptoms will be more effectively managed. 
Additionally, nursing staff can transfer their knowledge regarding LBD to other 
healthcare professionals and families to increase disease awareness (Galvin et al., 2010a; 
Galvin et al., 2010b; Leggett et al., 2010).  
Conclusion 
 The literature review reveals that LBD has a significant impact on quality of life, 
and there is a gap in disease-related knowledge in health care professionals. As evidenced 
in the literature, there is a lack of awareness concerning diagnosis and management of 
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LBD among health care professionals in general (Galvin et al., 2010a; Galvin et al., 
2010b; Leggett et al., 2010).  Furthermore, there is a lack of literature related to nursing 
knowledge of LBD in LTC specifically and the quality of care for these residents in LTC. 
The literature also demonstrates that there is an apparent overlap of symptoms between 
LBD, AD, and PD which may lead to misdiagnosis or underdiagnosis of LBD (Barber, 
Panikkar, & McKeith, 2001; McKeith, Perry, & Perry, 1999; Oliveria, Sampaio, Chen, & 
McKeith, 2001). Furthermore, it was acknowledged that the use of pharmacological 
options appropriate to AD has the potential to negatively impact quality of life in 
individuals with LBD (Culo et al., 2010; Larsson et al., 2011; McKeith, 2004). The 
literature strengthens the need for more educational resources for nursing staff related to 
LBD to lessen the knowledge gap regarding the disease in clinical practice in LTC. 
Developing a LBD resource manual for nursing staff in LTC based on evidence-based 
practices will be the first step toward improving resident-centered care for individuals 
with LBD. It is hoped that quality of care will be improved by addressing this lack of 
awareness in nursing staff. As a result, nursing staff will broaden their knowledge base 
and positively influence quality of life for individuals diagnosed with LBD in LTC. As 
the aging population is increasing and rates of LBD are expected to increase, it is 
imperative that nurses in LTC endeavor to incorporate evidence-based practices 
regarding LBD into care delivery. The LBD resource manual will be a fundamental tool 
in the care of individuals with LBD in LTC.  
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Table 1: Study Examining Neuropsychiatric Symptoms in DLB 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitation
s 
Conclusion and 
Rating 
 “Treating 
neuropsychiatr
ic symptoms 
in dementia 
with Lewy 
bodies” by 
Culo et al., 
(2010) 
 Objective: To 
investigate the 
tolerability 
and efficacy of 
citalopram and 
risperidone in 
the treatment 
of behavioral 
and psychotic 
symptoms in 
patients with 
DLB and AD. 
 n=31 DLB, n=66 
AD 
 Psychiatric 
Institute, PA, 
2000-2004 
 Inclusion 
criteria: 
dementia and 
moderate-severe 
behavioral/psycho
tic symptoms, 3 
or > on agitation 
or psychosis item 
Neurobehavioral 
Rating Scale 
 Exclusion: 
criteria: 
extensive 
exclusion criteria 
 Prospective, 
randomized 
double-blind, 
parallel 
treatment 
design 
 1 capsule 
bedtime x 3 
days, increased 
to 2 a day 
 After 2 wks, 2 
more increases 
up to 4 a day 
 Increases 
separated by 2 
wks. 
 Assessed at 
randomization, 
q2 wks and at 
termination. 
 NPI, E-
BEHAVE-AD, 
MMSE 
 
 
 DLB patients 
poorer 
outcome, 
67.7% DLB 
and 50% AD 
dropout rate 
due to 
intolerability   
 Dropout 
between groups 
or between 
DLB patients 
treated with 
citalopram or 
risperidone did 
not differ 
significantly. 
 DLB patients 
had minimal 
improvement or 
worsening. 
 Total side 
effect burden 
significantly 
higher in DLB  
Strengths: 
 Ethics approval 
 Informed consent 
 Stratified 
randomization of 
patients 
 Trained raters 
 Appropriate 
statistical tests for 
level of data 
 P= 0.05, two tailed 
 
Limitations: 
 Small sample size 
 Reliance on clinical 
diagnosis rather 
than autopsy 
confirmation of 
cases. 
 Loss to follow up 
 Conflicts of interest 
declared 
 
 Strong design 
 Strong quality 
 Extrapolation 
of evidence 
  Moderate 
generalizabilit
y 
 Patients with 
DLB and 
neuropsychiatr
ic disturbances 
show minimal 
benefit when 
treated with 
atypical 
antipsychotic 
or SSRI 
antidepressant. 
 Future studies 
should 
identify other 
treatments that 
are tolerable 
and 
efficacious. 
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Table 2: Study Examining Quality of Life and Memantine in DLB and PDD 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “Quality of 
life and the 
effect of 
memantine in 
dementia with 
Lewy bodies 
and 
Parkinson’s 
disease 
dementia” by 
Larsson et al., 
(2011) 
 Objective: To 
investigate 
QOL and the 
effect of 
memantine 
treatment in 
patients with 
LBDs. 
 n=36 placebo 
 n=35 
memantine 
 Sweden, 
Norway, UK, 
2005-2008 
 Random 
assignment to 
memantine and 
placebo 
 Assessed at 
baseline, 12 
wks and 24 
wks 
 QOL-AD given 
to patients and 
caregivers 
 Inclusion 
criteria: DLB 
or Parkinson’s 
diagnosis; 
MMSE score 
of 12 or > 
 Secondary 
analysis of 
randomized 
controlled, 
double blind, 
placebo 
controlled 
study design 
 Memantine 
5mg in 
morning then 
up to 20 mg by 
week 4.  
 Cholinesterase 
inhibitors, 
antiparkinsonia 
antidepressants, 
anxiolytics, 
antipsychotics 
meds were 
allowed to be 
taken by 
participants 
during study 
 Caregiver-rated 
QOL improved 
significantly 
when treated 
with memantine 
particularly 
aspects of body 
functions. 
 DLB and PDD 
might benefit 
globally from 
using 
Memantine. 
Strengths: 
 Ethical approval 
 Informed consent 
 Valid and reliable 
instruments 
 Appropriate 
statistical tests for 
level of data 
 P < 0.05, two tailed 
 First study of how 
pharmacological 
intervention may 
impact QOL in 
DLB and PDD 
Limitations: 
 Small sample  
 Reduced statistical 
power 
 Several patients 
lost to follow-up 
 Response shift 
phenomenon where 
QOL perception 
changes with health 
 Polypharmacy  
 Strong design 
 Moderate 
quality 
 Extrapolation of 
evidence 
 Moderate 
generalizability 
 No conflict of 
interest declared 
 Memantine can 
improve QOL 
for patients with 
DLB and PDD. 
 Future studies 
should have 
larger samples 
and additional 
instruments, and 
intervention 
studies using 
QOL as primary 
outcome 
measure 
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Table 3: Study Examining Attention and Fluctuating Attention in LBD and AD 
Name, 
Author, Date, 
Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristic) 
Design and 
Methodology 
Key Results/Findings Strengths/Limitations Conclusion and 
Rating 
 “Attention 
and 
fluctuating 
attention in 
patients 
with 
dementia 
with Lewy 
bodies and 
Alzheimer 
disease” by 
Ballard et 
al., (2001) 
 Objective: 
To 
investigate 
attention 
and 
fluctuating 
attention in 
DLB and 
AD 
patients. 
 n=85 DLB, 
n= 80 AD, 35 
spouse 
controls  
 dementia care 
registry, 
England 
 patients 
matched on 
MMSE 
scores 
 Inclusion 
criteria: 
LBD, AD  
 Cohort 
analytic 
design 
 Cognitive 
Drug 
Research 
Computerized 
Assessment 
System for 
Dementia 
Patients 
Computerized 
Neuropsychol
ogical Battery 
Informed 
consent 
 Ethics 
approval 
 Descriptive 
statistics  
 DLB significantly 
more cognitively 
impaired than AD 
on all tests  
 Neuropsychological 
and clinical 
observations 
strongly suggest 
DLB patients 
experience great 
difficulty in 
sustaining attention 
 Both groups 
significantly more 
impaired than 
controls for all 
comparisons other 
than cognitive 
reaction time 
  deficits of attention 
worsened with 
severe dementia for 
both groups 
Strengths: 
 Statistical tests 
appropriate for data 
collected 
 Significance P < 
.001 
 Use of control group 
 Groups well 
matched on severity 
of cognitive 
impairment  
 
Limitations:  
 More females in AD 
group 
 Small sample 
 No random 
sampling 
 Selection bias 
 
 Moderate design 
 Moderate quality 
 Moderate 
generalizability 
 Extrapolation of 
evidence 
 Findings indicate 
that the slowing 
of cognitive 
processing, 
attention and 
fluctuating 
attention are 
significantly 
more pronounced 
in DLB than AD 
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Table 4: Study Examining Early and Presenting Symptoms of Dementia with Lewy Bodies 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “Early and 
presenting 
symptoms of 
dementia with 
Lewy bodies” 
by Auning et 
al., (2011) 
 Objective: 
To explore 
the presenting 
and early and 
presenting 
symptoms of 
dementia with 
Lewy bodies 
(DLB). 
 n = 61 DLB 
 n = 109 AD 
  5 outpatient 
dementia 
clinics, 
Western 
Norway 
2005 – 2007 
 Inclusion 
criteria: DLB 
and AD , 
MMSE >20 
 Exclusion 
criteria: acute 
delirium or 
confusion, 
terminal 
illness, 
recently 
diagnosed 
major somatic 
illness, 
previous 
bipolar or 
psychotic 
disorder. 
 Retrospective 
cohort analytic 
design 
 NPI tool 
 Clinical 
Assessment of 
Cognitive 
Function or 
Mayo 
Fluctuation 
Scale assessed 
cognition 
 Standardized 
carer survey 
 Diagnosed by 
two clinicians  
 
 Memory 
impairment 
(57%), visual 
hallucinations 
(44%), 
depression 
(34%), and 
problem-
solving 
difficulties 
(33%) most 
common 
presenting DLB 
symptoms 
 Visual 
hallucinations 
(77%), 
parkinsonism 
(60%),delirium/ 
fluctuating 
cognition 
(43%), most 
common prior 
to first 
assessment 
 
Strengths:  
 Ethical approval 
 Informed consent 
 Validated 
instruments 
 Significance P < 
0.05 
 Statistical tests 
appropriate for level 
of data 
Limitations: 
 Recall bias 
 Selection bias 
 No random sampling  
 Sensitivity/specificit
y of identifying 
presenting 
symptoms  not 
assessed with a tool 
 No blinding or 
control 
 Small sample size 
 Moderate 
design 
 Medium quality 
 Moderate 
generalizability 
 Extrapolation 
of evidence 
 DLB should be 
suspected in 
pre-dementia 
cases with 
visual 
hallucinations 
 Future studies 
should include 
broader range 
of participants. 
 Authors noted 
funding for 
some aspects of 
study i.e. 
manuscript 
preparation and 
travel. 
 77 
 
Table 5: Study Examining Quality of Life and Determinants of Quality of Life 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “Patients with 
dementia with 
Lewy bodies 
have more 
impaired 
quality of life 
than patients 
with 
Alzheimer 
disease” by 
Bostrom et al., 
(2007). 
 Objective: To 
compare 
quality of life 
in patients 
with DLB and 
patients with 
AD; to 
investigate 
determinants 
of quality of 
life in DLB. 
 n = 34 DLB, n 
= 34 AD 
 participants 
were matched 
on sex, age and 
cognitive 
function 
 Patients 
selected from 6 
memory clinics 
in Sweden, 
Finland , 
Norway 
 Inclusion 
criteria:  
DLB, AD  
 
 Prospective 
cross-sectional 
descriptive 
design 
 QOL assessed 
EQ-5D 
instrument and 
QOL-AD 
 Administered 
to patients and 
caregivers 
 Examined at 
home/memory 
clinic with 
primary 
caregiver  
 MMSE for 
cognitive 
function 
 NPI for  
behavioral 
disturbances 
 DLB patients  
examined for 
ADL needs  
 Caregiver-
reported QOL 
significantly 
lower than 
patient-reported 
QOL. 
 DLB patients 
significantly 
lower QOL. 
 24% caregiver-
rated EQ-5D 
scores 
corresponded to 
below zero 
values, thus 
LBD state 
worse than 
death. 
 NPI score, I-
ADL, apathy, 
delusions, and 
living with 
caregiver were 
significant 
determinants of 
QOL in DLB. 
Strengths:  
 Validity and 
reliability of 
instruments 
reported. 
 P < 0.01 
 Same 
investigational 
protocol used with 
both groups 
 Appropriate 
statistical tests for 
level of data. 
 First study to 
describe QOL with 
DLB 
Limitations:  
 Recall bias 
 Selection bias 
 DLB and AD 
patients not selected 
from same 
population. 
 Small sample 
 
 Weak design 
 Low quality 
 Low 
generalizability 
 Extrapolation of 
evidence  
 Consequences 
of DLB and AD 
differ greatly. 
 DLB diagnosis 
predicts an 
almost 3-fold 
increase in 
resource use and 
significantly 
lower QOL than 
AD. 
 Future studies 
should examine  
caregiver QOL , 
use intervention 
studies of QOL 
outcome 
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Table 6: Study Examining Functional Impairments in LBD and AD 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “More severe 
functional 
impairment in 
dementia with 
Lewy bodies 
than Alzheimer 
disease Is 
related to 
extrapyramidal 
motor 
dysfunction” 
by McKeith et 
al., (2006) 
 Objective: To 
compare 
functional 
impairments in 
DLB and AD 
and their 
relationship 
with motor and 
neuropsychiatr
ic symptoms. 
 n = 41 DLB n 
= 43 AD 
 Recruited from 
old age and 
psychological 
units, England. 
 Inclusion 
criteria: DLB, 
AD  
 Cross-sectional 
descriptive 
design 
 NPI assessed 
neuropsychiatr
ic symptoms 
 BADLS 
assessed 
functional 
impairment 
(caregiver 
rated tool) 
 UPDRS-III 
assessed 
extrapyramidal 
motor 
symptoms 
 MMSE  
assessed global 
cognitive 
function 
 Greater overall 
functional 
impairment in 
patients with 
DLB 
 Total UPDRS 
III and total NPI 
scores 
significantly 
higher in DLB. 
 The highly 
significant 
correlation 
between total 
BADLS and 
total UPDRS III 
scores in DLB 
suggests that 
extrapyramidal 
motor 
dysfunction is a 
key factor  
Strengths:  
 P <0.01 
 Statistical tests 
appropriate for 
level of data 
 Informed consent 
 Study was funded 
 
 
Limitations: 
 Small sample 
 Little information 
on case selection 
and assessment as 
was previously 
described in another 
study. 
 No evidence of 
caregiver training to 
complete BADLS 
 Selection bias 
 No control 
 Weak design 
 Moderate 
quality 
 Moderate 
generalizability  
 Extrapolation of 
evidence 
 Extrapyramidal 
motor 
dysfunction may 
lead to greater 
functional 
impairment in 
DLB. 
 Treating 
extrapyramidal 
motor symptoms 
may help to 
improve patient 
function and 
caregiver well-
being. 
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Table 7: Study Examining Caregiver Burden and LBD 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitation Conclusion and 
Rating 
 “Lewy body 
dementia: 
caregiver 
burden and 
unmet needs” 
by Galvin et 
al., (2010a) 
 Objective: To 
ascertain the 
unmet needs 
of LBD 
caregivers and 
collect data to 
inform 
educational 
programming 
and enhance 
caregiver 
support. 
 Used data from 
LBDA 
generated 
survey  
 6 month 
period, Dec 
2007-Apr 2008 
 962 caregivers 
 83% of 
respondents 
completed 
entire survey 
 
 Cross-
sectional 
descriptive 
design 
 Internet-based 
survey 
 Zarit Burden 
Interview used 
to measure 
caregiver 
burden. 
 Asked to 
describe the 
first symptoms 
of LBD they 
noticed. 
 Early symptoms: 
cognitive (48%), 
motor (39%) or 
both (13%) 
 Initial symptoms: 
memory (67%), 
gait (47%), 
attention/alertness 
(43%), 
hallucinations 
(43%), driving 
(42%), 
tremor/abnormal 
movements (38%) 
or depression 
(37%) 
 Increased 
dependence of 
patients early in 
disease, high 
burden levels 
 Lacking support 
from family, 
friends, health 
care providers. 
Strengths:  
 Ethical approval 
 Met HIPAA 
requirements 
 Appropriate 
statistical tests 
used for level of 
data 
 Large sample size 
 High response 
rate 
Limitations: 
 88% of 
respondents 
female 
 Validity and 
reliability of 
instrument not 
discussed. 
 No P value stated 
 No comparison 
 Selection bias 
 Recall bias 
 Weak design 
 Moderate 
generalizability 
& quality 
 Extrapolation of 
evidence 
 Information and 
supports needed 
for  caregivers 
and healthcare 
professionals. 
 Significant 
unmet needs for 
patients/caregiv
ers 
 Improve 
education & 
social supports, 
so caregiver 
burden will 
decrease & 
outcomes 
improve for 
patients/caregiv
ers 
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Table 8: Study Examining Caregiver Experience When Seeking LBD Diagnosis. 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “Lewy body 
dementia: The 
caregiver 
experience of 
clinical care” 
by Galvin et 
al., (2015b) 
 Objective: To 
explore 
caregiver 
perceptions of 
the difficulty 
obtaining a 
diagnosis for 
the patient and 
their 
experience 
with health 
care providers. 
 Used data from 
LBDA 
generated 
survey  
 6 month period, 
Dec 2007- Apr 
2008 
 962 caregivers 
 83% of 
respondents 
completed 
entire survey 
 Volunteer 
survey  
 Posted for 6 
months online 
 Cross-sectional 
descriptive 
design 
 Internet-based 
survey 
 Zarit Burden 
Interview used 
to measure 
caregiver 
burden. 
 Analysis 
focused on 
experiences 
with obtaining 
a LBD 
diagnosis, 
experiences 
after diagnosis, 
and 
perceptions of 
physician 
knowledge. 
 
 Obtaining a 
LBD diagnosis 
often required 
multiple visits 
to multiple 
physicians 
causing delay in 
treatment 
 Over 40% 
reported it took 
more than 18 
mths to get 
LBD diagnosis. 
 Alternate 
diagnosis were 
given first in 
78% of cases 
 Reported 
physicians 
lacked 
knowledge on 
disease course, 
prognosis, and 
community 
resources. 
 
Strengths:  
 Ethical approval 
 Met HIPAA 
requirements 
 Appropriate 
statistical tests  for 
level of data 
 Large sample size 
 High response rate 
 
Limitations: 
 No validity and 
reliability of 
instruments  noted 
 No P value stated 
 No comparison 
group 
 No data on 
hours/wk of care 
giving  
 Selection/recall 
bias 
 88% respondents 
female 
 
 Weak design 
 Moderate 
quality 
 Moderate 
generalizability 
 Extrapolation of 
evidence 
 LBD less likely 
to be recognized 
in primary care 
settings, more 
commonly 
diagnosed AD. 
 Early diagnosis 
gives caregivers 
and families 
access to more 
therapeutic 
interventions, 
time to plan for 
patient decline 
and access 
resources. 
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Table 9: Study Examining Caregiver Stress and Burden. 
Name, Author, 
Date, Study 
Objective 
Sample/Groups 
(Size, Setting, 
Characteristics) 
Design and 
Methodology 
Key 
Results/Findings 
Strengths/Limitations Conclusion and 
Rating 
 “Stress and 
burden among 
caregivers of 
patients with 
Lewy body 
dementia” by 
Leggett et al., 
(2010) 
 Objective: To 
assess if 
disease and 
caregiving-
related issues 
in LBD add to 
explanations of 
subjective 
burden more  
than stressors 
in other types 
of dementia; 
assess 
structure/predic
tors of burden 
and if similar to 
other dementias 
 Used data from 
LBDA 
generated 
survey  
 6 month 
period, Dec 
2007- Apr 
2008 
 982 caregivers 
responded to 
survey but 611 
cases were 
eligible for this 
study 
 83% of 
respondents 
completed 
entire survey 
 Volunteer 
survey  
 Posted for 6 
months online 
 Cross-sectional 
descriptive 
design 
 Internet-based 
survey 
 Zarit Burden 
Interview used 
to measure 
caregiver 
burden. 
 Analysis of 
experiences of 
behavioral and 
emotional 
problems, 
ADLs and 
mobility, 
isolation, 
difficulty 
finding/evaluat
ing a 
physician, help 
received, and 
burden. 
 
 Higher scores 
for LBD  
subjective 
burden  
 Dimensions of 
burden: role 
strain, personal 
strain, worry of 
performance. 
 Burden related 
to poorer 
health, LBD 
caregivers need 
adequate help 
and services. 
 Predictors of 
burden: 
behavioral/ 
emotional 
problems ADL 
assistance, 
isolation due to 
lack of 
awareness in 
public and MD. 
Strengths:  
 Ethical approval 
 Met HIPAA 
requirements 
 Appropriate 
statistical tests for 
level of data 
 Large sample size 
 High response rate 
 Valid and reliable 
instruments  
 P < .001 
 
Limitations: 
 No comparison 
group 
 No data on 
hours/wk that 
caregivers provide 
care 
 Voluntary sample 
 Selection bias 
 Recall bias 
 88% respondents 
were female 
 Weak design 
 Moderate 
quality 
 Moderate 
generalizability 
 Extrapolation of 
evidence 
 Caregivers of 
LBD patients 
have significant 
burden 
increased by 
noted predictors 
of burden. 
 Future 
interventions 
should consider 
predictors.  
 Increased 
public 
awareness of 
LBD needed  
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Abstract 
Purpose: To determine the objectives and content that will be included in an educational 
resource regarding Lewy body dementia (LBD) to be used by nursing staff in long-term 
care (LTC) to enhance resident-centered care.  
Participants and Methods:  Purposive sampling was utilized to include nursing staff 
from Harbour Lodge Nursing Home in rural Avalon Eastern Health as well as nursing 
leaders in Ontario, Alberta, and Nova Scotia. These participants have been interviewed 
regarding LBD education at the LTC facilities where they are employed. These 
individuals are key informants because they have experience working with residents with 
LBD in LTC settings.  
Data Management and Analysis: The data obtained was coded into categories and 
comparisons made to create common themes. The data collected then created the 
foundation for this consultation report. 
Ethical Considerations: An information letter was sent to each participant outlining the 
purpose of the consultation and full disclosure of how the data collected would be utilized 
to develop the LBD educational resource. Verbal permission to participate was obtained 
and confidentiality was ensured. Ethical approval was not needed for these consultations. 
Findings: Nursing leaders and nursing staff indicate that there is a lack of awareness and 
a lack of educational resources regarding LBD in LTC settings. Nursing staff in LTC 
believe that current and relevant LBD educational resources based on evidence-based 
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practices will improve resident centered care and quality of life for residents with LBD in 
LTC. Through the consultation process it has been determined that the best type of 
educational resource to present the LBD information to nursing staff in LTC will be a 
brief presentation and a resource manual.  
Lewy body dementia (LBD) is ranked as the second most common type of 
dementia in Canada (Alzheimer Society of Canada, 2015a). As the population ages in 
Canada, it is estimated that those diagnosed with dementia over 65 years of age will 
double from 310,000 in 2011 to 639,000 by 2013 (Public Health Agency of Canada 
[PHAC], 2014a, p.66). It can be concluded that there will be a 90% increase in the 
number of new dementia cases in Canada (360 to 530 cases per 100,000; PHAC, 2014a, 
p.68). 
Living with LBD is challenging due to the early onset and rapid progression of 
symptoms, especially fluctuating cognition, hallucinations and aggression (McKeith et 
al., 2005; Walter, Edwards, Griggs, & Yehle, 2014). Diagnosis of LBD is challenged by 
the overlapping symptoms with other forms of dementia, especially AD and PD (Walter, 
Edwards, Griggs, & Yehle, 2014). Early admission to LTC often occurs in individuals 
with LBD because they become dependent at an early stage and the hallucinations and 
behavioral symptoms are better managed in this setting (PHAC, 2014b, p.8). Managing 
LBD is challenging because pharmacological interventions used with other types of 
dementia are often ineffective with LBD (Larsson et al., 2011). As well, there is limited 
literature available regarding non-pharmacological interventions to manage LBD. 
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Therefore, education on both non-pharmacological and pharmacological interventions as 
well as diagnosis is needed to better manage the clinical symptoms of LBD. Controversy 
exists surrounding the use of antipsychotics because these drugs can cause worsening of 
disease symptoms in individuals with LBD (Culo et al., 2010). 
 In Eastern Health LTC facilities, nursing staff receive general dementia education 
but nothing specific to LBD. Nursing staff in LTC need to acquire new knowledge on this 
disease as one can only conclude that staff have been and will continue to be caring for 
LBD residents on a regular basis in the future.  Presently, nursing staff feel care is 
compromised in LTC settings for residents with LBD because nursing staff lack 
awareness and understanding of the disease, thus care is not effectively resident-centered. 
Developing educational resources specific to LBD will promote effective differentiation 
between LBD, Alzheimer’s disease (AD), and Parkinson’s disease (PD) which will result 
in more resident-centered care and better resident outcomes. As a result, it is expected 
quality of life for LBD residents in LTC will improve.  
The literature review indicated that there are numerous issues related to the 
diagnosis and care of individuals living with LBD: lack of awareness about LBD among 
healthcare professionals; problems differentiating between LBD, AD, and PD due to 
overlapping symptoms, which impacts resident-centered care; comparatively reduced 
quality of life for LBD  residents, due to early dependency because of the rapid 
progression of neurological and psychiatric symptoms and functional impairments; little 
research on the non-pharmacological interventions to manage LBD, but current evidence 
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suggests that similar interventions used with other types of dementia, such as music 
therapy and reminiscence, are effective; and  pharmacological interventions such as 
antipsychotics versus other medications are controversial (Auning et al., 2011; Ballard et 
al., 2001; Culo et al., 2010; Galvin et al., 2010a; Galvin et al., 2010b; Larsson et al., 
2011; Leggett, Zarit, Taylor, & Galvin, 2010; McKeith, 2004; McKeith et al., 2005; 
McKeith et al., 2006; Neef & Walling, 2006; Yuhas, McGowan, Fontaine, Czech, & 
Gambrell-Jones, 2006; Zupancic, Mahajan, & Handa, 2011) 
The consultation process was formulated based on the results of the literature 
review. The consultation findings correlate to those of the literature review. The 
consultations helped identify areas of concern for nursing staff in LTC regarding LBD 
and will guide the development of the proposed LBD educational resources. The 
proposed 30 minute presentation and resource manual related to LBD will allow nursing 
staff in LTC to receive education that pertains to current and relevant evidence-based 
practices for care delivery to residents with LBD. Eastern Health defines nursing staff as 
Registered Nurses, Licensed Practical Nurses, and Personal Care Attendants. The hope is 
that the educational resource will enhance resident-centered care for individuals with a 
diagnosis of LBD. Key stakeholders at rural Avalon Eastern Health and Harbour Lodge 
Nursing Home will be invited to participate in the 30 minute presentation and review the 
manual for content and general satisfaction. There will also be a variety of problem-
solving tools utilized in the LBD educational resources, such as pre-post tests and case 
studies, to determine knowledge acquisition. The stakeholders will evaluate both the 
presentation and the resource manual so that revisions can be made accordingly. 
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Purpose of Consultations  
(1) To determine the information needs of nurses related to LBD that should be 
included in the educational resource. 
(2) To determine the existence of educational resources specific to LBD for nursing 
staff in LTC settings. 
(3) To determine the content related to LBD that should be included in the 
educational resource. 
(4) To determine how education related to LBD should be provided to nursing staff in 
LTC. 
(5) To determine if educational materials from other Health Authorities in Canada are 
applicable to the care of LBD residents in LTC facilities in Newfoundland. 
(6) To determine the approval of Eastern Health to incorporate a LBD educational 
resource into staff training into LTC settings. 
Setting and Sample 
Consultations occurred with nursing leaders and front-line nurses. It was planned 
that one leader from at least one LTC facility in two regions of Canada (Western and 
Atlantic) were going to be consulted. Leaders from two LTC sites in Ontario were going 
to be consulted because this province has a large population and a vast number of LTC 
facilities. As the consultations with nursing leaders progressed, one site in Edmonton, 
Alberta, one in Vancouver, British Columbia, one in Ontario (Waterloo), one in Halifax, 
Nova Scotia, and one within the rural Eastern Health Authority (Harbour Lodge Nursing 
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Home) were contacted to participate. In addition, nursing leaders were contacted in 
multiple sites throughout Ontario, but only one agreed to participate. A physician from 
urban Eastern Health Authority who specializes in neurocognitive disorders in geriatrics 
participated. As well, nursing staff on the dementia unit of Harbour Lodge Nursing Home 
(one senior and one junior RN, two senior and one junior LPN, and one senior and one 
junior PCA) were consulted because these individuals care for residents with LBD in 
LTC and will be involved in the implementation and evaluation of the practicum project, 
therefore their input is vital and practical. As well, a nurse leader at the largest Eastern 
Health LTC site in St. John’s was contacted but did not participate. Another well-known 
physician who specializes in geriatric medicine and neurology in Nova Scotia was also 
contacted but did not participate.  
Data Collection 
An introductory email was sent to each potential participant outlining the project 
purpose, contact information of the MN student, and a request for their participation in 
the consultations. A different information letter was sent to local and out of province 
nurses (Appendices A and B). These individuals were requested to respond to the email 
in order to set up a convenient time for a telephone interview, or face-to-face interview 
for local participants only. A total of three local nursing leaders responded to the email in 
order to set up a time to conduct the interviews. An additional four leaders at out of 
province LTC sites responded and agreed to set up an interview time. There were seven 
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members of the nursing staff at a local LTC site that responded to the email and agreed to 
an interview time.  
At the initiation of the interviews, participants were informed of the purpose of 
the interview and how the data collected would be utilized in the development of the 
LBD educational resource. Based on the literature review and my experience in LTC 
settings, two different sets of interview questions were developed to meet the needs of the 
key informants. One set of interview questions was for local and out of province nursing 
leaders (Appendix C) and another was developed for use with local nursing staff 
(Appendix D). The interviews were scheduled in 30 minute intervals and contained a 
series of open and closed ended questions. Notes were taken during the interviews and 
analyzed for content to identify exclusive categories and common themes. Member 
checking was used to ensure the data collected was accurate (Streubert and Carpenter, 
2011). At the end of each question during the interview, a quick summary was done with 
the participant to ensure accuracy and validity of the data provided (Streubert & 
Carpenter, 2011). Alphabetic coding was assigned to each interview to ensure privacy 
and confidentiality, and the data may be shared with Dr. Anne Kearney, MN supervisor, 
in the final consultation report.   
Data Management and Analysis 
 There were no interviews conducted in a face-to-face manner as all participants 
preferred the format of a telephone interview. At the initiation of the interview, verbal 
permission was sought and all questions or concerns of the participants were addressed. 
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Detailed notes were taken during the interviews, typed, and organized according to 
question response. These notes were summarized briefly with the participant after each 
question response to ensure validity and accuracy. The notes from the interviews were 
coded into mutually exclusive categories and comparisons were made on the basis of 
common themes (Streubert & Carpenter, 2011). This content analysis ensured that the 
most important points were identified and included in the consultation report. All 
participants were aware that the data would be analyzed and incorporated into the 
development of a LBD educational resource. 
Ethical Considerations  
 The Health Research Ethics Review (HREA) Board screening tool was completed 
prior to the consultation process (Appendix E). The tool determined that the sole purpose 
of the consultations was for program development quality and evaluation, therefore 
review by an Ethics Board was not needed. Consent to participate was implied when 
informants responded to the email containing the information letter to arrange a 
convenient interview time. Full disclosure concerning privacy, confidentiality, and the 
use of data in the development of the LBD educational resource was outlined for 
participants. All interviews were conducted via telephone in a private office with the door 
closed to ensure confidentiality. All participants were alphabetically coded to protect 
their identity and interview details. The data was kept in a locked filing cabinet in the 
locked office of the MN student. At the end of the practicum project, all data will be 
shredded. There are no risks to participants during the consultation process, and all 
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participants were aware the process was voluntary. They were aware they could 
discontinue the interview at any time.   
Key Findings  
 A total of 15 participants were interviewed. Two participants were in management 
roles within Eastern Health and one was a Clinical Nurse Specialist. One participant was 
a physician who is well known for his work in geriatrics and dementia in Eastern Health. 
Four participants were nurses who were either managers, directors of care, or educators 
in LTC facilities throughout Canada that cared for dementia residents. The remaining 
seven were a mixture of nursing staff in rural Avalon Eastern Health. Data analysis 
identified five major themes: (a) Lack of education resources specific to LBD in LTC; (b) 
Knowledge gaps of nursing staff in LTC regarding LBD; (c) Lack of diagnosis and care 
specific to individuals living with LBD; (d) Preferred learning styles of nursing staff 
related to LBD in LTC, and (e) Impact of LBD education on care delivery in LTC.  
 Lack of Education Resources Specific to LBD in LTC 
 The interview results across Canada indicate there is a lack of educational 
resources in LTC that focus specifically on LBD. Generally, the topic of LBD is covered 
briefly in staff orientation to LTC sites upon hiring. Out of province sites focus mainly on 
programs known as Supportive Pathways related to individualized care for AD, with only 
a brief discussion on definitions of other dementia types. The LTC site in Nova Scotia 
trains everyone employed there using a three day program called PIECES, which was 
derived from the Alzheimer Society of Ontario. The PIECES program is an initiative that 
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promotes understanding and enhancing care for individuals with AD with physical, 
cognitive and behavioral needs (Alzheimer Society of Ontario, 2015). In Eastern Health, 
nursing staff in LTC sites complete a 7.5 hour course in Gentle Persuasive Approaches 
(GPA) and a 6 hour Dementia Care Orientation related to responsive behaviors in 
Alzheimer’s disease (AD), under the direction of the Clinical Nurse Specialist. Education 
related to dementias other than AD is mainly self-initiated online by nursing staff through 
internet websites. The physician referenced a resource called First Link created by the 
Alzheimer Society of Canada that he often talks to nursing staff informally about to better 
inform them of dementia care services. The First Link program is a referral system that 
enables individuals diagnosed with dementia and their families to make informed choices 
through receiving support and education regarding dementia (Alzheimer Society of 
Canada, 2015b). Nursing staff noted that within Eastern Health there is a family 
handbook often utilized by staff to increase their knowledge base of dementia but, yet 
again, this handbook very generally discusses dementia, not the specific types.  
There were no resources in Newfoundland or most of Canada to be shared, as the 
nursing leaders indicated that well known dementia organization websites such as the 
Alzheimer Society of Newfoundland and Canada were the tools accessed to aid 
discussions with nursing staff. The only site that offered to send a resource used in LBD 
education was the facility in Nova Scotia. The resources that are to be sent are related to 
the PIECES program. All participants stated there was a need for further resources 
specific to LBD to enhance staff knowledge regarding the disease because more residents 
with LBD may be seen in LTC settings in the future.  
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Knowledge Gaps of Nursing Staff in LTC Regarding LBD  
There were numerous areas of knowledge deficits related to LBD evident in the 
interview findings. The main learning needs identified by the participants focus on the 
following areas: What is LBD? What are the signs and symptoms of LBD that distinguish 
it from other dementia types? What are the risks for being diagnosed with LBD? What 
are the pharmacological and behavioral interventions to manage symptoms? A need for a 
directory for, and quick access to, Canadian resources on LBD was also identified. All 
participants stated there was a lack of awareness, knowledge, and understanding of LBD 
among nursing staff, which prevents effective nursing interventions related to resident-
centered care. Members of the nursing staff were only aware of care approaches to be 
used with residents with AD rather than specific interventions for LBD. Both nursing 
leaders and nursing staff believe these knowledge deficits lead to frustrations for care 
providers in LTC and ineffective plans of care for residents.  
With respect to pharmacological and behavioral management of LBD symptoms, 
a key concern is when to choose appropriate antipsychotics versus behavioral approaches 
to manage signs and symptoms.  Nursing leaders indicated that non-pharmacological 
management is safer than antipsychotic use due to the negative effects from the 
medications, such as toxicity and worsening of cognitive symptoms. The nursing leaders 
feel that nursing staff need to be abreast of current and relevant alternatives to 
antipsychotic use, such as music therapy and aromatherapy, to better manage LBD 
residents’ symptoms. The physician reported that most nursing staff are routinely trying 
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to manage LBD symptoms using pharmaceutical interventions meant for general 
dementia care, which are proving ineffective, especially the use of atypical antipsychotics 
to treat hallucinations. The physician reports that atypical antipsychotics such as 
clozapine and risperidone can worsen the behavioral symptoms of LBD but 
cholinesterase inhibitors are more effective.  He cites experiences of nursing staff 
suggesting higher doses of atypical antipsychotics or alternative antipsychotics when 
caring for residents with LBD in LTC, which he feels also exacerbate the already 
challenging behaviors. With more education, nursing staff will be better able to 
differentiate the clinical manifestations of LBD from other types of dementia and provide 
appropriate interventions, thus encouraging resident and care plan re-evaluation to 
promote optimal care. 
Lack of Diagnosis and Care Specific to Individuals Living with LBD 
 This theme is closely tied to lack of educational resources in LTC related to LBD 
and knowledge gaps among nursing staff related to LBD in LTC. The general consensus 
from nursing leaders and nursing staff is that not many residents in LTC are definitively 
diagnosed with LBD; they more or less are given a general umbrella diagnosis of 
dementia. As a result, this impacts the ability of nursing staff to provide resident-centered 
care to individuals in LTC. The key issue experienced by nurses was frustration with 
handling the hallucinations and behavioral symptoms, such as aggression, experienced by 
residents with LBD. Nursing staff feel that they are not adequately informed on the LBD 
disease process, therefore care is not individualized and quality of life is negatively 
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affected. The physician suggested that nursing staff are not aware of the subtle features of 
Parkinsonism in LBD and that a high incidence of falls early in dementia could be 
indicative of a LBD diagnosis. If nursing staff are more aware of the clinical 
manifestations of the disease, they will be more alert to subtle changes in the residents’ 
disease state and notice the autonomic dysfunctions that happen early in LBD, which will 
aid diagnosis and promote more resident-centered care plans. 
With experience, nursing staff become aware that the pharmacological 
interventions utilized with AD to manage hallucinations and behavioral symptoms are not 
as effective with those suffering with LBD.  Nursing staff also explained that they notice 
a much faster physical progression of decline and more cognitive fluctuations in residents 
with LBD in LTC. Therefore, specialized care plans must be put into place containing 
relevant evidence-based information so that care approaches are current and effective. As 
well, the participants indicated that the lack of understanding experienced by nursing 
staff means that accurate and pertinent information related to a LBD diagnosis cannot be 
relayed successfully to families to aid in the coping process. 
Preferred Learning Styles of Nursing Staff Related to LBD in LTC 
During the interview participants stated that by addressing their needs in an 
educational resource, nursing staff will have enhanced knowledge of LBD, be more 
confident and competent in care delivery to residents with LBD in LTC and, as a result, 
care will be more resident-centered. In addition, it was indicated that quality of life and 
well-being for residents with LBD in LTC will improve. Nursing staff and leaders stated 
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that a presentation and resource manual was the preferred educational resource because it 
addressed many learning styles and best promoted retention of new material. A webinar 
was also suggested by a few members of the nursing staff, but others felt webinars were 
not interactive and did not promote learning. The only educational program that was 
discussed during the interview with local nursing staff was the GPA training which uses 
presentation, videos, and case studies to promote knowledge development. Nursing staff 
felt this same approach would work best with LBD educational resources as they were 
interactive, informative, and promoted retention of new information. Different 
approaches were not suggested for RNs versus LPNs versus PCAs in the development of 
the presentation and resource manual. 
 The main type of LBD educational resource identified by the participants is a 45 
minute presentation addressing the key areas of concern, and a resource manual to be left 
on the units for easy access by staff. Participants stressed the importance of easy, quick 
reading educational resources with minimal medical terminology because time is so 
limited on the LTC units and not all members of the nursing staff have high levels of 
educational training, such as the PCAs. The PCAs do not have university level education; 
therefore medical based information must be kept simple and clear so that all nursing 
staff benefit from the LBD educational resources. As well, many participants suggested 
the idea of using case studies and videos during the presentation and in the resource 
manual to allow participants to apply new knowledge and problem-solve, which would 
promote retention of the new information. 
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Impact of LBD Education on Care Delivery in LTC 
 The participants were extremely pleased with the idea of a LBD educational 
resource for LTC settings as there is such a lack of awareness amongst nursing staff and a 
lack of resources on the disease in LTC. By increasing the knowledge base of nursing 
staff, participants believe that care delivery to LBD residents should improve and be 
more resident-centered, resulting in enhanced well-being and quality of life. As indicated 
by the physician, with increased knowledge of LBD, nursing staff will be more in tune to 
the accurate symptoms of LBD and use effective behavioral interventions, especially to 
control hallucinations. Furthermore, better management of the challenging behaviors 
related to LBD, such as hallucinations and behavioral symptoms, will improve the overall 
atmosphere of the dementia unit. Being better able to meet the specific needs of LBD 
residents will promote positive change on the LTC units, and over time these 
interventions will become regular practice on dementia units. Easy access to relevant 
LBD resources will permit nursing staff in LTC to tailor interventions to meet resident 
needs, therefore allowing nursing staff to see the resident beyond the diagnosis. 
Preliminary discussions with the Clinical Nurse Specialist indicate that she is supportive 
of using the LBD resource manual during nursing staff orientation within LTC facilities 
in rural Avalon Eastern Health. It was indicated the CNS would do periodic updates of 
the resource manual as necessary. Further discussions with the CNS will occur in the 
development phase of the project.  
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Conclusion 
 The findings of the consultation process are consistent with the literature 
regarding LBD. The consultation process demonstrated that nursing leaders, nursing 
staff, and physicians feel that there is a need for education specific to LBD in LTC 
settings. Several areas of concern were identified that negatively impact dementia care 
delivery and thus quality of life for individuals with LBD in LTC. These concerns are 
consistent with the literature review related to LBD. The information from both the 
literature review and consultation process revealed that further education is needed in 
LTC regarding LBD disease processes, diagnostic criteria, and clinical manifestations, as 
well as behavioral and pharmacological approaches to promote more resident-centered 
care plans for residents with LBD. Canadian resources were recommended to be included 
in the LBD resource manual. 
 The proposed 30 minute presentation and resource manual will address selected 
needs determined by the literature review and consultation process. Currently, the 
presentation and the resource manual will be delivered to nursing staff on the locked 
dementia unit at Harbour Lodge Nursing Home as this is where the majority of dementia 
residents reside. The hope is that the presentation will introduce the basic information 
related to LBD, and the manual will be more extensive and readily available to staff at all 
times during work hours. The manual and presentation can also be utilized and updated 
by the Clinical Nurse Specialist for rural Avalon Eastern Health to use in training 
sessions for nurses in LTC as well as other health care settings. 
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Appendix A  
Information Letter for Leaders Outside of NL 
To Whom It May Concern; 
My name is Stephanie Hawco and I am currently completing my final practicum 
for the Master of Nursing degree at Memorial University.  My supervisor is Dr. Anne 
Kearney, Associate Professor at the School of Nursing, Memorial University. The goal of 
my practicum is to develop an educational resource regarding the care of residents with 
Lewy body dementia (LBD) to be used by nursing staff in long-term care (LTC) facilities 
throughout Eastern Health Regional Authority. Effective resident-centered care will help 
improve quality of life for residents with LBD in LTC facilities. 
As part of this practicum, I am conducting consultations with representatives from 
LTC facilities to determine the necessary information needed by nursing staff to promote 
knowledge development regarding LBD so that symptoms can be managed with resident-
centered care interventions that will improve quality of life. I am requesting your input 
because you and your facility have been identified as leading edge in the development of 
programs related to LBD. A 20-30 minute telephone interview will be conducted to assist 
in the development of a LBD educational resource. The privacy of all individuals will be 
protected. There will be no identifying information provided that will link participants to 
the interview responses provided.  
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It is my hope that you will be willing to share your knowledge, and/or any other 
relevant material related to LBD that is utilized at your facility. The information collected 
through the consultation process along with a comprehensive literature review will be the 
basis of the LBD educational resource.  
Participation in this project is voluntary. Please respond to the e-mail address 
below and indicate if you are willing to participate in the consultation process. If you 
agree to participate I will contact you to arrange a convenient time to conduct a short 
interview. If you do not feel you can contribute but know of someone with expertise in 
the area of LBD who may, then please share this email with them and invite them to 
contact me. I greatly appreciate your assistance and would be more than willing to share 
the results of the practicum project upon completion. 
Thank you for your time and consideration.  
Stephanie Hawco       
Master of Nursing Student  
Memorial University of Newfoundland          
Email:  steph@persona.ca  
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Appendix B  
Information Letter for Local Nurses 
To Whom It May Concern; 
My name is Stephanie Hawco and I am currently completing my final practicum 
for the Master of Nursing degree at Memorial University.  My supervisor is Dr. Anne 
Kearney, Associate Professor at the School of Nursing, Memorial University. The goal of 
my practicum is to develop a Lewy Body Dementia (LBD) educational resource 
regarding the care of residents with Lewy body dementia (LBD) to be used by nursing 
staff in long-term care (LTC) facilities throughout Eastern Health Regional Authority. 
Effective resident-centered care will help improve quality of life for residents with LBD 
in LTC facilities. 
As part of this practicum, I am conducting consultations with representatives from 
LTC facilities to determine the necessary information needed by nursing staff to promote 
knowledge development regarding LBD so that symptoms can be managed with resident-
centered care interventions that will improve quality of life. I am requesting your input 
because of your experience in providing care and/or education to residents living with 
dementia. A 20-30 minute telephone interview will be conducted to assist in the 
development of a LBD educational resource. The privacy of all individuals will be 
protected. There will be no identifying information provided that will link participants to 
the interview responses provided.  
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It is my hope that you will be willing to share your knowledge, and/or any other 
relevant material related to LBD that is utilized at your facility. The information collected 
through the consultation process along with a comprehensive literature review will be the 
basis of the LBD educational resource.  
Participation in this project is voluntary. Please respond to the e-mail address 
below and indicate if you are willing to participate in the consultation process. If you 
agree to participate I will contact you to arrange a convenient time to conduct a short 
interview. If you do not feel you can contribute but know of someone with expertise in 
the area of LBD who may, then please share this email with them and invite them to 
contact me. I greatly appreciate your assistance and would be more than willing to share 
the results of the practicum project upon completion. 
Thank you for your time and consideration.  
Stephanie Hawco       
Master of Nursing Student  
Memorial University of Newfoundland          
Email:  steph@persona.ca  
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Appendix C 
Interview Questions for Local and Out of Province LTC Leaders 
1. a) What current training is required in your facility for nursing staff who work with 
LBD  
     residents (if any)? 
b) What types of educational resources (i.e. pamphlets, presentations, etc.) are 
available? 
c) How effective are these educational resources? 
d) How would you change these educational resources? 
e) Are you willing to share these educational resources? 
2. What are the current issues experienced by individuals with LBD in your LTC facility? 
3. What are the experiences of nurses caring for individuals with LBD in LTC? 
4. What do you think are the knowledge gaps/concerns of nurses regarding care delivery 
to individuals with LBD in LTC? 
5. What would be important components to include in a LBD educational resource for 
nursing staff in LTC to improve care delivery? 
6. How should information/education be provided to nursing staff? 
7. How do you think education related to LBD can improve quality of life for 
individuals with LBD in LTC? 
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8. Is there anything else you would like to share to help develop an educational resource 
for nurses in LTC? 
9. Can you recommend any cutting edge LTC facilities, or nursing leaders in LTC, that I 
should contact to help inform the development of an educational resource for LBD? 
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Appendix D 
Interview Questions for Nursing Staff 
1. a).What has been your experience of the special needs of individuals with LBD? 
b) What has been your experience of nurses’ knowledge of LBD? 
c) What has been your experience of nurses’ ability to care for individuals with 
LBD?  
2. Do you have training specific to LBD at your facility? Or is the care related to this 
disease covered in general dementia care education? 
3. Do you have resources available on the nursing units for staff to refer to regarding 
care delivery to LBD residents? 
4. How are nursing staff kept current regarding changes to dementia care delivery to 
ensure care is resident-centered? 
5. Do you feel there is a need for more specific education among the nursing staff 
regarding LBD? 
6. How do you think specific education for nursing staff on LBD can impact care 
delivery? 
7. What form of educational tool do you find to be most effective with nursing staff 
(i.e. pamphlets, presentation, etc.)? Do you think this would work for LBD? 
8. What do you think are the key components to be included in a LBD educational 
resource for LTC? 
9. Is there anything else you would like to add? 
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Appendix E 
Health Research Ethics Authority Screening Tool 
 Question Yes   No 
1. Is the project funded by, or being submitted to, a research funding agency  for 
a research grant or award that requires research ethics review 
  
2. Are there any local policies which require this project to undergo review by a 
Research Ethics Board? 
  
 IF YES to either of the above, the project should be submitted to a Research 
Ethics Board. 
IF NO to both questions, continue to complete the checklist. 
 
  
3. Is the primary purpose of the project to contribute to the growing body of 
knowledge regarding health and/or health systems that are generally accessible 
through academic literature? 
 
  
4. Is the project designed to answer a specific research question or to test an 
explicit hypothesis? 
  
5. Does the project involve a comparison of multiple sites, control sites, and/or 
control groups? 
  
6. Is the project design and methodology adequate to support generalizations that 
go beyond the particular population the sample is being drawn from? 
 
  
7. Does the project impose any additional burdens on participants beyond what 
would be expected through a typically expected course of care or role 
expectations? 
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LINE A: SUBTOTAL Questions 3 through 7 = (Count the # of Yes responses)      1    6 
8. Are many of the participants in the project also likely to be among those who 
might potentially benefit from the result of the project as it proceeds? 
 
 
 
 
 9. Is the project intended to define a best practice within your organization or 
practice? 
  
  10. Would the project still be done at your site, even if there were no opportunity 
to publish the results or if the results might not be applicable anywhere else? 
 
  
11. Does the statement of purpose of the project refer explicitly to the features of a 
particular program, 
Organization, or region, rather than using more general terminology such as 
rural vs. urban populations? 
 
  
12. Is the current project part of a continuous process of gathering or monitoring 
data within an organization? 
  no 
LINE B: SUBTOTAL Questions 8 through 12 = (Count the # of Yes responses)      4    0   
 SUMMARY 
See Interpretation Below 
  
 
Interpretation: 
 If the sum of Line A is greater than Line B, the most probable purpose is research. 
The project should be submitted to an REB. 
 If the sum of Line B is greater than Line A, the most probable purpose is 
quality/evaluation. Proceed with locally relevant process for ethics review (may not 
necessarily involve an REB). 
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 If the sums are equal, seek a second opinion to further explore whether the project 
should be classified as Research or as Quality and Evaluation. 
These guidelines are used at Memorial University of Newfoundland and were 
adapted from ALBERTA RESEARCH ETHICS COMMUNITY CONSENSUS 
INITIATIVE (ARECCI).  Further information can be found at: 
http://www.hrea.ca/Ethics-Review-Required.aspx. 
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Appendix C – Lewy Body Dementia Resources for Nursing Staff in Long-term Care 
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Lewy Body Dementia:  
A Resource Manual for Nursing Staff  
In Long-term Care Settings 
 
Prepared for Eastern Health 
 Harbour Lodge Nursing Home  
August 30, 2016 
 
 
 
Developed by: 
© Stephanie Hawco BN RN 
& 
Dr. Anne Kearney 
School of Nursing, Memorial University of Newfoundland 
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If you wish to make revisions to the resource manual, contact the primary author at the 
following email address steph@persona.ca. Revisions can be made but authorship must 
remain as Stephanie Hawco and Dr. Anne Kearney. Ensure that the primary authors are 
credited and the revised work is noted as being adapted from the original resource 
manual. The primary author may request a copy of revisions completed.  
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Who Can Use the Resource Manual and Why? 
This resource manual was developed following a review of the literature and from 
consultations with nursing management, Registered Nurses, Licensed Practical Nurses, 
and Personal Care Attendants in long-term care settings. The consultation process and 
literature review demonstrated there is a lack of awareness regarding Lewy Body 
Dementia (LBD) among nursing staff.
31, 32, 40, 45, 66
  
This resource manual is designed to help nursing staff deliver care to residents who are 
diagnosed with LBD and residing in long-term care. It is a comprehensive and current 
resource that provides evidence-based information about dementia in general, LBD, 
pharmacological and non-pharmacological interventions, as well as professional 
resources related to LBD. The rationale of the resource manual is to enhance nursing 
knowledge regarding LBD to improve resident-centered care and quality of life for those 
diagnosed with the disease and living in long-term care. 
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How Can You Use This Resource Manual? 
This resource manual is divided into five chapters which will provide detailed 
information on LBD. The manual can be used as an educational tool and as a reference 
tool in long-term care to help problem-solve when providing care to residents living with 
LBD. It can also be used by other staff at Eastern Health who collaborate in the care of 
residents with LBD to heighten understanding of the disease and its management.  
The results of the consultation process indicated that nursing staff wanted two 
educational resources developed regarding LBD: a short presentation providing an 
overview of LBD and interventions for disease management; and a resource manual that 
provided more in-depth detail related to LBD, pharmacological and non-pharmacological 
interventions and useful resources to access additional information. As well, the nursing 
staff suggested the use of videos and case studies regarding LBD to promote problem-
solving skills and enhance learning.  
 
 
TEST YOUR KNOWLEDGE 
 
BEFORE READING THE MANUAL, COMPLETE THE PRE-TEST ON THE 
NEXT PAGE TO DETERMINE YOUR KNOWLEDGE REGARDING LBD. 
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Test Your Knowledge – Pre-Test 
Select True or False for each of the following statements: 
1. Lewy body dementia (LBD) is more common in men.   True   False 
 
 
2. The greatest risk for Lewy body dementia (LBD) is advanced age.   
 True   False 
 
3. Lewy body dementia (LBD) is the second common type of dementia. 
 True   False 
 
 
4. Lewy body dementia (LBD) can be dementia with Lewy bodies or Parkinson’s 
disease dementia.   True   False 
 
 
5. The hallmark symptoms of Lewy body dementia (LBD) are fluctuating alertness 
and confusion, visual hallucinations, and Parkinson motor symptoms. 
 True   False  
 
6. An early symptom of Lewy body dementia (LBD) is delusions.   
 True   False 
  
 
7. Acetylcholine is the only neurotransmitter affected in Lewy body dementia 
(LBD).  True   False 
 
 
8. Amyloid plaques are found in the brain of individuals of Lewy body dementia.  
 True   False 
 
9. The first line of treatment for the cognitive symptoms in Lewy body dementia is 
cholinesterase inhibitors.  True   False 
 
 
10. Typical antipsychotics are safe to use in the management of LBD behavioral 
symptoms.   True   False 
 
Answers can be found on page 75. 
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Chapter 1: Dementia 
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Dementia is a disorder that affects the brain, especially cognitive abilities such as 
thinking, problem-solving and language.
4
 It usually occurs in individuals over 65 years of 
age.
4, 74
 Physical changes occur in the brain resulting in progressively worsening 
symptoms overtime.
10
 There is no single known cause for dementia and the rate of 
disease progression varies among affected individuals.
 
Usually, dementia will severely 
impact activities of daily living as the disease progresses.
4
 
 
 
 
 
 Worldwide in 2015, 47.5 million people were living with dementia.57 
 This number will triple within the next 35 years as the population advances in 
age.
57
 
 In 2011, 747, 000 Canadians over the age of 65 years were living with dementia.7  
 By the year 2031, it is expected there will be 1.4 million cases of dementia in 
Canada.
7
 
 The risk for dementia doubles every five years after the age of 65 years.7 
 $33 billion dollars a year is spent on dementia care in Canada.7 
 
1a).What is Dementia? 
1b). Dementia Statistics 
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 Risk factors are characteristics that increase the likelihood of developing 
dementia.  
 There are modifiable and non-modifiable risk factors for dementia.12  
 Modifiable risk factors can be changed but non-modifiable risk factors cannot.12  
 Many of the modifiable risk factors such as smoking, high blood pressure, 
diabetes, and high cholesterol affect blood vessels which reduces blood flow to 
the brain. 
Modifiable risk factors  
1) Smoking – Quitting smoking can reduce the risk for dementia. Smokers have a 45% 
greater risk of developing AD.
12
 
2) High blood pressure – Elevated blood pressure affects the cardiovascular system, 
therefore increasing the risk for dementia, especially vascular dementia.
12
 
3) Diabetes – Individuals with type 2 diabetes are twice as likely to develop dementia.12 
4) High cholesterol – Individuals with higher levels of total cholesterol are at increased 
risk for dementia. Treating high cholesterol levels will decrease dementia risk.
12
 
5) Obesity & physical inactivity – Both factors increase the likelihood of developing 
high cholesterol, high blood pressure, and diabetes which elevates risk.
12
 
6) Alcohol – Individuals who drink excessively (more than 3-4 drinks a day) have the 
highest risk of developing dementia due to toxic effects of alcohol on brain tissue.
12
 
1c). Risk Factors for Dementia 
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Those who drink moderate amounts of alcohol (1-2 drinks a day) have the lowest risk 
of developing dementia.
12 
Not drinking alcohol at all puts one at a slightly higher risk 
of developing dementia because of the absence of the benefits of alcohol for a healthy 
heart.
12 
However, the literature is controversial on the positive effects of alcohol on 
the cardiovascular system. 
7) Depression – May be a risk factor or an early symptom of dementia. The literature is 
controversial on this topic.
12
 
8) Head injuries – Individuals who experience severe or repeated head injuries are at 
increased risk for dementia because plaques and tangles can form in the brain.
12
  
9) Lower education – Formal education is believed to lower the risk of dementia 
because higher educated individuals are more cognitively stimulated and are more 
likely to have healthy lifestyle practices. However, the amount and quality of 
education that lowers dementia risk is not clarified.
12
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Non- modifiable risk factors   
1) Age – The risk of developing dementia increases with age, particularly after 65 
years of age. Aging impairs the body’s ability to repair itself which greatly 
impacts brain functioning. As well, modifiable risk factors increase with age 
which also leads to increased dementia risk.
12
   
2) Family history and genetics – Some forms of dementia are believed to have a 
familial link, especially AD.
12
  
3) Gender – An association with gender has been noted with certain types of 
dementia. Studies are still investigating this factor.
12
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Generally, most types of dementia have the same characteristic symptoms:  
 Memory loss.  
 Problems with thinking, problem-solving and language abilities.  
 In early stages, individuals cannot recall recent events or conversations. 
 As dementia progresses, affected individuals will not recognize or be able to 
recall names of people and things. 
 
 Errors in conversation will occur due to forgetting words.  
 Eventually, managing money, personal care, and nutrition require assistance. 
 Other symptoms may include changes in mood, personality, and behavior:2, 4, 9 
o Emotional distress. 
o Restlessness, pacing, shredding things, wandering. 
o Aggression, agitation, anxiety, depression, anger, irritability, paranoia. 
o Confusion – Disorientation to person, place, and time. 
o Compulsion – A repeated act or ritual such as checking doors, repeating 
words, or hoarding items. 
o Resistant behavior. 
o Hallucinations and delusions. 
o Sleeplessness. 
1d). Clinical Manifestations of Dementia 
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o Sundowning – When symptoms of confusion and agitation occur late in 
the evening hours.  
o This could actually be delirium but not recognized as such. 
o Delirium – A short-term state of confusion affecting thinking and behavior 
including changes in attention, mood, and activity level.  
o People with dementia are at increased risk for delirium. 
Most often the early symptoms of dementia are not noticed by the individual themselves 
but by family members.
27
 Usually the symptoms progress to the point that home and 
family life are impacted resulting in admission to long-term care for management of 
complex care needs.
27 
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Research indicates there are seven stages of dementia that a person may experience as the 
disease progresses.
27
  
Stage 1: No cognitive impairment The person functions normally. There are 
no notable changes. 
Stage 2: Very mild cognitive decline The person experiences normal 
forgetfulness that occurs with the aging 
process but it is not noticeable to others. 
Stage 3: Mild cognitive decline The person experiences increased 
forgetfulness, minor issues with 
concentration, and errors in conversation. 
The person gets lost in familiar places and 
others begin to notice the dementia 
symptoms. 
Stage 4: Moderate cognitive decline 
 
The person has increased problems with 
concentration, recall of events/words, and 
handling money. The person generally is in 
denial and isolates themselves from others. 
At this point, the primary care provider will 
notice the cognitive changes in the 
individual upon examination. 
Stage 5: Moderately severe cognitive decline The person experiences significant memory 
loss and requires moderate help with 
hygiene and nutrition. 
Stage 6: Severe cognitive decline The person requires extensive help with 
daily living as little long-term memory 
remains. Family members are forgotten and 
there are issues with incontinence, 
muteness, delusions, compulsions, 
agitation, and anxiety. 
Stage 7: Very severe cognitive decline The person does not speak or communicate 
in other ways. Around the clock care is 
needed. All meaningful movement is lost. 
1e). Stages of Dementia 
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There are reversible and irreversible forms of dementia that have many overlapping 
symptoms.
5
 With reversible forms of dementia, once the cause is treated, the dementia 
may be cured or controlled.
5
 Some common causes of reversible dementias are:
3
   
o Depression.  
o Medications. 
o Alcohol and drug abuse. 
o Lack of vitamins/minerals. 
o Trauma. 
o Hormonal changes. 
o Infections. 
o Uncontrolled medical conditions.  
Irreversible forms of dementia result in deterioration of the brain and normal 
functioning.
6 
There is no cure for irreversible dementias, but symptoms can be managed 
with appropriate interventions. The common forms of irreversible dementia are:
6
 
o Alzheimer’s disease.  
o Vascular dementia (Multi-infarct). 
o Frontotemporal dementia (Pick’s disease). 
o Lewy body dementia. 
1f). Reversible and Irreversible Forms of Dementia 
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Alzheimer’s Disease 
 AD is the most common dementia.11 
 Worldwide, it affects approximately 60-80% of those with dementia.1  
 Worldwide, AD occurs in 10 per 100 people.74 
  In Canada, AD accounts for 64% of dementia diagnoses.7  
 Commonly occurs between the ages of 65-69 years.74 
 AD affects both men and women equally.74 
 It is believed that risk for AD increases 30% if an immediate family member is 
diagnosed with the disease.
74
 
 Familial AD accounts for less than 5% of AD cases.12 
 Short-term memory loss is present upon diagnosis.6 
 Individuals affected will experience changes in cognition, functional abilities, 
emotions, mood, behavior, and physical abilities.
11
 
 Beta amyloid plaques and neurofibrillary tangles made of tau protein are scattered 
throughout the brain.
1
 
 These deposits in the brain and a lack of the neurotransmitter acetylcholine 
produce symptoms characteristic of the disease.
1
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Vascular Dementia 
 Vascular dementia is also known as multi-infarct dementia.6 
 Vascular dementia is the second most common dementia in Canada.6 
 Up to 20% of all dementia cases in Canada are diagnosed as vascular dementia.6 
 Vascular dementia commonly occurs as a result of a stroke when brain cells do 
not get proper oxygen.
6
 
 With this type of dementia, there are sudden impairments in cognition, emotion, 
motor, and autonomic functioning.
6
 
 Risk is increased in individuals over 65 years of age, those with heart disease, 
high blood pressure, and diabetes.
6
 
 These risk factors can be controlled by reducing the risk for stroke and therefore 
vascular dementia.
6
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
Frontotemporal Dementia 
 Frontotemporal dementia is also known as Pick’s disease.6 
 Accounts for 2-5% of all dementia cases worldwide.6 
  It affects only the frontal and temporal lobes of the brain which control 
personality and behavior.
6
 
 In some cases, brain cells in the frontal and temporal lobes shrink or die. In other 
cases, the brain cells in the frontal and temporal lobes get larger and contain 
round, silver Pick’s bodies which are a build-up of tau protein.6 
 There is little known about the risk factors for frontotemporal dementia in the 
literature. 
 Presenting symptoms include sudden onset of memory loss, behavior changes, or 
difficulty with speech and movement.
6
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Lewy Body Dementia 
 Accounts for 15-20% of dementia diagnoses worldwide.41 
 Globally, LBD occurs in 7 out of 1000 people over 75 years of age and older.74 
 In Canada, LBD accounts for 5-15% of dementia cases.8 
 LBD is the third most common dementia in Canada.6 
 LBD is an umbrella term for two related diagnoses:42 
o Dementia with lewy bodies (DLB) 
o Parkinson’s disease dementia (PDD) 
 The central feature in each diagnosis is dementia. The timeframe of the dementia 
will determine the diagnosis.
42
 
 Individuals can have three clinical presentations:42 
o If a person presents with a movement disorder, they are diagnosed with 
Parkinson’s disease. If dementia develops a year or more later, then the 
person is diagnosed with PDD.  
o If a person presents with a cognitive disorder before or within one year of 
Parkinson’s symptoms, then it is diagnosed as DLB. 
o If a person presents with neuropsychiatric symptoms, such as 
hallucinations, behavioral problems, and issues with complex activities, 
the diagnosis is DLB (this presentation is less common). 
o The 12 month cut off is somewhat arbitrary. 
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 The three clinical presentations have different symptoms initially, but over time 
will develop similar cognitive, physical, sleep, and behavioral problems.
42
 
 Individuals diagnosed with LBD will have deposits of Lewy bodies in the 
midbrain, brainstem, temporal, and frontal lobes of the brain which contain the 
protein alpha-synuclein.
41
 
 Affected individuals experience the hallmark symptoms of fluctuating alertness 
and confusion, recurrent vivid visual hallucinations, and Parkinson motor 
symptoms.
74
 
 LBD is a multi-system disease affecting thinking and movement, thus producing 
symptoms similar to AD and PD.
8
  
 LBD is often misdiagnosed as AD because of the cognitive symptoms, or 
misdiagnosed as PD because of the motor symptoms.
74
 
 Generally, there is a two year lag between onset of symptoms and diagnosis, 
possibly due to lack of awareness among healthcare professionals regarding LBD 
and the issue of overlapping symptoms with other forms of dementia, particularly 
AD and PD. 
46
 
 Affects more men than women.45, 74 
 LBD can occur as early as 50 years of age but is most common after 60 years of 
age.
48, 74
 
 On average, men are diagnosed at 72.2 years of age and women at 73.6 years of 
age, which is earlier than other forms of dementia.
74
 
 Advanced age is the greatest risk factor for LBD.43 
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 Controversy exists in the literature regarding a familial link for LBD.45, 74 
 80% of cases have visual hallucinations.48 
 25-50% of LBD cases have Parkinsonism upon diagnosis.55 
 Individuals with LBD require earlier admission to nursing homes than those with 
other types of dementia because this multi-system disease impacts independence 
early in the disease course.
77
 
 LBD is a rapidly progressing form of dementia.6,42 
 Death usually occurs 5-7 years after diagnosis.46 
 LBD has a higher mortality and earlier death than other dementias.77, 78 
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Chapter 2: Clinical Manifestations of LBD, AD, and PD 
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There are two diagnostic tools used to diagnose LBD:
56, 74
  
 The Diagnostic and Statistical Manual of Mental Health Disorders, Fifth Edition 
(DSM-5).  
  Consortium on Dementia with Lewy Bodies Consensus Guidelines.  
Both diagnostic tools have the same criteria for diagnosing LBD and both diagnostic 
tools are being used in practice. 
The DSM-5 criteria are based on more recent research and incorporate the Consensus 
Guidelines into its diagnostic tool; as well, it identifies the similarities and differences 
between LBD, AD, and PD.
74
  
Two issues may contribute to the issue of the two year lag from onset of symptoms to 
receiving a definitive diagnosis of LBD as well as to misdiagnosis and underdiagnosis:
46, 
62  
 Primary care providers may lack clinical familiarity with the LBD diagnostic 
criteria; and 
 Many healthcare professionals lack awareness of when symptoms occur at each 
stage in LBD, AD, and PD.
13, 15
 
 
2a). Common Diagnostic Tools for LBD 
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The DSM-5 provides clear guidelines for dementia and dementia subtypes under the 
category of neurocognitive disorders.  
 The DSM-5 diagnoses of a neurocognitive disorder requires evidence of 
decreased cognitive decline and decline on standardized testing such as the Mini 
Mental Status Exam (MMSE) in one of the following areas:
74
  
o Attention. 
o Decision-making and working memory. 
o Learning and short/long-term memory.  
o Visual, auditory, and fine/gross motor skills.  
o Attitude. 
o Behavior. 
 Furthermore, clinical manifestations are assessed in detail with neurological and 
physical examinations.  
 The DSM-5 identifies the clinical manifestations of LBD, AD, and PD so that 
these diseases can be clearly differentiated from one another which can result in 
faster diagnosis and earlier treatment.
74
  
 
The criteria set forth by the Consortium on Dementia with Lewy Bodies Consensus 
Guidelines use categories of features to diagnose LBD.
56
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The criteria examine symptoms in relation to central, core, suggestive, and supportive 
features of LBD.  
According to the Consensus Guidelines, the following core features must be present for a 
definitive diagnosis of LBD:
56
  
 Fluctuating cognition with prominent variations in attention and alertness. 
 Recurrent, vivid visual hallucinations which are detailed and well-formed. 
 Spontaneous Parkinsonism. 
 The criteria require that physicians be suspicious of LBD when screening for any 
type of dementia. 
 Recent modifications to Consensus Guidelines have resulted in a high specificity 
in identifying those who do not have LBD but low sensitivity in correctly 
detecting those who have LBD; therefore, errors in diagnosis are possible, 
including misdiagnosis and underdiagnosis.
56, 74
 
 
 
 
  
 
 
142 
 
 
 
There are at least two biological processes underlying dementia:  
o Foreign bodies.  
o  Neurotransmitters.  
Foreign bodies: 
 With AD, plaques and neurofibrillary tangles affect the brain.1 
  In DLB and PDD, Lewy bodies affect the brain.6, 74  
 The foreign bodies impact the structures of the brain which disrupt the brain’s 
normal functioning.   
 Definitive diagnosis of dementia type can only be determined through autopsy.45 
Neurotransmitters: 
The symptoms of AD, PD, and LBD are the result of decreased neurotransmitters in the 
brain including acetylcholine and dopamine. 
43, 48, 74
  
o Acetylcholine is responsible for cognition including, learning and 
memory functioning. 
o Dopamine is responsible for motor functioning, or movement.  
 In AD, only acetylcholine is decreased producing the cognitive symptom of 
memory loss.  
2b). Learning How to Differentiate between LBD, AD, and PD 
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 In PD, only dopamine is affected. 
  In LBD, the sequence of changes in neurotransmitters determines the type: DLB 
or PDD.  
o In DLB, the neurotransmitter acetylcholine is decreased first which 
produces the fluctuations in alertness and confusion. This is followed 
by a decrease in dopamine, which produces the later parkinsonian 
symptoms.  
o In PDD, the neurotransmitter dopamine is affected first which 
produces the movement symptoms. This is followed by a decrease in 
acetylcholine, resulting in the later cognitive changes.  
 Pharmacological management targets the loss of these neurotransmitters as the 
disease progresses.
44, 4, 8, 74 
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Lewy Body Dementia 
The Lewy Body Dementia Association (LBDA) follows the categories of symptoms as 
specified by the Consortium on Dementia Consensus Guidelines:
42
 
o Central feature:   
 Dementia with problems in the areas of planning, judgment, processing, and 
understanding information.  
 
o Core (Hallmark) symptoms:  
 Fluctuating cognition with variations in attention and alertness. 
o Short-term memory is intact in early stages. 
 Recurrent vivid visual hallucinations which are well-formed and detailed. 
 Spontaneous features of Parkinsonism such as tremors, stiffness, slowness, 
and difficulty walking. 
 
o Suggestive features: 
 Rapid eye movement (REM) sleep behavior disorder that involves talking and 
acting out dreams while asleep. 
 Severe sensitivity to neuroleptics such as atypical and typical antipsychotics. 
 Low dopamine transporter uptake that can cause depression, apathy, anxiety, 
and agitation. 
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o Supportive features: 
 Repeated falls and fainting. 
 Short-term unexplained loss of consciousness. 
 Autonomic dysfunction such as blood pressure control, temperature 
regulation, and bowel and bladder control. 
 Hallucinations that involve touch or hearing. 
 Problems processing and interpreting visual information such as the ability to 
orient oneself in the environment. 
 Other psychiatric disturbances such as delusions and paranoia. 
 
Fluctuating cognition may cause the person with LBD to have:
 13, 15, 48, 52, 74
 
o A blank stare, be very sleepy, and have scattered ideas. 
o At other times to be alert, capable of self-care, and logical conversation.  
 
 Fluctuating cognition is a challenging and difficult aspect of LBD because short-
term memory is still intact in the early stages and individuals are aware of their 
changes in cognition.  
 The hallucinations that occur with LBD can be severely distressing for the person 
and can result in agitation and aggression.
48
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 The symptoms of fluctuating cognition and visual hallucinations do not often 
occur during examination by a physician which can make an accurate diagnosis 
difficult.
48
  
The motor symptoms that occur during LBD can be subtle at first then become more 
prominent in later stages of the disease.
13, 15, 48, 52, 74
 Individuals experiencing LBD may 
have the following Parkinsonian symptoms:
48
  
 Muscle rigidity or stiffness.  
 Shuffling gait. 
 Slow movement.  
 Freezing of movements.  
 Tremor of the hands even at rest.  
 Balance problems resulting in falls.  
 Issues with handwriting. 
 Difficulties with facial expressions and swallowing.  
 Decreased strength of voice. 
These symptoms in combination with the cognition symptoms greatly impact functional 
abilities and quality of life early in the disease course of LBD.
19, 54
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Behavioral changes also occur in LBD: 
 It is possible for individuals with LBD to experience a lack of interest in things 
they previously enjoyed, as well as anxiety and agitation. 
48
  
 Anxiety and agitation can be a result of the confusion and visual hallucinations 
but can also be present in the absence of hallucinations. 
 
Common sleep problems experienced by individuals with LBD are:
42, 48
  
o Rapid Eye Movement (REM) sleep behavior disorder.  
o Excessive daytime sleeping. 
o  Insomnia.  
o Restless leg syndrome.   
 
 REM sleep behavior disorder involves acting out vivid dreams while asleep 
through talking and violent movements.
48
  
 Even though individuals with LBD may get sufficient sleep at night they often 
experience excessive day time sleepiness as well.
42, 48
  
 Some individuals with LBD may experience insomnia where they cannot fall 
asleep or stay asleep at night.
48
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 Restless leg syndrome may occur in people with LBD in which their legs are 
constantly twitching and moving in an attempt to decrease unusual sensations and 
discomfort in the legs.
42, 48
 
 
Autonomic dysfunction may also occur in individuals with LBD which affects the 
involuntary activities within the body.
42, 48
 Such symptoms may consist of variations in 
the following:
42, 48
 
 Body temperature.  
 Changes in blood pressure.  
 Dizziness.  
 Fainting.  
 Sensitivity to temperature changes.  
 Falls. 
 Problems with sexual functioning.  
 Constipation. 
 Changes to the sense of smell.  
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Alzheimer’s Disease 
The hallmark symptoms of AD are:
74
 
o Problems with short-term memory loss.  
o Early symptoms of recall, learning, and orientation deficits.  
 AD is progressive but at a much slower rate than LBD.11 
  Early in the AD course the symptoms are similar to the late stages of LBD:74 
o Problems with planning, problem-solving, and judgment.  
o Disorientation to person, place, and time. 
 As AD advances to the later stages:74 
o  Psychiatric symptoms such as hallucinations and delusions are common. 
o  Problems with movement, speech, activities of daily living (ADL’s), and 
long-term memory.  
o At this late stage there is no intact memory.27  
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Parkinson’s Disease 
 The symptoms of Parkinson’s disease are the result of Lewy bodies found in the 
midbrain. 
74
  
 Parkinson’s disease is most common in individuals over the age of 70 years.74  
 Globally, PD occurs in 8 per 1000 people commonly over 80 years old.74  
 Parkinson’s disease dementia will occur in 50-80% of those with PD; as a result, 
most individuals with PD will progress to LBD.
3
  
 The risk of males developing PD is 1.5 times greater than females.74  
 The hallmark symptom of PD is tremors.74  
 The early symptoms of PD are movement problems such as stiffness, difficulty 
with balance, and coordination.
74
  
 Cognition, problem-solving, planning, and memory dysfunction can also occur 
early in the disease.
74
  
 As PD progresses, the motor symptoms become severe resulting in safety issues 
for those diagnosed such as swallowing, bathing, and falls. 
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Table 1 below summarizes the similarities and differences among LBD, AD, and PD.
74
 
 LBD AD PD 
Age of Onset Generally > 60 
years old, but can 
be as young as 50. 
> 60 years old > 70 years old 
Gender  More men Men=women Risk is 1.5 times 
higher in men 
Family history Possible  Yes No 
Hallmark 
symptoms 
Fluctuating 
alertness and 
confusion. 
Recurrent and 
vivid visual 
hallucinations in 
80% of cases, 
spontaneous 
Parkinsonism. 
Short-term 
memory loss. 
Tremor  
Early symptoms Depending on the 
clinical 
presentation: 
Motor, dementia, 
or 
neuropsychiatric 
symptoms. 
Difficulty with 
person, place, time, 
and planning. 
Rigidity, difficulty 
with movement, 
balance, and 
coordination. 
Problems with 
planning, problem-
solving, and 
functioning. 
Late symptoms Agitation, 
aggression, 
hallucinations, 
memory loss, 
parkinsonism. 
Hallucinations, 
delusions, 
problems with 
movement, speech, 
ADL’s, long-term 
memory, planning, 
Worsened 
problems with 
planning, problem-
solving, judgment, 
slowed thinking, 
rigidity, 
2c). Table 1: Similarities and Differences among 
LBD, AD, and PD 
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judgment, and 
relationship among 
objects. 
movement, and 
coordination. 
Pathology Lewy bodies 
containing alpha-
synuclein protein. 
Beta amyloid 
neural plaques and 
neurofibrillary 
tangles composed 
of tau protein. 
Lewy bodies 
containing alpha-
synuclein protein. 
Affected 
neurotransmitter 
Dopamine & 
acetylcholine. 
Usually 
acetylcholine first. 
Acetylcholine Dopamine & 
acetylcholine. 
Usually dopamine 
first.  
Medications Cholinesterase 
inhibitors, NMDA, 
levodopa-
carbidopa, 
benzodiazepines, 
atypical 
antipsychotics. 
Cholinesterase 
inhibitors, NMDA. 
Levodopa-
carbidopa, 
cholinesterase 
inhibitors, 
antipsychotics 
cautiously. 
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Chapter 3: Pharmacological Management of LBD 
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 Pharmacological management of LBD is complex because the commonly used 
medications were initially developed for use with AD and PD and are used off 
label in the management of LBD.
44  
 As well, the medications may improve some symptoms of the disease but also 
have the potential to worsen others.
48
 
 
 There are no medications to cure LBD so the disease will inevitably progress, but 
medications can reduce symptoms of the disease.
48
 
 
 A combination of medications is generally the course of action to treat LBD.44, 48, 
74   
 Residents should be monitored closely during the medication regimen for adverse 
reactions.
44, 48, 55  
 Certain medications must also be avoided in the management of LBD.44 
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The medications commonly used are 
44, 48, 55, 56, 58, 65, 74, 77
 
 Cholinesterase inhibitors. 
o N-methyl-D-aspartate receptor antagonists (NMDA). 
 Levodopa-carbidopa. 
 Benzodiazepines. 
 Atypical antipsychotics. 
 
 
 
 Ex: Aricept (donepezil HCl)24 
 Cholinesterase inhibitors are the recommended first course of treatment for mild 
to moderate LBD.
44, 48
 
 These medications decrease the loss of acetylcholine in mild to moderate 
dementia which will help decrease problems with memory, thinking, and 
alertness.
44, 48
 
 These medications are long-term drugs so it may take time to see improvements 
in symptoms. 
3b). Cholinesterase Inhibitors 
3a). Things to Know about Pharmacological Management of LBD 
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 These medications are generally safe and tolerated well in individuals with 
LBD.
44, 48
 
 Recommended dose:24  
o 5 mg daily for 4-6 weeks then increased to maximum dose of 10 mg daily. 
o Recommended to be given either in the morning or evening. 
 Side effects: 24, 44  
o Nausea, vomiting, diarrhea  
o Insomnia  
o Muscle cramps  
o Fatigue 
o Anorexia 
 Discontinue if cognitive improvement is not possible due to progressing severity 
of dementia or if side effects are intolerable. 
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 Example: Ebixa (Memantine HCl)24 
 Used in moderate to severe stages of dementia.24, 65 
 Can be used when cholinesterase inhibitors are ineffective or the person has a 
sensitivity to them.
44
 
 Inhibits activation of the excitatory neurotransmitter glutamate in the brain that is 
involved with learning and memory.
70
 
 These medications may slow the loss of learning and memory skills such as 
toileting and dressing.
65
 
 Recommended dose:  
o 5 mg daily then titrated slowly over weekly intervals to maximum dose of 
20 mg per day.  
o The10 mg to 20 mg doses are given as divided daily doses.24 
 Side effects:24  
o Headache.  
o Sleepiness.  
o Constipation.  
o Tiredness. 
o  Confusion.  
o Hallucinations.  
o Vomiting.  
N-Methyl-D-Aspartate Receptor Antagonists 
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o Loss of appetite.  
o Dizziness.  
o Sleep disturbances.  
o Anxiety. 
o  Elevated blood pressure. 
o  Changes in urinary frequency. 
 Discontinue when there is no longer any potential to preserve cognitive 
functioning or side effects become intolerable.
24
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 Example: Sinemet.24 
 This medication is the initial treatment protocol for PD and is beneficial for 
management of Parkinson symptoms in LBD.
44, 48
 
 A levodopa-carbidopa combination medication is commonly used. 44, 48 
  The carbidopa increases the uptake of levodopa to improve motor symptoms 
such as rigidity, tremors, and restless leg syndrome.
44, 48
 
o Carbidopa enables better control of Parkinsonism with lower doses of 
levodopa.
24
 
 Should be started at the lowest dose and titrated slowly to allow for close 
monitoring of adverse effects.
44, 48
 
 Dosing should be kept at the lowest effective level to control symptoms and 
adverse effects.
44, 48
 
 Adverse effects include:  
o Increased hallucinations so may not be recommended if motor symptoms 
are mild.
44
 
o Abnormal movements and nausea.24 
  The low doses of levodopa decreases the incidence of nausea and vomiting and 
allows for more rapid titration.
24
 
 
3c). Levodopa-Carbidopa 
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 Dosing practices may vary for levodopa-carbidopa and nurses should 
ascertain agency policy/practice guidelines.  
 Levodopa-carbidopa is available in the following ratios:24  
o 4:1 (100/25 – 100 mg of Levodopa and 25 mg of Carbidopa) 
 This dosage is available in immediate release and controlled 
release tablets. 
o 10:1 (100/10 – 100 mg of Levodopa and 10 mg of Carbidopa or 250/25 – 
250 mg of Levodopa and 25 mg of Carbidopa or 200/50 – 200 mg of 
Levodopa and 50 mg of  Carbidopa). 
 The 100/10 and 250/25 doses are immediate release tablets. 
 The 200/50 dose is a controlled release tablet. 
 Dosage depends on whether the person is presently taking levodopa.24 
 
 Recommended dose if the person is not currently taking levodopa: 24 
o A ratio of 4:1 (100/25 tabs) TID is given. 
o This can be titrated up by a tablet every three days to reach 300/75 – 300 
mg of Levodopa and 75 mg of Carbidopa. 
o Normally a resident would not receive more than 1500 mg/day of 
Levodopa, but if they need to receive above 1800 mg/day then follow the 
instructions below. 
 
 
161 
 
o If further titration is necessary after a daily dose of 6 tablets of 4:1 
(100/25) ratio, then additional tablets of 10:1 ratio (100/10 or 250/25) 
may be used to reach the optimal dose. 
 Recommended dose if the person is currently taking levodopa alone: 24 
o Discontinue the levodopa 12 hours before beginning levodpa-carbidopa. 
o Start the levodopa-carbidopa the morning after levodopa is discontinued. 
o The dose of levodopa-carbidopa should be enough to provide 20% of the 
previous daily dose of levodopa. 
o 4:1 ratio is the tablet of choice to reach desired dosage. 
 
 Side effects:24  
o Worsening of hallucinations.  
o More pronounced abnormal movements such as chorea and dystonia.  
 Chorea – involuntary movements of the shoulders, hips, and face. 
 Dystonia – muscle spasms and abnormal posture. 
o Nausea 
 Decrease the dosage of levodopa if worsening or new involuntary movements 
occur, as this should be regarded as a sign of levodopa toxicity and an indicator 
of overdosing.
24
 
 Plasma levels of levodopa should be monitored to prevent toxicity. 
 Discontinue if Parkinson symptoms are not controlled and/or neuropsychiatric 
symptoms and confusion worsen. 
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 Example: Clonazepam (Klonopin)24 
 Used to treat REM sleep disorder and restless leg syndrome.70 
 Produces a sedative effect in the central nervous system.70 
 The individual may have paradoxical episodes of sedation and agitation that may 
result in discontinuation.
24,
 
44
 
 Recommended Dose:  
o 0.5 mg TID that can be increased by a 0.5-1 mg every three days.  
o Not to exceed 20 mg daily.24 
 Side effects:24  
o Drowsiness.  
o Behavioral changes.  
o Lack of coordination.  
o Increased confusion. 
 Discontinue if there is worsening of cognitive symptoms, anxiety, paradoxical 
agitation and sedation, falls, and impulsive behavior. 
 
 
  
3d). Benzodiazepines 
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 All antipsychotics increase the chance of death in people with dementia.44, 48 
 Atypical antipsychotics can be used to treat hallucinations and/or delusions that 
occur in LBD.
44, 48
 
 These medications are only used if long-term cholinesterase inhibitors have been 
ineffective or better behavioral control is warranted.
44, 48, 56, 74
  
 When atypical antipsychotics are prescribed, the lowest dose should be used for 
the shortest amount of time.
44, 48, 56, 74
 
 The recommended atypical antipsychotics to be prescribed are Quetiapine and 
Clozapine in this order.
44, 48, 56, 74
 
 Extreme caution and close monitoring is required when atypical antipsychotics 
are prescribed because neuroleptic sensitivity and neuroleptic malignant 
syndrome are possible.
44, 48
 
3e). Atypical Antipsychotics 
Typical antipsychotics, such as haloperidol, should NEVER be used to 
manage LBD because they affect the brain differently in LBD and can produce 
neuroleptic sensitivity and neuroleptic malignant syndrome which can be fatal. 
44, 
48, 56, 74
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 Neuroleptic sensitivity results in worsening of cognitive symptoms, 
hallucinations, and Parkinsonism. Occurs in up to 50% of LBD patients treated 
with atypical antipsychotics.
44
 
 Neuroleptic malignant syndrome is a rare life-threatening adverse effect that 
produces symptoms of fever, generalized rigidity, and breakdown of muscle tissue 
that can result in kidney failure and death.
44
 
 Antipsychotics stabilize mood and behavior by interfering with serotonin and 
dopamine to increase binding in the brain.
70
 
 Atypical antipsychotics are safer than typical antipsychotics, but there is no 
antipsychotic medication that is absolutely safe for the management of LBD 
behavioral symptoms. 
 Atypical antipsychotics are discontinued if there is worsening of Parkinson and 
cognitive symptoms and increased sedation is noted. 
 
 
 Quetiapine (Seroquel):24 
o Recommended dose:  
 25 mg BID which can be titrated with increases of 25-50 mg BID 
per day to a maximum dose of 300 mg/day. 
  Dosage adjustments should be at intervals no less than 2 days 
apart. 
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o Side effects:  
 Increased blood sugar.  
 Light headedness.  
 Dizziness.  
 Drowsiness. 
  Falls.  
 Dry mouth.  
 Weight gain. 
o Regular blood sugar checks should be ordered to monitor sugar levels. 
 
 Clozapine (Clozaril):24 
o Recommended dose:  
 12.5 mg once or twice daily initially, then can be increased over a 
2 week period by 25-50 mg up to a maximum dose of 300-450 
mg/day. 
o Side effects:  
 Drowsiness.  
 Dizziness.  
 Weakness.  
 Fainting.  
 Low blood pressure.  
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 Rapid heartbeat.  
 Constipation. 
  Increased saliva.  
 Weight gain. 
 Urinary retention. 
o Blood monitoring for agranulocytosis is required with this medication as 
residents are at increased risk of frequent bacterial infections. 
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 If cholinesterase inhibitors are effective, atypical antipsychotics are not prescribed 
because they have serious side effects including death.
44
 
 Avoid the atypical antipsychotics Risperidone and Olanzapine, as they have an 
increased likelihood of increasing side effects such as increased Parkinson 
symptoms, sedation, and orthostatic hypotension.
44
 
 Avoid the following medications used with Parkinson’s disease because they 
worsen cognitive impairment:
44
 
o Amantadine.  
o Catechol-O-methyltransferase (COMT) inhibitors (ex: Entacapone). 
o Monoamine oxidase (MAO) inhibitors (ex: Selegiline).  
o Anticholinergics (ex: Benztropine).  
 Avoid dopamine agonists such as Pramipexole and Bromocriptine because they 
cause excessive daytime sleepiness and swelling of the legs
.44
 
 Avoid over-the-counter sleep agents such as Tylenol or Advil PM and bladder 
control medications may cause agitation.
44
 
 
  
3f). Medications That Should Be Avoided With LBD 
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Chapter 4: Non-pharmacological Management of LBD 
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Little research exists regarding non-pharmacological approaches that are specific to 
managing the behavioral challenges of LBD.  
Much of the literature indicates that the approaches used with other types of dementia, 
such as behavioral and communication strategies, reminiscence, music therapy, doll 
therapy, and aromatherapy, are beneficial in the management of behavioral challenges 
that occur in LBD.
18, 29, 49, 54, 55, 56, 58, 76, 77
  
Using a combination of comprehensive approaches that are individualized to the resident 
is the best course of action.
44 
Resident-centered care focuses on the whole resident and their active participation in the 
care process.  
Resident preferences and ideals guide care decisions so that care specifically meets the 
needs of the resident and clinical manifestations are better managed. Resident-centered 
care will maintain the individual’s self-identity, lead to more positive outcomes, and 
promote quality of life. 
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 Effective behavioral strategies  can help to lessen disruptive behaviors.76 
 Here are some tips for managing behaviors associated with dementia generally 47, 
76
: 
o Keep a consistent schedule on the unit. 
o Read the admission history of the resident and ask family members about 
the jobs or activities residents liked in former years so these can be used to 
provide resident-centered care; for example, knowing a resident was a 
farmer and talking about farm animals during care delivery may decrease 
the resident’s challenging behavior. 
o Cue residents to participate in activities of daily living. For example, 
imitate for them what you would do with a comb. 
o Be flexible in the schedule to be able to deal with the unexpected. 
o Schedule meal and toileting to ensure needs are met. 
o Encourage regular exercise to decrease wandering and sundowning. 
o Use easy-to-use clothing to lessen disruptive behaviors during ADL’s. 
o Encourage adequate nutrition and fluids to decrease sundowning. 
o Limit caffeine as this can heighten disruptive behaviors. 
o Limit napping so that residents will sleep more at night. 
o Ensure adequate nighttime sleep so that residents are not drowsy in the 
daytime. 
4a). Behavioral Strategies 
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 Effective communication strategies can lessen disruptive behavior.76 
 Here are tips for communicating with a resident with dementia47, 65, 76: 
o Address residents by name for orientation purposes. 
o Use eye contact during conversations. 
o Do not argue with residents when they are confused or hallucinating as 
this can increase agitation. 
o Avoid quizzing the person or trying to teach them to remember as this is 
frustrating for them. 
o Do not try to orient the person to reality, instead provide reassurance and 
comfort. 
o Encourage reminiscence to promote positive emotions. 
o Step away from aggressive behavior and approach the resident later. 
o Give one step instructions in clear short phrases to avoid further 
confusion. 
o Break tasks down into steps so it is easier for them to accomplish. 
o Use a respectful tone of voice with low volume. 
o Be aware of your facial expressions. 
o Limit distractions and noise in the environment to prevent overstimulation. 
o Repeat information using the same wording to avoid confusion. 
4b). Communication Strategies 
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o Ask one question at a time to lessen confusion. 
o Try to use only questions that require yes/no answers to promote 
communication. 
o Do not give residents too many choices as this heightens confusion. 
o Use cuing or visual examples when trying to encourage their participation 
in activities. 
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 Music therapy involves the use of music either, individualized or in a group 
setting.
49,  68, 75
 
 Listening to music chosen by the resident is the most common type of music 
therapy.
49,  68, 69,  75
 
 Music therapy can also involve the active use of instruments.  
 The therapy can be monitored by a music therapist or trained nursing staff. 
 The use of music therapy helps to bring back memories of happier times thus 
helping the person relax. 
 The positive outcomes of music therapy have the potential to decrease medication 
usage to manage agitation and aggression.
17, 64
 
 Music therapy can be used in all stages of dementia because it does not require 
alertness to be a meaningful form of treatment 
49, 64, 73
 
 The nervous system is activated during music therapy releasing stress reduction 
hormones.
49, 64, 73
 
 The stress reduction hormones lessen the behavioral and psychological symptoms 
of dementia such as agitation, aggression, and hallucinations, which can improve 
quality of life.
49, 63, 64, 73
 
 There are no documented negative side effects with music therapy.72 
4c). Music Therapy 
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 Music therapy is a relatively new complementary therapy in the management of 
dementia but it does support the concept of resident-centered care.
73
 
 
 
 
 Reminiscence involves the discussion of past experiences and memories with the 
help of such tools as music, photos, memory boxes, and life story books.
14, 21, 22, 23, 
28, 33, 36, 38, 39, 51, 52, 59, 61, 67 
 Reminiscence as a form of resident-centered care has demonstrated significant 
improvement in quality of life for people with dementia.
35
 
 Individuals in all stages of dementia can participate in reminiscence.22 
 Reminiscence can be done in a group setting or one-on-one with nursing staff 
and/or family members.  
 Individualized reminiscence is best for those people who do not want to 
participate in group activities.
71 
 Reminiscence has been used in dementia care since the 1980s.26 
 This complementary therapy stimulates the person with dementia to engage in 
their surroundings, promotes communication, and enhances physical and mental 
functioning to improve well-being and quality of life.
38, 71
 
 Reminiscence enhances resident-centered care as it allows insight and 
understanding into another’s life.35 
  
4d). Reminiscence 
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 This complementary therapy involves the use of dolls to reduce anxiety and 
agitation and promote attachment in individuals with dementia.
18
 
 Doll therapy can be used in all stages of dementia but the resident should choose 
if they want to participate or not so that they do not feel like a child.
34
 
 Caring for a doll allows the person with dementia to feel as if they are useful and 
needed.
18
 
 Doll therapy reduces behavioral symptoms and improves social interaction and 
communication.
18
 
 It has been noted that doll therapy reduces anxiety, wandering, and drug usage as 
well as increases happiness, activity levels, interactions with nursing staff, and 
ease of care – all contributing to improved well-being.20, 34 
 Doll therapy is a growing practice in dementia care.57 
 
 
 
 
 
  
4e). Doll Therapy 
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 Aromatherapy involves the use of essential oils, such as lavender, that can be 
absorbed directly into the bloodstream when applied to the skin or inhaled.
29, 30
 
  The oils  interact with hormones and enzymes to produce a physical reaction 
similar to the mood regulating neurotransmitter serotonin.
29, 30
 
 Lavender is often used as it has a calming effect, decreases wandering, and 
promotes sleep.
 29, 30, 37
 
 Residents can be more alert and in better moods during the daytime allowing 
better social functioning and engagement.
29, 30, 37
 
 It is the fastest growing complementary therapy and has few adverse effects.50 
 
 
 
 
  
4f). Aromatherapy 
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Chapter 5: Resources 
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1. Alzheimer Society of Canada. (http://www.alzheimer.ca/en) 
 This is a not-for-profit organization that works to improve the quality of 
life for Canadians experiencing dementia, their families and caregivers. 
 The website provides information related to the types of dementia, causes 
and risk factors, statistics, living with dementia issues such as care, 
communication, understanding behaviors, and preparing for the future.  
 The website provides details on how to get involved with the Alzheimer 
Society, recent research and news events.  
 
2. Alzheimer Society of Newfoundland. (http://www.alzheimer.ca/en/nl) 
 This organization is a provincial branch of the Alzheimer Society of 
Canada. The website will provide you with the same details as those listed 
above.  
 
 
3. Alzheimer Association Canada (http://www.alz.org/ca/dementia-alzheimers-
canada.asp) 
 This organization is committed to dementia care, support and research in 
hopes to improve quality of life for those with Alzheimer’s disease and 
other dementias.  
5a). Resource Description 
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 The website will provide you with information related to research funded 
by the organization, educational resources, awareness campaigns, and 
government initiatives. 
 
4. Lewy Body Dementia Association (United States) (http://www.lbda.org/) 
 This association is a nonprofit organization that is geared toward raising 
awareness of LBD as well as supporting individuals diagnosed with LBD, 
their families and caregivers.  
 The website offers a vast amount of educational information on LBD and 
the latest details regarding LBD research.   
 
5. Lewy Body Society (United Kingdom) (http://lewybody.org/) 
 
 The mission of this organization is to increase awareness of DLB in both 
the public and the medical profession.  
 The link to the resource Information about Lewy body dementia is very 
beneficial.  
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6. Parkinson Canada  
(http://www.parkinson.ca/site/c.kgLNIWODKpF/b.8647145/k.6D4A/Diffuse_Le
wy_Body_Disease.htm) 
 
 This organization provides support and education to individuals diagnosed 
with Parkinson’s disease, their families, caregivers and healthcare 
providers.  
 Information can be found on the website related to education, advocacy 
efforts and support services as well as research. 
 
7. Dementia Care Central(United States) (http://www.dementiacarecentral.com/) 
 
 This website is a resource center for dementia caregivers.  
 Links are provided to up-to-date dementia information that is applicable to 
practice. 
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Videos 
 The video links below provide information related to the various behavioral 
challenges associated with LBD as well as possible reasons as to why these 
behaviors occur and ways to manage them.  
 These videos are great resources that can be used during orientation to the 
dementia unit for new nursing staff or with students on clinical placements to 
summarize the various behavioral challenges that individuals with LBD 
experience. 
 
Mayo Clinic. (2011, August 22). Living with Lewy Body Dementia [Video file]. (2 min 
58 sec). Retrieved May 28, 2016 from: 
https://www.youtube.com/watch?v=RSRbR1R4mz 0 (2min 58sec) 
 
Lewy Body Dementia Association. (2006, June 08). Behavioral Challenges in Dementia 
with Lewy Bodies [Video file]. Retrieved July 06, 2016 from:  
Part 1: https://www.youtube.com/watch?v=3nJQncMlneI ((8 min 30 sec) 
Part 2: https://www.youtube.com/watch?v=Ks12t8niET8 (6 min 17 sec) 
Part 3: https://www.youtube.com/watch?v=I4iBJazhNQY (6 min 13 sec) 
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Part 4: https://www.youtube.com/watch?v=I4iBJazhNQY (7 min 35 sec) 
Part 5: https://www.youtube.com/watch?v=egRxkTRp9-c (5 min 43 sec) 
Part 6: https://www.youtube.com/watch?v=ApL_ZazuYVU (7 min 26 sec) 
Part 7: https://www.youtube.com/watch?v=9uay245oOr0 (9 min 22sec) 
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Appendix A 
Case Study A  
A 78 year old gentleman is newly admitted to a long-term care facility with a diagnosis of 
Lewy body dementia. During morning care, he becomes aggressive during a tub bath. 
After speaking with the nursing team and reading the resident’s history on his chart, you 
know the gentleman was a farmer and becomes increasingly agitated when his stuffed 
animals are rearranged in his room. You also notice that he occasionally becomes very 
agitated and confused, picking at items that are not there. He sometimes appears 
frightened. The resident displays appropriate emotions, for example, he appears upset 
when discussing sad things but when asked about his work as a farmer he quickly 
reverses his emotions and becomes content and happy.  
1. How would you provide resident-centered care to this resident? 
2. What are the possible causes of his behavior? 
3. What are possible medications that can be recommended to the primary care 
provider? 
4. What are some non-pharmacological strategies that can be used to meet the needs 
of the resident? 
 
 
 
Adapted from: (Hamilton, P,  Harris, D., Le Clair, K., & Collins, J. (2008). Putting the 
P.I.E.C.E.S. Together: A model for collaborative care and changing practice. A 
learning resource for professionals providing long-term care to older adults with 
complex physical and cognitive/mental health changes. (6
th
 ed.). Retrieved July 
27, 2016 from: http://pieceslearning.com/model/) 
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Answers to Case Study A Questions 
1. Resident-centered care can be provided by learning about the life history of this 
resident from his or her family member, by documenting it on his chart, and using 
this information in care delivery to encourage participation and ensure his needs 
are met. For example: asking what types of animals were on the farm and the  
names of the animals may distract the resident during care delivery and lessen 
agitation. 
 
2. The resident may be having visual hallucinations that are causing him to be 
frightened, aggressive, agitated, and uncooperative. 
 
 
3. If the patient is experiencing visual hallucinations that are disturbing and affecting 
his quality of life, then a cholestinerase inhibitor may be prescribed initially. If 
these are ineffective after long-term use or better behavioral control is warranted, 
a cautious course of atypical antipsychotics may be used starting with Quetiapine 
then Clozapine. Close monitoring is required when atypical antipsychotics are 
prescribed to monitor for adverse effects. 
 
4. Non-pharmacological strategies: 
 
 Reminiscence may help to provide care to this resident.  
 
 Knowledge of the resident’s life history as a farmer and his love of 
animals can be used to carry on conversation and elicit positive emotions 
during care.  
 Music therapy may also be an option if staff are aware of the resident’s 
music preferences or if he played an instrument.  
 Behavioral approaches such as calm, low tone of voice with eye contact 
can also be helpful.  
 When agitated or aggressive, leave the resident to safely calm down and 
then try again later when his emotions and mood are more positive.  
 Communication strategies such as reassurance, breaking tasks into steps, 
sticking to a regular routine, and ensuring basic nutritional needs are met 
can lessen episodes of agitation. 
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Case Study B 
 
A 69 year old woman was being seen by a neurologist for questionable Parkinson’s 
disease. After further examination a referral was made to a geriatric psychiatrist.   
 
Medical history: 
o 2 year history of hand tremor for which patient was prescribed Levodopa. 
o 14 month history of progressive short-term memory loss and mild cognitive 
problems 
o 8 months ago the Levodopa was discontinued because it caused the patient severe 
nausea and she began to experience distressing visual hallucinations.  
o High blood pressure 
o Query history of mini stroke 
o Younger sister with potential AD, not yet diagnosed 
 
Assessment findings: 
o Fluctuating cognition 
o Responding appropriately to questions 
o Soft, slow speech with mild slurring 
o Bilateral tremor at all times in hands/arms 
o Mild degree of mask-like facial expression 
o Shuffling gait that required assistance due to fall risk 
 
Plan: 
o Aricept was prescribed for the mild cognitive changes. 
o Quetiapine was prescribed for the distressing visual hallucinations. 
o Levodopa-carbidopa prescribed for motor symptoms. 
 
1 month follow-up: 
o Patient began acting out dreams in her sleep and experiencing restless leg 
syndrome. 
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1. What type of dementia does this woman most likely have? 
 
2. What 3 symptoms are indicative of LBD?  
 
3. What medications can be recommended to the physician to control the acting out 
of dreams and restless leg syndrome? Why should the patient be monitored 
closely when taking this medication? 
 
4. What non-pharmacological interventions could be used to assist in the care of this 
individual to manage motor symptoms and memory loss? 
 
Adapted from: (Kaufer, D. I. (2004). A case study in the treatment of dementia with 
Lewy bodies. Acta Psychiatrica Scandinavica, 110(1), 73-76. doi: 
10.1111/j.1600-0447.2004.00323.x) 
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Answers to Case Study B Questions 
1. LBD 
 
2. The three symptoms indicative of LBD are: fluctuating cognition, recurrent vivid 
visual hallucinations, and Parkinson symptoms. 
 
3. Medications that can be prescribed to control the acting out of dreams and restless 
leg syndrome are benzodiazepines. The patient should be monitored closely for 
paradoxical sedation and agitation as well as worsening cognitive symptoms 
which may require discontinuing the medication. 
 
 
4. Non-pharmacological approaches that can be used to manage the motor 
symptoms: 
o Suggest the use of clothing that is easy to take on and off 
o Encourage the use of walkers/wheelchairs/bed rails/ and easy to use eating 
utensils 
o Aromatherapy and music therapy for relaxation 
Non-pharmacological approaches that can be used to help with memory loss: 
o Always use your name and the patient’s name. 
o Break tasks down into steps. 
o Keep a consistent schedule. 
o Cue residents to trigger their memory - for example, role play for them 
what a fork is used for. 
o Reorient residents – for example, tell them the day, month and year 
o Use clocks, calendars, pictures for orientation 
o Reminiscence – for example, talk about their families or past jobs. 
o Use music therapy if acceptable to the resident 
o Use doll therapy if acceptable to the resident. 
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TEST YOUR KNOWLEDGE! 
 
NOW THAT YOU HAVE READ THE MANUAL, COMPLETE THE POST-TEST 
ON THE NEXT PAGE TO DETERMINE WHAT YOU HAVE LEARNED 
REGARDNG LBD. 
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Appendix B 
Test Your Knowledge – Post-Test 
Select True or False for each of the following statements: 
1. Lewy body dementia (LBD) is more common in men.   True   False 
 
 
2. The greatest risk for Lewy body dementia (LBD) is advanced age.   
 True   False 
 
3. Lewy body dementia (LBD) is the second common type of dementia. 
 True   False 
 
 
4. Lewy body dementia (LBD) can be dementia with Lewy bodies or Parkinson’s 
disease dementia.   True   False 
 
 
5. The hallmark symptom of Lewy body dementia (LBD) is fluctuating alertness and  
confusion,  vivid visual hallucinations and Parkinson motor symptoms. 
 True   False 
 
6. An early symptom of Lewy body dementia (LBD) is delusions.   
 True   False 
  
 
7. Acetylcholine is the only neurotransmitter affected in Lewy body dementia 
(LBD).    True   False 
 
 
8. Amyloid plaques are found in the brain of individuals of Lewy body dementia.  
 True   False 
 
9. The first line of treatment for cognitive symptoms in Lewy body dementia is 
cholinesterase inhibitors.  True   False 
 
 
10. Typical antipsychotics are safe to use in the management of LBD behavioral 
symptoms.   True   False 
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Answers to Test your knowledge - Pre and Post Tests (page 7 and page 74). 
1. T 
2.  T 
3.  T  
4. T  
5. T  
6. F 
7. F 
8. F  
9. T  
10. F 
If you answered any of the questions incorrectly, please go back and review the 
appropriate chapter of this resource manual. 
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Appendix C 
Evaluation Survey 
Age: _____  Gender: _____ Are you an RN, LPN or PCA? _____ 
How long have you been working in long-term care? _______ 
 
Please complete the following survey using the 5 point Likert scale for each question.  
1-Strongly disagree 2- Disagree    3- Undecided     4- Agree    5- Strongly agree 
 
1. The resource manual was easy to understand. 
   1 2 3 4 5 
2. The resource manual will help me care for residents with LBD. 
   1 2 3 4 5 
3.  I understand the symptoms of LBD. 
   1 2 3 4 5 
4. I understand that LBD can look like AD and PD.  
1 2 3 4 5 
5. I understand the medications used to manage LBD. 
   1 2 3 4 5 
6. I understand that strategies other than medications can be used to manage LBD. 
   1 2 3 4 5 
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7. The case studies were helpful to apply new knowledge about LBD. 
   1 2 3 4 5 
8. The information provided about LBD resources was helpful. 
   1 2 3 4 5 
9. The pre-post tests were helpful in determining if new knowledge was gained about 
LBD. 
   1 2 3 4 5 
 
 10. What did you like best about the resource manual? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
11. What did you like least about the resource manual? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
12. Do you have any suggestions to improve the resource manual? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
Thank you for taking the time to complete this survey  
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Appendix D 
LBD Nursing Presentation 
Slide 1 
 
LEWY BODY DEMENTIA: 
A RESOURCE MANUAL FOR NURSING STAFF
IN LONG-TERM CARE SETTINGS
PREPARED FOR EASTERN HEALTH
HARBOUR LODGE NURSING HOME
AUGUST 18, 2016
Developed by:
© Stephanie Hawco BN RN
&
Dr. Anne Kearney
School of Nursing, Memorial University of Newfoundland
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Slide 2 
 
OBJECTIVES
 Define Lewy Body Dementia (LBD).
 Identify the cause and risks of LBD.
 Identify the clinical manifestations of LBD, Alzheimer’s 
disease (AD), and Parkinson’s disease (PD).
 Identify various non-pharmacological and 
pharmacological management approaches. 
 Identify why resident-centered care is important in the 
management of LBD.
 Identify the contents of the LBD Resource Manual.
 Enhance new knowledge of LBD using a case study.
 Demonstrate the clinical manifestations of LBD through 
the use of a video.
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Slide 3 
 
WHAT IS DEMENTIA?
 Dementia is the term used to describe disorders that 
affect cognition.
 There is no known cause for dementia.
 The rate of  disease progression is different for everyone.
 There are both reversible and irreversible forms of 
dementia.
 Irreversible dementia results in inevitable decline over 
time.
 Reversible dementias occur because of existing medical 
conditions such as toxic reactions to medications, 
Vitamin B12 deficiencies, infections, tumors, and mental 
health issues. 
 When treated the symptoms of reversible dementia can be controlled 
and cured.
 
 
Alzheimer Society of Canada, 2015a 
Alzheimer Society of Canada, 2015b 
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Slide 4 
 
DEMENTIA STATISTICS
Global
 In 2015,  47.5 million people worldwide were living with dementia. 
 This number will triple within in the next 35 years as the population 
advances in age.
 The risk for dementia doubles every 5 years after 65 years of age.
 Alzheimer’s disease (AD) occurs in 10 per 100 people commonly 
over 65-69 years old.
 Parkinson’s disease (PD) occurs in 8 per 1000 people over 80 years 
old.
 Parkinson’s disease dementia (PDD) will occur in 50 – 80% of those 
with Parkinson’s disease.
Canada
 In 2011 – 747, 000 Canadians over 65 had some form of dementia.
 $33 billion dollars a year is spent on dementia care in Canada.
 
 
Alzheimer Association, 2016c 
Alzheimer Society of Canada, 2015d 
Walter et al., 2014 
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Slide 5 
 
CLINICAL MANIFESTATIONS OF DEMENTIA
 Symptoms of dementia will become severe enough to impact every 
day living.
 Symptoms include:
 Memory loss 
 Problems with thinking, problem-solving, and 
language abilities.
 Changes in mood, personality and behavior such as:
 Emotional distress.
 Restlessness, pacing, shredding things, and wandering.
 Aggression, agitation, anxiety, depression, anger, irritability,  
and paranoia.
 Resistant behavior.
 Hallucinations and delusions.
 Sleeplessness.
 
 
 
Alzheimer Society of Canada, 2015f 
Lewy Body Dementia Association, 2016f 
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CLINICAL MANIFESTATIONS OF DEMENTIA
 Confusion – Disorientation to person, place and time.
 Compulsion – A repeated act or ritual such as checking 
locks, repeating words, and hoarding items.
 Sundowning – When symptoms of confusion and 
agitation occur late in the evening hours.
 This could actually be delirium but not recognized as 
such. 
 Delirium – A short-term state of confusion affecting 
thinking and behavior including changes in attention, 
mood and activity level. 
 People with dementia are at increased risk for 
delirium.
 
 
Alzheimer Association, 2016b 
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STAGES OF DEMENTIA
(1) No cognitive impairment: No concerns noted. Person 
functions normally.
(2) Very mild cognitive decline: Experiences normal 
forgetfulness that occurs with aging and it is not 
noticeable to others.
(3) Mild cognitive decline: Increased forgetfulness, minor 
issues with concentration and finding right words in 
conversation, and getting lost in familiar places. Others 
begin to notice symptoms. 
(4) Moderate cognitive decline: Increased issues with 
concentration, recall of events/words, and managing 
finances. The person is usually in denial and withdraws 
from others. A primary care provider can notice 
cognitive changes upon examination at this point.
 
 
Dementia Care Central, 2016 
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STAGES OF DEMENTIA
(5) Moderately severe cognitive decline: Significant 
memory loss is noted and moderate help with hygiene 
and nutrition is required. 
(6) Severe cognitive decline:  Extensive help with ADL’s is 
needed. Forget family members and little long-term 
memory intact. Issues with incontinence, muteness, 
delusions, compulsions, agitation and anxiety occur. 
(7) Very severe cognitive decline: The person does not 
speak or communicate in other ways. Requires 24 hour 
complex care. Loss of meaningful movement with arms, 
hands, fingers and feet.
 
 
Dementia Care Central, 2016 
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COMMON IRREVERSIBLE FORMS OF DEMENTIA
(1) Alzheimer’s disease 
 The most common type of dementia. 
 Caused by beta amyloid plaques and neurofibrillary tangles 
made of tau protein  scattered throughout the brain.
 60-80% of dementia cases worldwide.
 64% of dementia cases in Canada.
 Short-term memory impairment  is present upon diagnosis.
 Risk increases 30% if you have an affected family member.
(2) Vascular dementia (multi-infarct)
 Second most common type of dementia.
 Cells in the brain do not get enough oxygen. Stroke is a 
common cause. 
 20% of dementia cases in Canada.
 Impairment of cognition, emotion, motor and autonomic 
functioning happens suddenly.
 
 
Alzheimer Society of Canada, 2015c 
Lewy Body Dementia Association, 2016g 
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COMMON IRREVERSIBLE FORMS OF DEMENTIA
(3) Frontotemporal dementia (Pick’s disease)
 Produces symptoms similar to AD but affects only 
the frontal and temporal lobes of the brain.
 In some cases, brain cells in the frontal and 
temporal lobes shrink or die.
 In other cases, the brain cells in these areas get 
larger and contain round, silver Pick’s bodies 
which are a build up of tau protein.
 Accounts for 2-5% of all dementia cases worldwide.
 
 
Alzheimer Society of Canada, 2015c 
Lewy Body Dementia Association, 2016g 
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COMMON IRREVERSIBLE FORMS OF DEMENTIA
(4) Lewy Body Dementia (LBD)
 Occurs because of deposits of Lewy bodies in the brain.
 Lewy bodies contain a protein called alpha-synuclein.
 Individuals with LBD require earlier admission to nursing 
homes than seen with other types of dementia because this 
disease impacts independence early.
 LBD has a higher mortality and earlier death than other 
dementias because symptoms of both PD and dementia are 
occurring together.
 
 
Alzheimer Society of Canada, 2015e 
Lewy Body Dementia Association, 2016a 
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What is the most common dementia in Canada?
 
 
Ans: Alzheimer’s disease 
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LBD STATISTICS
 LBD is the 3rd most common type of dementia 
worldwide. 
 Accounts for 15-20% of dementia cases worldwide.
 Accounts for 5-15% of dementia cases in Canada.
 LBD occurs in 7 out of 1000 people over 75 years of age 
and older.
 LBD affects more men than women.
 On average, men are diagnosed at 72.2 years of age and 
women at 73.6 years of age which is earlier than other 
forms of dementia.
 25-50% of LBD cases have Parkinsonism upon 
diagnosis.
 80% of cases have visual hallucinations.
 Death usually occurs 5-7 years after diagnosis.
 
 
Lewy Body Dementia Association, 2016 
Lewy Body Dementia Society, 2016e 
Walter et al., 2014 
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Which gender is affected more by LBD? 
 
 
Ans: Male 
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AFFECTED NEUROTRANSMITTERS & RISK OF LBD
 Decreased levels of the neurotransmitters acetylcholine 
and dopamine result in difficulties with cognition and 
movement noted in LBD.
 Acetylcholine – cognition
 Dopamine - movement
 Controversy exists in the literature regarding a familial 
link for LBD.
 Advanced age (50 – 85 years) increases risk for LBD. 
 
 
 
 
Lewy Body Dementia Association, 2016c 
Walter et al., 2014 
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Which two neurotransmitters are affected in LBD?
 
 
Ans: Acetylcholine & dopamine 
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LEWY BODY DEMENTIA
 LBD is often misdiagnosed as AD  or PD. 
 AD because of the cognitive symptoms.
 PD because of the motor symptoms.
 Generally there is a two year lag between onset of 
symptoms and diagnosis due to lack of awareness among 
health care professionals regarding LBD and the issue of 
overlapping symptoms with other forms of dementia.
 LBD is a complex and challenging disease to manage.
 
 
Lewy Body Dementia Association, 2016a 
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LBD is often misdiagnosed as which two diseases?
 
 
Ans: AD & PD 
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LEWY BODY DEMENTIA
 LBD is an umbrella term for two related diagnoses:
 Dementia with Lewy bodies (DLB).
 Parkinson’s disease dementia (PDD).
 The central feature in each is dementia. The timeframe of the 
dementia determines the diagnosis.
 Individuals can have  3 different clinical presentations:
 If a person presents with a movement disorder, they are 
diagnosed with Parkinson’s disease. If dementia develops a year 
or more later, then the person is diagnosed with PDD.
 If a person presents with a cognitive disorder before or within 
one year of Parkinson’s symptoms, then the person is diagnosed 
as DLB.
 If a person presents with neuropsychiatric symptoms such as 
hallucinations, behavioral problems and issues with complex 
activities, the diagnosis is DLB (this diagnosis is less common).
 The 12 month cut off is somewhat arbitrary.
 
 
 
 
Alzheimer Society of Canada, 2015e 
Lewy Body Dementia Association, 2016h 
Lewy Body Dementia Society, 2015 
 
 
  
 
 
213 
 
Slide 20 
 
What is the difference between LBD and DLB?
 
 
Ans: LBD includes both DLB and PDD diagnoses.  
 
DLB: Cognition affected first, then movement and could also be neuropsychiatric 
features.  
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LEWY BODY DEMENTIA
 The 3 presentations have different symptoms initially but 
overtime will develop similar cognitive, physical, sleep 
and behavioral problems.
 The symptoms of LBD are categorized accordingly by 
the Lewy Body Dementia Association (LBDA):
Central Feature:
Dementia  with problems in the areas of planning, 
judgment, processing and understanding 
information. 
Memory impairment is usually not present upon 
diagnosis. 
 
 
Lewy Body Dementia Association, 2016b 
Lewy Body Dementia Association, 2016h 
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LEWY BODY DEMENTIA
Core (Hallmark) Features:
 Fluctuating cognition with variations in attention and 
alertness.
 Recurrent, vivid visual hallucinations that are well-formed 
and detailed.
 Spontaneous features of Parkinsonism such as tremors, 
stiffness, slowness, and difficultly walking.
Suggestive Features:
 Rapid eye movement (REM) sleep behavior disorder that 
involves acting out dreams.
 Severe sensitivity to neuroleptics 
 Low levels of dopamine that can cause depression, apathy, 
anxiety, and agitation
 
 
Lewy Body Dementia Association, 2016b 
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LEWY BODY DEMENTIA
Supportive Features:
 Repeated falls and fainting.
 Short-term unexplained loss of consciousness.
 Autonomic dysfunction such as blood pressure control, 
temperature regulation, and bowel and bladder control.
 Hallucinations that involve touch or hearing.
 Problems with processing and interpreting visual 
information such as ability to orient oneself in their 
environment.
 Other psychiatric disturbances such as delusions and 
paranoia.
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What are the three hallmark symptoms of LBD?
 
 
Ans: Fluctuating attention and alertness, vivid visual hallucinations, and spontaneous 
parkinsonism 
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PHARMACOLOGICAL MANAGEMENT OF LBD
 Controversy exists surrounding the use of medications in the 
management of LBD as many of the medications were  developed 
for use with AD and PD.
 The meds are often used off label in the treatment of LBD.
 Pharmacological treatment is different depending on what symptoms 
present first:
 Cognitive symptoms are initially treated with cholinesterase 
inhibitors.
 Motor symptoms are initially treated with levodopa-carbidopa .
 Neuropsychiatric symptoms are initially treated with 
cholinesterase inhibitors.
 The  medications can improve some symptoms but worsen others  so 
caution should be exercised and residents monitored closely  for 
adverse reactions during the medication regimen.
 A combination of medications is generally the course of action to 
treat all symptoms.
 
 
Lewy Body Dementia Association, 2016d 
Lewy Body Dementia Society, 2015 
McKeith, 2004; Walter et al., 2014 
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PHARMACOLOGICAL MANAGEMENT OF LBD
 Common medications are:
Cholinesterase inhibitors.
N-Methyl-D-Aspartate (NMDA) Receptor 
Antagonists. 
Levodopa-carbidopa.
Benzodiazepines. 
Atypical antipsychotics.
 
 
Lewy Body Dementia Association, 2016d 
Lewy Body Dementia Society, 2015 
McKeith, 2004; Walter et al., 2014 
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PHARMACOLOGICAL MANAGEMENT OF LBD
Cholinesterase inhibitors
 Ex: Aricept (donepezil HCl).
 Recommended initial treatment for LBD.
 Primarily indicated in mild and moderate stages of dementia 
for the treatment of cognitive symptoms including 
hallucinations.
 It is a long-term drug so it may take time to see an effect.
 Maintains acetylcholine levels to help with memory, thinking 
and alertness.
 Tolerated well by most individuals. 
 Dose: 5 mg daily for 4-6 weeks  then increased to max dose of 
10 mg daily. Recommended to be given either in the morning 
or evening.
 Discontinue if cognitive improvement is not possible, if 
dementia worsens, or side effects are intolerable.
 Side effects: nausea, vomiting, diarrhea, insomnia, muscle 
cramps, fatigue, and anorexia.
 
 
Lewy Body Dementia Association, 2016d 
Lewy Body Dementia Society, 2015 
Walters et al., 2015 
McKeith, 2004 
McKeith et al., 2005 
Vallerand & Sanoski, 2015 
Canadian Pharmaceutical Association, 2015 
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PHARMACOLOGICAL MANAGEMENT OF LBD
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
 Ex: Ebixa (Memantine HCl).
 Used in moderate to severe stages of dementia.
 Can be used when cholinesterase inhibitors are 
ineffective or there is a hypersensitivity to them.
 Inhibits activation of the excitatory neurotransmitter 
glutamate in the brain that is involved with learning and 
memory. 
 These medications may slow the loss of learning and 
memory skills such as toileting and dressing.
 Dose: 5 mg daily then titrated slowly over weekly 
intervals  to max dose of 20 mg/day. 
 Increases should be done in 5 mg increments. 
 The 10 mg to 20 mg doses are given as divided daily doses. 
 
 
Lewy Body Dementia Association, 2016d 
Vallerand & Sanoski, 2015 
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PHARMACOLOGICAL MANAGEMENT OF LBD
NMDA Continued 
 Side effects: headache, sleepiness, constipation, 
tiredness, confusion, hallucinations, vomiting, loss of 
appetite, dizziness, sleep disturbances, anxiety, elevated 
blood pressure, and changes in urinary frequency.
 Discontinue when there is no more potential to preserve 
cognitive functioning or side effects become intolerable.
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PHARMACOLOGICAL MANAGEMENT OF LBD
Levodopa-carbidopa
 Ex: Sinemet 
 A levodopa-carbidopa combination is often used because the 
carbidopa increases the uptake of levodopa to improve motor 
disturbances such as restless leg syndrome, rigidity, and tremors.
 Initial treatment for motor disturbances associated with LBD.
 If motor symptoms are mild it may be best not to treat in order to 
avoid the medication side effects.
 Dosing should be kept at the lowest, most effective level with 
slow titration to monitor for adverse effects.
 Dose depends on if the resident is presently taking levodopa alone or 
not.
 Dosing practices may vary for Levodopa-carbidopa and nurses 
should ascertain agency policy/practice guidelines.
 
 
Lewy Body Dementia Association, 2016d 
Lewy Body Dementia Society, 2015 
McKeith, 2004 
McKeith et al., 2005 
Walter et al., 2014 
Zupancic et al., 2011 
Vallerand & Sanoski, 2015. 
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PHARMACOLOGICAL MANAGEMENT OF LBD
 Levodopa-carbidopa is available in the following ratios: 
 4:1 (100/25– 100 mg of Levodopa and 25 mg of Carbidopa)
 This can be an immediate release or controlled release tablet.
 10:1(100/10 – 100 mg of Levodopa and10 mg of Carbidopa or
250/25 – 250 mg of Levodopa and 25 mg of Carbidopa or 
200/50 – 200 mg of Levodopa and 50 mg of Carbidopa)
 The 100/10 and 250/25 doses are immediate release tablets.
 The 200/50 dose is a controlled release tablet.
 If the resident is not currently receiving levodopa: 
 A ratio of 4:1 (100/25) TID is given. This dosage provides 
300/75 – 300 mg of levodopa and 75 mg of carbidopa per day. 
 Dosage can be titrated up by one tablet every 3 days to  
reach optimal dosage. 
 If further titration is necessary after a daily dose of 6 tablets of 
4:1 (100/25) ratio then additional tablets of 10:1 ratio (100/10 
or 250/25) may be used to reach the optimal dose.
 
 
 
 
Note: Normally a resident would not receive more than1500 mg/day of levodopa, but if 
they need to receive above 1800 mg/day then follow the above instructions. 
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PHARMACOLOGICAL MANAGEMENT OF LBD
 If the resident is currently receiving levodopa then:
 Discontinue the levodopa 12 hours before beginning levodopa-carbidopa.
 Start the levodopa-carbidopa the morning after the levodopa was 
discontinued.
 The dose of levodopa-carbidopa should be enough to provide 20% of the 
previous daily dose of levodopa.
 4:1 (100/25) ratio is the tablet of choice to reach the desired dosage.
 Side effects: more pronounced abnormal movements such as chorea and 
dystonia and nausea.
 Chorea – involuntary movements of the  shoulders, hips, and face.
 Dystonia – muscle spasms and abnormal posture.
 Dosage must be decreased if worsening or new involuntary movements 
occur and these should be regarded as a sign of levodopa toxicity and 
overdosing.
 Plasma levels of levodopa should be monitored to prevent toxicity.
 Discontinue if Parkinson symptoms are not controlled and/or 
neuropsychiatric symptoms such as hallucinations and confusion worsen.
 
 
 
 
dyskinesia – difficulty or distortion in performing voluntary movement that worsens in 
PD due to longterm use of levodopa. Chorea and dystonia are the most common.  
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PHARMACOLOGICAL MANAGEMENT OF LBD
Benzodiazpines
 Ex: Clonazepam (Klonopin).
 Used to treat REM sleep disorder and restless leg syndrome.
 Produces a sedative effect in the central nervous system.
 The individual may have paradoxical episodes of sedation and 
agitation.
 This can result in discontinuation.
 Dose: 0.5 mg TID that can be increased by 0.5 – 1 mg every 3 
days.
 Not to exceed 20 mg daily.
 Side effects: drowsiness, behavioral changes, lack of 
coordination,  and increased confusion.
 Discontinue if there is worsening of cognitive symptoms, 
anxiety, paradoxical agitation and sedation, falls, and 
impulsive behavior.
 
 
Lewy Body Society, 2015 
Vallerand & Sanoski, 2015 
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What is the first line of pharmacological treatment for the 
cognitive symptoms associated with LBD?
 
 
Ans: Cholinesterase inhibitors 
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What is the recommended pharmacological treatment to 
manage the motor symptoms of LBD?
 
 
Ans: Levodopa-carbidopa 
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PHARMACOLOGICAL MANAGEMENT OF LBD
Atypical Antipsychotics
 Requires extreme caution and close monitoring for adverse effects.
 All antipsychotics increase the risk of death in individuals with 
dementia.
 Should use the lowest dose for the shortest amount of time.
 Used to treat distressing or disturbing hallucinations and/or 
delusions that occur in LBD.
 These drugs are used if long-term use of cholinesterase inhibitors is 
ineffective or better  behavioral control is needed 
 Stabilizes mood and behavior by interfering with serotonin and 
dopamine binding in the brain.
 Quetiapine and Clozapine are the recommended atypical 
antipsychotics used in this order.
 Atypical antipsychotics should be discontinued if there is worsening 
of Parkinson and cognitive symptoms and increased sedation.
 
 
Lewy Body Dementia Association, 2016d  
Lewy Body Dementia Society, 2015 
McKeith et al., 2005 
Walter et al., 2014 
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When would atypical antipsychotics be used in LBD?
 
 
Ans: When long-term use of cholinesterase inhibitors are ineffective or better behavioral 
control is warranted. 
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What are the two recommended atypical antipsychotics, in 
correct order, that can be used with LBD?
 
 
Ans: Quetiapine & clozapine 
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PHARMACOLOGICAL MANAGEMENT OF LBD
Quetiapine (Seroquel)
 Dose: 25 mg BID which can be titrated with increases of 
25-50 mg BID per day to max dose of 300 mg/day.
 Dosage adjustments should be at intervals no less than 2 days 
apart.
 Side effects: increased blood sugar, light headedness, 
dizziness, drowsiness, falls, dry mouth, and weight gain.
 Regular blood sugar checks may be ordered to monitor 
sugar levels.
 
 
Canadian Pharmaceutical Association, 2015 
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PHARMACOLOGICAL MANAGEMENT OF LBD
Clozapine (Clozaril)
 Dose: On the first day, 12.5 mg once or twice can be 
given, followed by one or two 25 mg tablets the second 
day. 
 If well tolerated the dose can be increased over a 2 week 
period by 25–50 mg up to max dose of 300 – 450 mg/day.
 Side effects: drowsiness, dizziness, weakness, fainting, 
low blood pressure, rapid heart beat, constipation, 
increased saliva, weight gain,  and urinary retention.
 Blood monitoring for agranulocytosis is needed with 
Clozapine.
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PHARMACOLOGICAL MANAGEMENT OF LBD
 Typical antipsychotics, for example haloperidol, should never be used:
 They affect the brain differently in LBD and can produce dangerous side 
effects that may result in death.
 They have the potential to worsen all symptoms,
 Side effects include sedation, increased parkinsonism, neuroleptic 
sensitivity and neuroleptic malignant syndrome (NMS)
 The serious and possibly fatal side effects of antipsychotics are:
 Neuroleptic sensitivity – Occurs when individuals are sensitive to 
neuroleptics which results in worsening of cognition, hallucinations and 
Parkinsonism. 
 Affects up to 50% of LBD cases.
 Neuroleptic Malignant Syndrome – A  rare, life threatening adverse effect 
that produces symptoms of fever, generalized rigidity and breakdown of 
muscle tissue that can result in kidney failure and death.
 
 
Lewy Body Dementia Association, 2016d 
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PHARMACOLOGICAL MANAGEMENT OF LBD
Drugs that should be avoided include:
 Typical antipsychotics.
 They increase morbidity and mortality and can be fatal.
 Atypical antipsychotics, Risperidone  and Olanzapine
 They can increase side effects such as Parkinson symptoms, sedation and 
orthostatic hypotension.
 The following medications used with Parkinson’s disease: 
Amantadine, Catechol-O-Methyltransferase (COMT) inhibitors (ex: 
Entacapone), Monoamine Oxidease (MAO) inhibitors (ex: 
Selegiline) and anticholinergics  (ex: Benztropine).
 These can worsen cognitive impairment in LBD.
 Dopamine agonists (ex: Pramipexole)  
 They cause excessive daytime sleepiness and swelling of the legs.
 Over-the-counter sleep agents such as Tylenol or Advil PM and 
bladder control medications.
 These may cause agitation.
 
 
Lewy Body Dementia Association, 2016d 
Lewy Body Society, 2015 
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What is the danger with giving typical antipsychotics to an 
individual with LBD?
 
 
Ans: Neuroleptic sensitivity and neuroleptic malignant syndrome both which can be 
fatal. 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
 Non-pharmacological approaches to manage the 
behavioral challenges of LBD are similar to those used 
with other types of dementia.
 These approaches will promote optimal functioning and 
quality of life when tailored to the needs of the resident.
 Examples:
Behavioral strategies.
Communication strategies.
Music therapy.
Reminiscence.
Doll therapy.
Aromatherapy.
 
 
Bullet 1: No literature exists on non-pharmacological interventions specific to LBD but 
many research articles demonstrate evidence that techniques used with other types of 
dementia are beneficial for LBD as well (Neef & Walling, 2006; McKeith, 2004; 
McKeith et al., 2005; Yuhas et al., 2006; Zupancic et al., 2011). 
 
 
Lewy Body Dementia Association, 2016f 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Behavioral Strategies
These strategies will lessen disruptive behaviors:
 Keep a consistent schedule.
 Have knowledge of what job or activities resident’s liked 
in their former years and use this as a tool during care 
delivery.
 Cue residents to participate in activities of daily living. For 
example, demonstrate what to do with a hair brush.
 Be flexible with activities of daily living.
 Have a consistent toileting and meal schedule.
 Offer regular exercise.
 Ensure safe use of bed rails and walkers.
 Only use easy to use clothing.
 Ensure adequate nutrition and fluid to decrease agitation.
 
 
Yuhas et al., 2006 
 
Bullet 2: If a resident was a fisherman all his/her life, then conversations about fishing 
and the ocean may calm a resident that is agitated so that care can be provided.  
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What are two behavioral strategies that can be used to 
manage LBD?
 
 
Ans: Any listed on prior slide. 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Communication Strategies
The following communication strategies can lessen 
disruptive behaviors:
 Address residents by name.
 Use eye contact.
 Give one step instructions in clear short phrases.
 Break tasks down into steps so individuals do not 
become overwhelmed.
 Use nonverbal cues to lessen agitation and anxiety:
- smile.
- low, gentle tone of voice.
- hand holding.
 
 
Yuhas et al., 2006 
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What are two communication strategies that can be used 
with LBD?
 
 
Ans: Any on prior slide 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Music Therapy
 Involves the use of music to alleviate the behavioral and 
psychological symptoms of dementia, such as agitation, 
aggression, delusions, and hallucinations.
 Can be individualized or in a group
 Can be carried out by a music therapist or trained nursing 
staff.
 Can be used in all stages of dementia because it does not 
require cognitive functioning to be successful.
 Evokes memories of happy times that help relax the 
person.
 
 
Lin et al., 2011; Raglio et al., 2008; Sung, Lee, Li, & Watson, 2012 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Reminiscence
 Involves the discussion of past experiences and 
memories with the aid of such media as music, photos, 
memory boxes, and life story books. 
 Can also involve family members in this activity.
 Evokes feelings of comfort and promotes memory recall 
to alleviate challenging behaviors.
 Can be used in all stages of dementia.
 
 
Azcurra, 2012; Haslem et al., 2014; Subramaniam, Woods & Whitaker, 2014; Van 
Bogaert et al., 2013).  
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Doll therapy
 Involves the use of dolls to reduce anxiety and agitation 
as well as meeting attachment needs. 
 Allows the person to mimic caring for a child and can 
increase their feelings of being useful and needed.
 Behavioral issues of dementia are reduced and social 
interaction and communication improve as a result.
 Can be used in all stages of dementia.
 
 
Bisiani & Angus, 2015 
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NON-PHARMACOLOGICAL MANAGEMENT OF LBD 
Aromatherapy
 Involves the use of essential oils such as lavender either 
absorbed directly on the skin or inhaled. 
 Lavender acts as an antidepressant, has a calming effect, 
reduces agitation and promotes sleep.
 It is a fairly new treatment option so research is limited.
 Can be used in all stages of dementia.
 
 
Forrester et al., 2014 
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Based on your current knowledge of LBD, reflect on how 
you would change past care practices for a resident with 
this disease.
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WHY RESIDENT-CENTERED CARE?
 Resident-centered care focuses on the whole resident and 
their active involvement in the care process. 
 It is an interplay of the environment, person and 
relationships .
 Resident preferences and values guide care decisions so 
that care is individualized.
 It will preserve the resident’s identity to promote quality 
of life.
 Resident-centered dementia care will lead to more 
positive outcomes as clinical manifestations are better 
managed.
 
 
Bullet 1: Holism will preserve a sense of self (Chenoweth et al., 2009).  
 
Bullet 2: All aspects of a clients life including clinical, social and functional history, 
along with preferences and needs are important to individualized care (Stein-Parbury et 
al., 2012) 
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HOW TO PROVIDE RESIDENT-CENTERED CARE
 Gather a life history from residents, if early in the disease, and 
from family members.
 The life history is generally done in the assessment by the 
social worker and placed in the resident’s chart.
 Pertinent information that family members found helpful 
during care delivery at home can be discussed with the 
nursing team via the Resident Care Manager upon the 
residents admission to the unit.
 It is important to reinforce the remaining strengths of the 
resident to achieve well-being and quality of life.
 Once nursing staff become familiar with the resident’s care 
needs they can share helpful information during ward 
conferences regarding what was useful from the life history to 
aid in meeting care needs. 
 This can be added to the care plan.
 
 
Stein-Parbury et al., 2012 
Hoe & Thompson, 2010 
 
Through empathetic interactions between the nurse and client in dementia care, the client 
will have a better sense of self and nursing staff will have an increased understanding of 
the importance of life history to preserve the client’s identity, well-being and overall 
quality of life (Kitwood & Bredin, 1992; Stein-Parbury et al., 2012). 
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Why is resident-centered care important with LBD?
 
 
Ans: To ensure resident needs to maintain well-being and quality of life. 
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LBD RESOURCE MANUAL IN LTC
The LBD Resource Manual will contain the following 
information:
Chapter 1: 
 General discussion of dementia including common types.
 Definition of LBD.
 Two common diagnostic tools for LBD.
 Relevant statistics.
 Risk factors.
Chapter 2:
 Clinical manifestation of LBD, AD and PD.
 Differentiating characteristics of LBD, AD, and PD.
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LBD RESOURCE MANUAL IN LTC
Chapter 3: 
 Pharmacological approaches to manage LBD
 Cholinesterase inhibitors.
 N-Methyl-D-Aspartate (NMDA) receptor antagonist.
 Levodopa-carbidopa.
 Benzodiazepines.
 Atypical antipsychotics.
 Medications not prescribed to individuals with LBD.
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LBD RESOURCE MANUAL IN LTC
Chapter 4
 Non-pharmacological approaches to enhance resident-
centered care:
 Behavioral strategies.
 Communication strategies.
 Music therapy.
 Reminiscence.
 Doll therapy.
 Aromatherapy. 
Chapter 5:
 Canadian and international resources related to LBD with a 
description of each.
 Organizational websites deemed important .
 
 
-The enhanced knowledge regarding LBD will improve care practices and hopefully 
improve quality of life. 
 
-Treatment options that are resident-centered to specifically meet each residents needs 
will enhance quality of life and patient outcomes. 
 
-If nursing staff are better informed on the disease process of LBD then they are more 
prepared to communicate with families and physicians regarding the disease trajectory 
and care options. 
 
- the resource manual can be used at the learner’s own pace when time permits and is 
deemed to be a good education tool in the literature to enhance learning and knowledge 
for nurses (Sparling, 2001). 
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LBD RESOURCE MANUAL IN LTC
The manual will also contain:
 Pre-post tests to assess knowledge levels regarding LBD 
before and after reading the manual.
 2 Case studies to promote problem-solving abilities 
using newly acquired knowledge.
 Evaluation survey to assess satisfaction with the resource 
manual.
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 LBD progresses very rapidly. 
 LBD greatly impacts quality of life.
 LBD has 3 clinical presentations with the timeframe of the 
dementia determining the diagnosis.
 The presenting symptom determines the pharmacological 
course of treatment.
 A combination of individualized non-pharmacological and 
pharmacological interventions is most effective for the 
management of LBD.
 Resident-centered care as a result of enhanced nursing 
knowledge will enhance quality of life.
 Enhanced knowledge of nursing staff regarding LBD is 
necessary because the aging population is increasing,  and 
more individuals will be diagnosed with LBD and need care.
SUMMARY
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Mayo Clinic. (2011, August 22). Living with Lewy 
Body Dementia [Video file]. 
2 mins 58 secs
Retrieved May 28, 2016 from: 
https://www.youtube.com/watch?v=RSRbR1R4mz 0
VIDEO OF PERSONAL ACCOUNT OF LBD
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RECOMMENDED VIDEOS OF LBD
Behavioral Challenges in Dementia with Lewy Bodies 
by Dr. Ferman at the Mayo Clinic, Jacksonville, Fl:
Part 1: 
https://www.youtube.com/watch?v=3nJQncMlneI
Part 2: 
https://www.youtube.com/watch?v=Ks12t8niET8
Part 3: 
https://www.youtube.com/watch?v=I4iBJazhNQY
Part 4: 
https://www.youtube.com/watch?v=I4iBJazhNQY
Part 5: 
https://www.youtube.com/watch?v=egRxkTRp9-c
Part 6: 
https://www.youtube.com/watch?v=ApL_ZazuYVU
Part 7: 
https://www.youtube.com/watch?v=9uay245oOr0
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See hand-out for case study.
Adapted from:
Khotianov, N., Singh, R., & Singh, S. (2002). Lewy body dementia: 
Case report and discussion. The Journal of the American 
Board of Family Practice, 15(1), 50-4. Retrieved from: 
http://www.jabfm.org
CASE STUDY
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